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Towards Synthetic Peptide Ligation
ABSTRACT
Presented is a novel protocol for the ligation of protected peptide segments that relies on 
a selective ruthenium-catalyzed cross metathesis reaction. Amino acid A-termini were 
acryloylated using acryloyl chloride and triethylamine and C-termini were coupled to 
homoallylamine using standard coupling conditions. The conditions used in both 
reactions are suited to use on protected peptides.
Peptide
Peptide
Peptide
O O R
Model studies were performed on a range of single protected amino acids. This 
demonstrated the applicability of the technique. The synthetic ligation between a 
protected dipeptide bearing a C-terminal homoallyl amide and a protected A-acryloyl 
tripeptide was achieved.
Application to the total chemical synthesis of modified Crambin was then investigated. A 
site was chosen for ligation and syntheses of the appropriate peptide segments were 
attempted using solid phases peptide synthesis techniques and an Fmoc protection 
approach.
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Chapter 1 -  INTRODUCTION
1.1 -  The Importance of Peptide Synthesis
The new research work presented in this thesis is directed toward the development of new 
methods for the chemical synthesis of proteins. The importance of having proteins 
available to us via chemical synthesis is twofold. First, the ability to dictate primary 
structure, which is solely responsible for the protein’s higher-order structures, allows, in 
theory, for total control of protein folding and thus function. This is fundamental to 
understanding biological systems. Second, the selective modification of a single amino 
acid allows for the introduction of novel functionality, or site-specific conjugation to a 
functional structure, such as a nanoparticle1 or an organic fluorophore.2 These techniques 
afford the potential for different proteins to be monitored in isolation or in vivo, in turn 
enhancing our understanding of their function. For example Cole et al., by modification 
of a single amino acid in tyrosine phosphatase SHP-2, have illuminated the role of this 
protein in signal transduction;3 Raines et a l  have reported the altered folding dynamics 
and structural stability of RNase A upon insertion of a non-natural amino acid;4 Muir et 
a l, using a main-chain amide to ester substitution, have explored the factors affecting K+ 
conduction properties in potassium channels.5
Whilst this ability to manipulate proteins to ‘probe nature’ is an exciting area, there is a 
second, less traditional reason for obtaining reliable synthetic protocols to construct and 
modify proteins. Biological systems are incredibly complex, and protein function is 
specific often to a point that far surpasses that obtainable in organic chemical systems. It 
is therefore a goal to harness some aspects of this specificity, which has been perfected in 
nature over at least 3.5 billion years, and modify it to perform a useful function. For 
example, the ability of proteins to be integrated into or interfaced with living systems 
could allow for transport of otherwise toxic molecules by conjugation to the protein at a 
modified site, and the specificity may result in the ability to deliver this to a particular site 
within a living organism. Although this is somewhat speculative, it is necessary to 
highlight the shift in science from observation of the workings of systems in nature to 
their active manipulation in order to produce highly functional unnatural materials. When
10
this endeavour incorporates the wealth of functional moieties offered by nature, the 
potential is great. For example, Davis et al. have described the potent inhibition of 
bacterial aggregation by glycodendrimer-functionalized proteins;6 DeGrado et a l, have 
synthesized an artificial metalloprotein with potentially tuneable photophysical 
properties;7 Poulter et al. have developed a technique for site-specific covalent 
immobilization of proteins on glass slides, applicable to the development of protein 
chips.8
1.2 -  The Synthesis of Peptides and Proteins
1.2.1 -  Molecular Biology Approaches
Proteins can be effectively produced using recombinant DNA technology, which 
harnesses the translational hardware of a microorganism such as E. coli to produce large 
quantities of proteins. These are formed by the random cleavage and re-joining of 
wild-type DNA, amplification and then screening for function of the resultant protein. 
This technique does not, however, allow for facile access to selective post-translational 
modifications, such as phosphorylation, which occur in many naturally occurring proteins. 
Furthermore, in the synthesis of modified proteins with specific functions, site-specific 
modification of the amino-acid sequence with an unnatural amino-acid is difficult to 
achieve as it requires transfer RNA that is capable of associating with the amino acid and 
is compatible with the ribosome during translation. An elegant solution to the problem 
has been described by Schultz et al.9
In the Schultz method oligonucleotide-directed mutagenesis is employed to substitute the 
codon corresponding to the amino acid of interest with a nonsense codon. Then the 3’ 
hydroxyl group of tRNA possessing a complementary anticodon is functionalized with 
the desired non-natural amino-acid. The functionalized tRNA will therefore associate 
with the mRNA during in vitro translation, thus introducing the non-natural amino acid. 
This ‘cell-free’ methodology has been used in a variety of protein modifications. These 
include preparation of glycopeptides,10 alteration of luciferase emission wavelengths,11 
increasing fluorescence of green fluorescent protein (GFP)12 and site specific fluorescent
11
labelling.2 Incorporation of non-natural amino-acids has been taken one step further and 
methods for genetically encoding has been achieved.13
7.2.2 -  Linear Solid-Phase Synthesis
Synthetic chemistry can be used to build peptides sequentially and the field of peptide 
chemistry has become very reliable, boasting a host of orthogonal protecting groups (PG) 
and solid-phase techniques.14 This approach is particularly attractive as it is possible to 
introduce amino acids in any order, and introduce any number of non-natural amino-acids 
into the sequence trivially. The ability to access any sequence of amino acids, natural and 
non-natural is potentially very powerful and could indeed be the foundation of a future 
‘ synthetic biology’.15
The basic mechanism of linear peptide synthesis involves nucleophilic attack of the 
//-terminus of the peptide chain at the C-terminus of the //-protected amino acid to be 
added (Scheme 1.1). Thus solid phase peptide synthesis (SPPS) usually proceeds with 
C—►// directionality. The //-terminal protecting group must then be removed, yielding the 
free amine for subsequent nucleophilic attack. The C-terminus, a carboxylic acid, is 
activated, rendering the carbonyl more susceptible to nucleophilic attack. The //-terminal 
free amine then adds to the carbonyl, producing a tetrahedral intermediate; and the 
activating group leaves, picking up a proton and forming a urea; and an amide bond is 
generated. Once the desired number of amino acids has been added, the peptide is 
cleaved from the resin, usually with removal of side-chain protection simultaneously.
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Scheme 1.1 -  Solid phase peptide synthesis. PG = protecting group
The two protecting group schemes most widely used are 9-fluorenylmethyl carbamate 
(Fmoc) and tert-butyloxycarbonyl (Boc), both requiring orthogonal side-chain protection. 
These are illustrated in Scheme 1.2.
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Scheme 1.2 -  (A) SPPS using Bex: protection. (B) SPPS using Fmoc protection.
The activation of the C-terminal carbonyl introduces the possibility of oxazolone 
rearrangement and subsequent racemization according to Scheme 1.3.
B
Scheme 1.3 -  Mechanism of oxazolone rearrangement
Additives such as copper (II) chloride and 1-hydroxybenzotriazole (HOBt) have been 
shown to dramatically reduce racemization16 and HOBt is now commonly used in the 
synthesis of peptides. Presumably this forms the corresponding ester with the C-terminus 
of the peptide, rendering it less prone to cyclization. Thus if the conversion of the diimide 
activated species to the HOBt ester is quick enough, racemization is suppressed.
This approach to protein synthesis does, however, have serious limitations. It is restricted 
to the synthesis of short peptide chains of up to about 50 amino acids, depending on the 
sequence. This is due to the higher number of deletion peptides, sequences missing amino 
acids, generated at greater peptide lengths, and the increased difficulty of their removal. 
Furthermore, at longer lengths the peptide may aggregate into secondary structures, and 
this could render the /V-terminus unavailable for reaction.
The synthesis of proteins consisting of much longer amino-acid chains therefore requires 
a convergent approach, which involves first synthesizing shorter peptide segments either 
by recombinant DNA technology or by synthetic techniques. Such segments are more 
easily purified, and subsequent joining of these segments can yield peptides with lengths 
unattainable by the linear synthesis previously described. Using appropriate amino-acid 
side-chain protection, it is possible to join peptide segments by appropriate synthetic 
approaches. However side-chain protection often results in poorly soluble peptide 
segments and associated problems, such as a very low rate of reaction. Convergent 
synthesis remains very limited.
Given the problems associated with peptide solubility, it is worthwhile considering 
synthetic techniques which are unaffected by the presence of the functionalities exhibited 
by the 20 naturally occurring amino acids. Peptide segments could then be joined without 
the need for protecting groups.
15
1.3 -  Methods of Peptide Ligation
1.3.1 -  Native Chemical Ligation -  Introduction
Two fully unprotected peptide sequences can be joined in water at or around neutral pH 
by a process termed Native Chemical Ligation (NCL), first reported by Kent et al.17 in 
1994. For it to occur, the C-terminus must comprise a thioester and the /V-terminus a 
cysteine residue, the sulfhydryl group of which undergoes a reversible 
transthioesterification reaction with the thioester moiety. In doing this, the free amine is 
brought into close enough proximity for a spontaneous rearrangement to occur, yielding 
an amide bond (Scheme 1.4).
HO
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— ( Peptide 2  )— NH2
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/ W SH
Catalytic
HO
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Scheme 1.4 -  Native chemical ligation
Despite the fact that in-chain unprotected cysteines also possess the sulfhydryl group, the 
reversible nature of transthioesterification, and the fact the rearrangement is only 
available to the W-terminal cysteine, lead to the reaction being chemoselective.
NCL is a reliable technique for synthesizing proteins that are unavailable by linear 
synthesis, and has been used for the synthesis of many proteins.18'23 Notably, it has been 
employed by Kent et al. to access the 70 amino-acid potassium channel regulatory 
subunit KChIP2,24 a preliminary step towards investigating its role in channel regulation. 
The same group has used three successive NCL steps in the synthesis of the 130
16
amino-acid human lysozyme,25 which allowed for the high-resolution x-ray structure to 
be determined. They have also reported the total chemical synthesis of the HIV-1 
protease dimer,26 access to which is highly desirable for the development of treatments 
for AIDS.
NCL has also shown promise in applications beyond the synthesis of native proteins. 
Bertozzi et a l, for example, have used it to lipidate GFP and thus mimic the native 
glycosylphosphatidylinositol linkage exhibited by membrane-anchored proteins.27 
Additionally, Nagamune et a l have described conjugation of biotin and fluorescent 
proteins to oligonucleotides.28
1.3.2 -  Native Chemical Ligation -  General Procedure
The general procedure is as follows. Peptide segments are synthesized by SPPS as 
previously described. Peptides requiring C-terminal thioester functionalization can be 
prepared in several ways. These include solution-phase synthesis from fully protected 
peptide segments, prepared by Fmoc techniques.20, 21 ’ 29, 30 This approach utilized 
acid-labile chlorotrityl resins for SPPS of peptides, replacing the V-terminal Fmoc for a 
Boc group, and then cleaved with acetic acid, a milder alternative to TFA which leaves 
all the protecting groups intact. Thioester generation is then carried out in solution 
(Scheme 1.5).
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Scheme 1.5 -  Solution-phase thioester generation
The use of a sulfonamide ‘safety-catch’ linker has also been reported.31 Efficient loading 
of such linkers can be achieved using Fmoc amino-acid fluorides.32 After SPPS, the 
group is alkylated and thus converted into a good leaving group. Cleavage with a thiol 
can therefore be achieved and the resultant thioester deprotected ready for NCL 
(Scheme 1.6).
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Scheme 1.6 -  Synthesis of thioesters using a sulfonamide safety-catch linker
It has been shown that the rate of ligation is influenced by the side-chain of the amino 
acid bearing the thioester moiety;33 the amino acids resulting in a slow ligation were 
found to be valine, isoleucine and proline. So this provides yet another limitation, should 
one of these residues occur next to the cysteine at the chosen ligation site.
NCL commonly requires an additional thiol additive, such as thiophenol, to increase the 
rate, presumably by providing an additional transthioesterification step yielding the more 
reactive thioester (Scheme 1.7).19
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Scheme 1.7 -  Mechanism of transthioesterification
Associated with the further activation of the C-terminal carbonyl with thiophenol is the 
danger of racemization via the oxazolone rearrangement. The final proteins are almost 
exclusively characterised by soft ionization mass spectrometry techniques such as 
MALDI33 or E l19,33,34 Any racemization occurring during the process will therefore not 
be detected, and chiral HPLC may have difficulty differentiating between such high Mw 
diastereoisomers. The function of the protein is also used as a means of characterisation18 
although this is only relevant if a single epimerisation event interferes with biological 
function.
The issue of racemization has been addressed,33 by comparison of a small peptide 
synthesized using NCL in standard aqueous conditions and the same peptide synthesized 
using standard coupling conditions. Chiral HPLC was employed and the amount of 
racemization was established to be <2% in the case of the His-Cys ligation. A situation 
can be easily envisaged in which racemization occurs during ligation at a single site in the 
polypeptide chain and, due to it being positioned in an area of the protein’s tertiary 
structure not directly involved with the protein’s function, has no observable effect. Thus 
the issue of racemization, whilst being worth addressing, may not actually present a 
palpable problem in the syntheses of functional peptides using NCL. To achieve 
academic satisfaction, however, one would wish to be convinced of the preservation of 
any stereochemistry when using this technique.
One limitation of NCL is the requirement of a cysteine residue for the reaction to occur. 
Cysteine occurs with a low frequency relative to other amino acids in both proteins and 
cyclic peptides. Indeed many peptide sequences do not possess a cysteine at a site, the 
choice of which would allow division into appropriately sized portions for synthesis and 
subsequent NCL.34,35 One solution relies on a removable auxiliary which mechanistically 
mimics cysteine and thus undergoes NCL. Removal yields an amide bond at any chosen 
position.34, 35 For example utilization of an Aa-(l-Phenyl-2mercaptoethyl) derivative 
(Scheme 1.8), has allowed for generation of cyclic peptides by NCL at non-cysteine 
containing sites, and the synthesis of cytochrome b562.34
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Scheme 1.8 -  NCL using a removable auxiliary
1.3.3 -  Other Methods o f Peptide Ligation
Due to the inherent drawbacks of NCL, a number of other ligation methods have been 
developed. The Staudinger ligation (Scheme 1.9) is one such method, and was first 
reported by Nilsson et al.36 This has no reliance on cysteine residues and, being a 
modification of the Staudinger reaction, requires one peptide segment to possess an azide 
moiety. The reaction between this and a thioester in the presence of a phosphinothiol 
species results in an amide bond and no residual atoms. In essence, the phosphinothiol 
species acts as a temporary connector.
21
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Scheme 1.9 -  Mechanism of the Staudinger ligation
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Nilsson et al. initially produced a dipeptide using diphenylphosphinobenzenethiol, 
however the most efficient phosphinothiol species, with ligations proceeding with high 
(>90%) yields at junctions with a glycine residue at the A-terminus, is 
diphenylphosphinomethanethiol. The yield drops to below 50% in the case of other 
residues, the by-product being a phosphonamide. A recent study has investigated the 
effect substitution of the phenyl rings with chlorine and methoxy groups has on the 
reaction,37 predicting the electron-donating methoxy groups to increase electron density 
on the tetrahedral phosphorous intermediate and thus favour the product pathway 
(Scheme 1.10).
,NR'P
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; pph2
X T  -
S ^ O — PPh2
/ R'N
I
PP h2
S  Desired interm ediate
Ph2P \  /F t '  
N 
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Scheme 1.10 -  The two product pathways in the Staudinger ligation
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This was indeed found to have the predicted effect, the chloro groups in turn lowering the 
yield of ligated product. With this improved protocol, an Ala-Ala coupling proceeded 
with 61% yield in DMF; 99% in toluene. Despite toluene not being a conventional 
solvent for the manipulation of large peptides, these results are the highest yielding for 
any non-glycyl Staudinger ligation, and thus are an early indication of what this 
technique may achieve in the future.
The reaction between a-ketoacids and A-alkylhydroxylamines, with the loss of water and 
carbon dioxide, has been used to ligate small unprotected peptides in DMF, with yields 
ranging from 58-80% (Scheme 1.11).38
HoN
COOH
COOH
DMF (aq.) 
4 0  °C
COOH
Scheme 1.11 -  Ligation between an A-alkylhydroxylamine and an a-ketoacid
The reaction has also been shown to be applicable to aqueous media, rendering it an 
attractive option for the semisynthesis of proteins. The mechanism has not yet been 
determined; however we are informed that this is currently under investigation by 
Baucom et al., along with a new approach to the preparation of enantiopure ketoacids, 
which is essential for the general applicability of this methodology.
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The Diels-Alder cycloaddition reaction is tolerant of functional groups and occurs under 
mild conditions, rendering it worthy of the ligation of deprotected peptide fragments. 
Waldmann et al. have ligated a variety of appropriately functionalized short peptides 
using this cycloaddition,39 as illustrated in Scheme 1.12.
{ Peptide 1 Peptide 2
A queous m edia, 
RT
{ Peptide 1 )— ^ P ep tid e2
1.2 H
Scheme 1.12- Diels Alder ligation
Despite high conversions (>90% except for one case) and good isolated yields (>60% 
except for one case), this methodology leaves a non-natural linker between peptide 
segments, which differs significantly from the native peptide structure. For this reason, 
the technique may be somewhat more worthy as a means to conjugate proteins. This was 
also achieved in the study of Waldmann et al, dansyl and fluorescein-malemide being 
conjugated to streptavidin (Scheme 1.13) and dansyl-malemide being attached to a Rab 
protein. The dye-functionalized malemides were attached to streptavidin via a lysine 
residue and to the Rab protein at the C-terminus, which had been functionalized 
appropriately.
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Lysine
R esid ue
O
water, 25°C
O Fluorescein
M alem ide, 30 equiv.
O O
Streptavidiy— N
&  °
N -\
Scheme 1.13 -  Conjugation via Diels Alder ligation
Finally, we turn to a ligation technique that utilizes a ring-opening cross-metathesis 
(ROCM) reaction.40 Metathesis is integral to this project, and is discussed in detail in the 
next section. This study, despite describing a theoretical ligation sensitive to peptide 
directionality, presents results for ligation between two different amino acids, dipeptides 
or tripeptides, C-terminus to C-terminus.
The peptide C-termini are first functionalized with olefinic groups of different reactivity 
and, as shall be discussed in the next section, this leads to selective generation of the 
required product. This was achieved by coupling the termini to a cyclic, olefinic amine, 
and hexenol (Scheme 1.14).
y ~ ( Peptide 1 )— NHF i:m oc y — ( Peptide 2 )—  NHFm oc
HO HO
T B T U ,0 °C 
various so lven ts
DCC, DMAP, 
DCM, 0  °C
\  PG
f Peptide 1 )— NHFt
PG
:m oc
V ~ ( Peptide 2 )— NHFirm oc
Scheme 1.14 -  Functionalization of peptide C-termini with olefinic moieties
The two functionalized peptides can now be subjected to metathesis conditions, yielding 
a longer peptide that contains a non-natural linker and exhibits non-natural directionality 
(Scheme 1.15). With the exception of one example which yields below 5%, the ROCM 
reactions yield between 30% and 83% with stereoselectivity of approximately 2:3 E:Z.
PG PG
Peptide 1 )— NHFmoc Peptide 1 ")— NHFm oc
5 mol% HG, DCM
Fj>G
Peptide 2  ]— NHFmoc
reflux PG
^ — ( Peptide 2  ]—  NHFmoc
Scheme 1.15 -  Ligation via ring opening cross-metathesis
1.4 -  Metathesis
1.4.1 - Introduction
Metathesis has had a huge impact on organic chemistry. This is largely because of the 
technique’s generality. Its history, especially the elucidation of the mechanism, is very 
interesting, however is outside the scope of current discussion. Grubbs, metathesis 
pioneer and Nobel laureate, has written an excellent historical review on the subject.41 
Metathesis essentially cleaves carbon-carbon double bonds and rejoins them, as shown in 
Scheme 1.16.
M etathesis
Catalyst
Scheme 1.16 -  Olefin metathesis
It relies on a catalytic species, the most frequently used catalysts being ruthenium 
alkylidenes. Schrock catalysts, usually arylimido complexes of molybdenum, are also 
used, exhibiting much greater activity at the expense of water and air sensitivity. The 
ruthenium alkylidene complexes can be weighed out on the bench and so are particularly 
easy to use. Metathesis is reversible, and thus an equilibrium between starting materials
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and products exists in a typical reaction. However, frequently one of the products is 
ethene which, being volatile, is removed from the reaction mixture thus driving the 
equilibrium to completion. Metathesis is not restricted to terminal olefins, and in such 
cases, which are outside the scope of this discussion, it is possible that no volatile by­
product is lost. In this case the equilibrium is not driven towards the products in the same 
way as with terminal olefins.
Examples of the ruthenium alkylidene species responsible for metathesis are the Grubbs 
first generation catalyst (GI), the second-generation catalyst (GII)42 or the 
Hoyveda-Grubbs catalyst (HG),43 shown in Figure 1.1. The catalytic mechanism first 
involves the dissociation of one of the ligands. The presence of the cyclic bis-amino 
carbene species was intended to stabilize the resultant intermediate.44 Indeed, G II and 
HG have greater stability and activity, capable of involving electron-deficient olefins 
such as acrylic acid derivatives in cross metatheses.45 HG contains a chelating ligand in 
place of a phosphine, a feature that results in enhanced stability to chromatography and 
thus greater potential for recovery. Furthermore, the phenyl ring can be substituted in 
such a way as to fine-tune reactivity.
ci*
GI
f a-Ru^\
PCy3
GII HG
c 6h 5
M es
Cl*
.vCI Ru=\
PCy3
Mes" M es
Figure 1.1- Commercially available ruthenium metathesis catalysts
The mechanism for G II (Scheme 1.17) involves the empty coordination site left by the 
phosphine being replaced by a q2 coordinated olefin. Next a 2+2 cycloaddition occurs, 
forming a metallocyclic intermediate with conservation of ruthenium’s oxidation state. 
This process can be reversed either back to the original q2 coordinated ruthenium 
complex, or a new olefin is generated, resulting from exchange of alkylidenes. The 
reversibility of these key steps leads to, essentially, a ‘scrambling’ of alkylidenes. From
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the symmetry of the mechanistic Scheme 1.17 one can see how, in the presence of mixed 
olefins, the process occurs. Any olefin, which is free to coordinate to the ruthenium, can 
be split and re-joined.
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Scheme 1.17 -  The catalytic cycle of metathesis
1.4.2 -  Ring-Closing Metathesis and Ring-Opening Metathesis Polymerisation 
Perhaps the most widely applied class of metathesis is ring-closing metathesis (RCM), i.e. 
metathesis involving the intramolecular cyclisation of two alkenes. In the reaction of two 
terminal olefins, the release of ethene as a gas in this process is entropically favourable. 
In essence, two molecules, one of them gaseous, are generated from one. As early as 
1996 this was being used as a key step in total syntheses, for the example in the 
generation of a 12-membered ring in the enantiomerically pure total synthesis of 
Lasiodiplodin,46 as shown in Scheme 1.18.
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OMe O
6  mol% GI, 
DCM, RT
OM e O
MeO'
94%
OM e O
H2, Pd/C
EtOH, RT
MeO'
94%
Scheme 1.18- Employment of RCM in the total synthesis of Lasiodiplodin
If a number of rings are subjected to metathesis conditions, they can open and polymerize 
in a process termed ring-opening metathesis polymerisation (ROMP). Any ring strain in 
the precursor will render the process enthalpically favourable, and as an ethene molecule 
is generated per reactant molecule, the process remains entropically favoured. The 
process is illustrated with an early example of the polymerization of functionalized
cyclo-octenes by Grubbs utilizing a ruthenium alkylidene complex (Scheme 1.19).47
25°C , various solvents
Scheme 1.19- ROMP of a cyclooctene
More recently, ROMP polymers bearing amino-acid groups have been synthesized from 
the metathesis of strained cyclobutene-glycine derivatives using the 3rd generation 
Grubbs catalyst,48 which shall not be discussed in detail here.
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1.4.3 -  Cross Metathesis
Far less developed than RCM and ROMP is cross-metathesis (CM), i.e. metathesis 
between two olefins contained in different molecules. In the case of the molecules being 
the same, the reaction is referred to as a self cross-metathesis or homodimerization. In 
this thesis the terms homodimerization and self cross-metathesis will be used to 
distinguish these processes from cross-metathesis, i.e. the metathesis between two 
different olefins. Scheme 1.20 shows the reaction between two olefins of similar 
reactivities yielding a statistical mixture of products.
r 2
Scheme 1.20 -  Cross metathesis reaction performed in the presence of a Grubbs catalyst.
Of course, this would be far from ideal in a synthetic context in which a single product is 
usually required. Changing relative equivalents of starting materials naturally can provide 
a method for improving the product distribution. This is inefficient; however reasonable 
selectivity can be achieved by using olefins of different reactivities. It possible to obtain 
high yields of a single product in the metathesis of appropriate olefin combinations. In a 
review dedicated to the issue of selectivity in cross-metathesis, Chatteijee et al. 49 define 
the key factor in predicting of the outcome of a cross-metathesis to be the ability of each 
olefin to homodimerize. Olefins can be divided into those that undergo rapid 
homodimerization (Type I), those which homodimerize slowly (Type II), those that do 
not homodimerize (Type III) and those that are not involved in any metathesis events 
(Type IV). If the two olefins required for cross-metathesis undergo metathesis and are 
from different groups, selective cross-metathesis can occur. This is illustrated in 
Scheme 1.21. Reaction A represents homodimerization of the reactive olefin; B the 
reaction of the resultant homodimer with the unreactive olefin; C the significantly slower 
homodimerization of the unreactive olefin; and D the reaction of the CM product with the 
unreactive olefin. C and D do not occur because they produce the less favoured
R2' ^ ^
+
r 2 25%
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homodimer, and thus the primary product is the desired cross-metathesis product. It has 
actually been proposed that the reason for less-reactive olefins to not undergo 
homodimerization is their inability to form an alkylidene complex with ruthenium.
A +    R’ ^  ^
B R2^  + + ^ R’
c r2^ ^  + r2^ ^  — *—
R2/ : : ' ':  + ^  R2 — ^
Scheme 1.21 -  Metathesis reactions performed in the presence of a Grubbs catalyst. Ri ^ R2, 
Reactivity = CH2CHRi > CH2CHR2
There are a large number of examples of successful cross metatheses in the literature; 
indeed, a good overview is given in the cross-metathesis chapter of the Handbook o f 
Metathesis.50 One particularly high-yielding example is given in Scheme 1.22.
Scheme 1.22 -  CM between olefins of different reactivity
It has been suggested that a, P-un saturated carbonyls are very slow to undergo 
homodimerization due to the instability of the a, P-un saturated alkylidene intermediate,51 
shown in Figure 1.2.
Cl".... Bi
O
Figure 1.2 -  a,P-unsaturated alkylidine
31
This is consistent with the finding that homodimerization of a,p-unsaturated amides 
requires a slightly modified version of G II52 (Figure 1.3). The double bond presumably 
renders the A-heterocyclic carbene more electron rich, and this in turn can donate more to 
the ruthenium centre which affords the alkylidene intermediate greater stability.
Figure 1.3 -  Modified GII
The further selectivity issue, common to all metathesis reactions, is cis-trans selectivity. 
In many cases of RCM reactions which produce five or six membered rings, only one 
geometry is possible. When ring sizes get much larger, however, the reaction often yields 
mixed geometries. In these cases, and for ROMP and CM reactions, the geometric 
outcome is dictated by thermodynamics. For example, cross-metathesis reactions 
involving initial loss of ethene afford products which continue interconverting, as long as 
they are in the presence of the catalyst. Therefore the thermodynamically favoured trans 
isomer is produced in greatest yield. Indeed in many cases of cross-metathesis the trans 
product is favoured, although often there is also a small accompanying yield of the cis 
product.
1.5 -  Metathesis as a Tool in Chemical Biology
1.5.1 — Peptidomimetics via RCM
Perhaps of more relevance to this project are instances of metathesis used as a tool in 
peptide chemistry; and, indeed, such examples frequently occur in the literature. A few of 
the more relevant examples will now be considered. Often the metatheses are performed 
on-resin, a feature that makes the removal of ruthenium impurities facile.
f = \
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Often the olefin moiety is used to afford a natural peptide greater metabolic stability by 
replacing a native feature such as a disulfide or hydrogen bond. RCM, with its entropic 
diving force, is an elegant means by which to achieve this. a-Helix mimics, for example, 
can be prepared by an on-resin RCM with HG53 (Scheme 1.23). The precursors are 
simply synthesized using standard techniques and thus this may offer a simple route to 
robust a-helix analogues. This methodology has also been shown to be enhanced by use 
of microwave irradiation to effect the union of less reactive alkenes,54 such as those 
bearing amino acids with tert-butyl protection.
O f
3
(i) 15-25%  mol% HG, 
DCE, 6 0  °C
(ii) Et3 N, MeOH, THF
OMe
HN
HN-
R
50-90%
HN
Scheme 1.23 -  a-Helix mimic prepared by RCM
Additionally, RCM has been used in the preparation of cyclic peptides with improved 
biological properties.55 Olefins are easily incorporated into peptide side-chains in the 
form of allyl glycine. The cyclic hexapeptide cyclo(D-Phe-L-Allgly-L-Pro-D-Phe-L- 
Allgly-L-Pro)cyclo(2-5) has been synthesized by an RCM with GI on resin prior to 
cleavage and cyclization (Scheme 1.24).
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BocHI
5 mol% GI, 
DCM, 40  °C
HN
BocHI
(i) TFA, DCM
(ii) HF, an isole  0  °C
(iii) HBTU, HOBt, 
DIPEA, DMF
Scheme 1.24 -  Synthesis of cyclic peptide analogues via RCM
The bridging olefin affords the compound greater conformational restraint, a 
phenomenon that has been reported to result in a 10-100 fold increase in binding 
affinities of cyclohexapeptide Neurokinin A receptor antagonists upon introduction of a 
second ring via a lactam cyclization.56 Additionally, the reaction is trans selective, 
presumably due to the conformational restriction afforded by the small ring structure. 
Disulfide bridges between cysteine residues can achieve this, but have lower metabolic 
stability. The replacement of sulfur-containing bridging groups with more metabolically
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stable moieties via metathesis has also been used to synthesize modified portions of the 
lantibiotic nisin Z.57 This was carried out using alkyne RCM with a tungsten catalyst to 
generate carbon-carbon triple bonds in place of sulfide bridges, in the solution phase. 
Scheme 1.25 shows the synthesis of one portion mimic as an example.
S P P S , C leavage
BocHI
>Me
13 mol%
(tB u 0 3 )3 W =C *B u  
T oluene 80  °C
NH
Me
BocHI
Scheme 1.25 -  Synthesis of a portion of a Nisin Z analogue. Ri = C(CH3)CH2CH3;
R2 = CH2C(CH3) 2
More recently a modified lantibiotic was synthesized by solid phase peptide synthesis 
with three sequential RCM steps,58 on resin with G II (Scheme 1.26). In this example, an 
alkenyl group replaces the thioether.
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(i) 20  mol% GII, DCM, 40°C
(ii) DMSO
FmocHN,
'NH
PmcHN
S u b seq u en t S P P S  
, and RCM ste p s
Peptide A nalogue
Scheme 1.26 -  The first RCM in the synthesis of a tricyclic peptide. E/Z ratio not quoted
Cleavage yielded the desired analogue, however biological screening revealed the 
replacement of sulfide bridges with alkenes to be, in this case, deleterious. In contrast, 
when the disulfide bridge is replaced with an alkenyl group in the production of Oxytocin 
analogues,59 the compound shows reduced, but still high, activity combined with a 
markedly increased half-life. This difference in activity is presumably due to the closer 
resemblance of the olefin moiety to the disulfide group than to the sulfide.
Noteworthy is the use of a similar on-resin RCM simply to produce a cyclic peptide. 
Schmiedeberg et al. report a synthesis of particular interest as it involves a cyclic 10-mer
NH
HN=^
NHPm c
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involving no proline residues.60 Until that time RCM-synthesized cyclic peptides always 
contained proline. Their poor yields could be significantly improved by introduction of a 
pseudoproline in a serine position (Scheme 1.27).
PG HN— ( Peptide
(i) GII, DCM, reflux, >90%
(ii) DCM, AcOH, A cetic acid, TFE
(iii) Pd/C , H2
H2 N— ( Peptide Ser~{ Peptide )— OH
2 3  56-84%
Scheme 1.27 -  RCM in peptides containing no proline residues
Solution phase RCM has been used to generate 16-membered peptidomimetics of the 
cyclic tetrapeptide Apicidin A in an analogous manner to equivalent on-resin 
cyclizations.61
These few examples highlight the applicability of metathesis with ruthenium catalysts in 
the presence of a wide range of functional groups. Increasing use of water soluble 
ruthenium precatalysts derived from functionalized GII to effect aqueous metathesis62-64 
indicates that the future of this area may well rely on aqueous-phase reactions and non­
protected peptides. For this to work in peptide chemistry, cysteine and lysine residues 
will always require protection as they are known to poison Grubbs catalysts.
1 .5 .2 - Peptide Modification via CM
So far the examples we have seen have been RCM. We shall now turn to the applications 
of CM in peptide chemistry. CM was first used on protected amino acids by Gibson et al. 
using GI.65 A number of differently protected homoallyl glycines were reacted, variously,
Peptide ) — Q
37
with styrene, hex-l-ene, and oct-1 -ene, yielding in all cases homodimerization products 
in addition to the desired CM products in yields ranging from 52-66% (Scheme 1.28).
RlHN.
2  equiv.
Scheme 1.28 -  CM functionalization of homoallyl glycine. Ri = Boc, Ac, Fmoc, Phth; R2 = Me, 
Bn, tBu, H; R3 = Ph, Bu, Hex.
X)R2
52-66%
This was not a particularly selective CM as the olefins have similar reactivity.49 It was, 
however, an early demonstration of CM in the presence of Boc and Fmoc protecting 
groups and a free carboxylic acid. Far more recently CM has been use in the preparation 
of exotic a-substituted a-methyl amino acids in a similar side-chain metathesis reaction 
between olefinic compounds and an a-alkenyl side-chain on the a-methyl amino acid.66 
A typical example is given in Scheme 1.29.
"in,,..
5  equiv.
CbzHN
0 2Me 5 mol% GII, to lu en e, 95°C
Pd/C, H;
'OpMe
CbzHN
48%
•illlin.
C 0 2Me
89%
Scheme 1.29 -  Synthesis of a-substituted a-methyl amino acids via CM
A logical development of such side-chain functionalizations would be the conjugation of 
amino acids to biomolecules such as sugars and fatty acids. Indeed Vemall et al. have 
achieved this using lysine and cysteine functionalized with an olefinic moiety, thus 
avoiding the use of expensive allyl and vinyl glycines.67 These were reacted with a fatty 
acid and a glucoside, both bearing an olefinic group, yielding cross products and 
homodimers (Scheme 1.30). The homodimers of functionalized cysteine are potential 
candidates for replacement of disulfide bridges.
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3 equiv. 
^ j N s ^ / C 0 2Me
0 ,2,8
0 ,2,8
20  mol% GII, DCM, reflux 4 5  - 69%BocHN'
BocHN'
3 equiv.
‘OBn20  mol% GII, 
DCM, reflux
'OBnBni
OBn
0 ,2,8
'OBnBni
OBn
3 3  - 65%BocHI
Scheme 1.30 -  CM Functionalization lysine with a fatty acid or a glucoside
Some excellent CM selectivity in similar amino acid-sugar couplings was demonstrated 
in the synthesis of C-linked ‘glyco’ amino acids,68 exotic building blocks for the 
synthesis of antifreeze glycoprotein analogues that ultimately replace a threonine derived 
ether linkage with an aliphatic carbon chain of variable length (Scheme 1.31).
39
.OH
HO/
1- 3'
Mimic
.OH
AcHN
Scheme 1.31 -  Saturated hydrocarbon mimic of glycosyl linkage
High yields were obtained for two metatheses (Scheme 1.32), however one proved 
problematic. It has been suggested that steric crowding is responsible for the lack of 
reaction in this example. In addition the oxygen atom in this case may chelate to the 
ruthenium, forming an inert metallocarbene, thus removing the catalyst from equilibrium. 
A more extensive study of CM generated glycosyl amino acids has dealt with selectivity 
in this reaction, and the results show that its success is dependant on the number of 
methylenes separating the olefin from both the glycoside and the amino acid.69
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20 mol% GII, 
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Scheme 1.32 -  C-Linked glycoprotein analogues obtained by CM.
Various glycosphingolipid analogues have been synthesized by CM.70 These proceed via 
a very selective CM using GII between an appropriate glycoside and various terminal 
olefins, the minimum yield being 76% (Scheme 1.33). It is worth highlighting that this 
reaction was an example of complete trans selectivity in most cases.
„OPiv
NHFm oc P ivn  -O P iv
3 mol % GII, DCM, reflux
Piv
1.4 equiv.
NHFm oc
OPMB OPiv OPMB
Scheme 1.33 -  Synthesis of glycosphingolipids via CM. R = C5Hn, C7Hi5, C13H2 7, Ci5H31
When a CM between the glycoside and an ethylene glycol derivative (Figure 1.4) was 
attempted, no product was obtained; the explanation given was the possible production of 
chelated metallocarbene intermediates.
Figure 1.4
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Interestingly, this problem has been overcome in the selective cross-metathesis between 
an adenosyl derivative and an olefinic six-carbon amino acid by switching to HG, 
affording impressive yields of 51%-77%.71 This methodology seeks to prepare 
adenosylhomocysteine analogues and is, incidentally, another good example of the 
olefinic moiety replacing a sulfur-containing bridge (Scheme 1.34).
Mimic
NH.
Scheme 1.34 -  CM side-chain functionalization to mimic a sulfur-containing group.
A = Adenine
Continuing the discussion of CM couplings to amino acids, phenylalanine and a 
macrocyclic lactam have been joined via CM,72 the idea being to develop the utility of 
macrocyclic lactams as scaffolds for peptidomimetics (Scheme 1.35). The CM product 
yield was only 48%, 45% of phenylalanine-derived material was isolated, however no 
macrocyclic lactam homodimer was observed. Cis : trans selectivity was 1:1.2. This 
example, despite not exhibiting great selectivity, highlights the potential of CM to 
generate interesting biologically inspired structures -  the homodimer side products being 
of interest.
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2  equiv.
1 equiv.
5 moll% GII 
CHCI3 , reflux
BocHI
48%
BocHI
NH Boc
45%
Scheme 1.35 -  Synthesis of phenylalanine-macrocyclic lactam conjugate
On-resin CM has also been successful in the synthesis of functionalized p-lactams 
(Scheme 1.36).
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5  equiv.
5 mol% GII, DCM,
TFA, DCM
Scheme 1.36 -  CM synthesis of functionalized p-lactams
Although this allows impurities to be simply washed away, in a typical CM five 
equivalents of non resin-bound olefin are used, and this is repeated a second time. The 
CM yields are fair (38-78% isolated), but this is only of any use if the excess olefin is 
cheap and readily available as ten equivalents are used. In this study the olefin was cheap, 
and the idea was to generate libraries of P-lactam derivatives.
In summary, metathesis, with its selectivity and mild reaction conditions, is a very good 
candidate for the modification of peptides and peptide mimetics. Indeed it has been 
widely used already, mostly for the generation of peptidomimetic structures by 
replacement of metabolically unstable structural features with non-natural structures 
which exhibit improved metabolic stability. Approaches appear to fall into two broad 
categories, RCM reactions which are typically performed on-resin, and CM 
functionalization of amino acids, which are more commonly used to provide a modified 
side chain.
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1.6 -  Crambin, a Small Hydrophobic Plant Protein
In order to investigate the utility of novel protocols for the chemical synthesis of proteins, 
the target protein should ideally be accessible by SPPS and well understood in terms of 
structure and folding. This allows for the effect of synthetic modifications to be 
effectively assessed. The plant protein Crambin is an ideal candidate.
Crambin is a hydrophobic protein 46 amino acids in length, first isolated from the seeds 
of the Abyssinian cabbage in 1965. Its primary structure has been determined by 
digestion and subsequent solid-phase Edmann degradation,74 and it was found that it bore 
structural homology with plant toxins viscotoxin and purothionin. Crambin is non-toxic, 
possibly owing to its relative hydrophobicity, which may prevent it reaching the site of 
toxicity. Crambin could therefore be thought of as a ‘cellular appendix,’ although it is 
possible that its function has simply not been identified yet. It has also been established 
that Crambin exists in two forms in nature, one exhibiting Ser[22] and fle[25] (SI form), 
the other Pro[22] and Leu[25] (PL form) (Figure 1.5).
SI form Crambin
T h r - T h r - C y s - C y s - P r o - S e r - I l e - V a l - A l a - A r g - S e r - A s n - P h e - A s n - V a l -  
C y s - A r g - L e u - P r o - G l y - T h r - S e r - G l u - A l a - I l e - C y s - A l a - T h r - T y r - T h r -  
G l y - C y s - l i e - I l e - I l e - P r o - G l y - A l a - T h r - C y s - P r o - G l y - A s p - T y r - A l a -  
A s n
PL form Crambin
T h r - T h r - C y s - C y s - P r o - S e r - I l e - V a l - A l a - A r g - S e r - A s n - P h e - A s n - V a l -  
C y s - A r g - L e u - P r o - G l y - T h r - P r o - G l u - A l a - L e u - C y s - A l a - T h r - T y r - T h r -  
G l y - C y s - l i e - I l e - I l e - P r o - G l y - A l a - T h r - C y s - P r o - G l y - A s p - T y r - A l a -  
A s n
Figure 1.5
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These forms have been physically separated and crystal structures obtained, 7 5 showing 
the protein to include three disulfide bridges and consist of two a-helices and a (3-sheet 
(Figure 1.6). Other regions constitute alternative turn-like structures.
T h r - T h r - C y s - C y s - P r o - S e r l l e - V a l - A l a - A r g - S e r - A s n - P h e - A s n - V a l -
C y s - A r g - L e u - P r o - G l y - T h r - P r o - G l u - A l a - L e u - C y s - A l a - T h r - T y r - T h r -
Gly-Cys-Ile-Ile-Ile-Pro-Gly-Ala-Thr-Cye-Pro-Gly-Asp-Tyr-Ala- 
A s n
Figure 1.6 -  The 3-D structure of Crambin and its amino acid sequence. Regions of a-helix are 
shown in blue; regions of |3-sheet are shown in pink
The structure of Crambin has been probed by x-ray diffraction, 7 5 ' 7 7  NMR , 7 8 -8 1  circular 
dichroism , 8 2 8 3 Raman spectroscopy8 4  and sulfur atom scattering. 8 5  Molecular dynamics8 6
8*7and Monte-Carlo techniques have been employed to study its folding. Data obtained 
from a synthetic Crambin analogue could therefore be compared to the extensive 
literature, and it would thus be possible to accurately determine the effect the inclusion of 
the non-natural linker has on its structure.
46
Two chemical syntheses have been reported, both by the Kent group, and are especially 
worthy of discussion as they provide excellent examples of the use of NCL and related 
strategies. The first approach initially sought to prepare the protein by NCL between two 
peptide segments.88 Two strategies were investigated, ligation between the 
Cram[1-31 ]athioester and Cram[Cys32-46] in the synthesis of the SI form; and between 
the Cram[ 1 -15]athioester and Cram[Cys 16-46] in the case of the PL form. Residue 15 
happens to be valine and so, due to the anticipated difficulty of achieving NCL at a 
Val-Cys junction, the sterically encumbered valine was substituted for alanine. Peptides 
were synthesized using solid phase techniques and a Boc-protection approach.
There was a serious issue with purification in the synthesis of both the 
Cram[ 1 -31 l^hioester and Cram[Cys 16-46] resulting from deletion sequences eluting very 
close to the product. This resulted in unfavourable isolated yields in the case of 
Cram[Cys 16-46], 4.7%. When optimization failed to provide a solution to this issue, a 
three segment ligation approach was used (Scheme 1.37).
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56% 49% 49%
lAcm
( Cram[1-15] Cram[16-31] C ram [32-46])
SR
NCL
46%  I Rem oval of Acm
Cram[16-31]
H2N
Cramf32-461 )
SH
70% NCL
( Cram[1-15]
O
,SH q
\ — f  Cram[16-31]1—
NH -------------------------- NH
80%
Cramr32-461 )
Folding SH
PL Crambin
Scheme 1.37 -  3-segment approach to the chemical synthesis of Crambin
The linear peptide was characterised by electrospray MS, and after folding the mass 
change was consistent with the formation of disulfide bonds. Circular dichroism and 
NMR data were compared with the literature and thus the structure was confirmed to be 
identical to that of Crambin isolated from the Abyssinian cabbage. The overall yield was 
-25%.
The second synthesis built upon this methodology in the development of a one-pot total 
synthesis of Crambin.89 Use of the Acm protecting group on the Cram[16-31] segment is 
problematic in a one-pot approach as the second NCL works significantly better when the 
deprotected Cram[ 16-46] is purified. Replacement of Cys[16] with the l,3-thiazolidine-4- 
carboxo group allowed for generation of the N-terminal cysteine and resulted in a crude 
mixture amenable to the second ligation, and thus potential for use in a one-pot approach 
(Scheme 1.38).
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o
Cram[16-31])— ^
Cramf32-4611
MeO-NH3CI
>_^ ) — ( Cram[16-31])— ^
Cramf32^611
SH
Scheme 1.38 -  Alternative cysteine-protection approach
The perfected one-pot protocol allowed for generation of Crambin in an improved overall 
yield of ^40%, in less than a quarter of the time taken for the previous synthesis.
In conclusion, Crambin is an excellent choice for investigating the applicability of novel 
synthetic peptide-modification protocols. Its structure has been extensively studied and 
has a small size, and so the SPPS steps promise to be reasonably straightforward. Indeed 
work synthesizing Crambin by the Kent group using a Boc-protection approach has been 
fruitful.
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Chapter 2 -  Novel Synthetic Ligation -  Results and Discussion
2 .1 -  Introduction
2.1.1 — Overview
The main aim of the project was to examine the possibility of using metathesis to ligate 
two peptide fragments in a ‘semisynthetic’ manner, analogous to the various reported 
ligation methods described in Chapter 1 (Scheme 2.1).
M etathesis
Ethene
Scheme 2.1 -  Proposed ligation method based on metathesis
The metathesis reaction is attractive in this context due to its high functional group 
tolerance and, as has been discussed, it has been used for a number of applications in the 
field of peptide chemistry. Furthermore, native peptides possess no olefinic groups. As 
any ligation strategy relying on metathesis would generate an olefin, the potential would 
exist for site-specific attachment of one of any number of functional motifs to a protein 
via an olefin-specific reaction. Thus the application of metathesis to the ligation of 
peptide fragments in the synthesis of proteins would allow for manipulation of their 
finely tuned biological specificity in the development of new functional materials.
The success of metathesis as a means of peptide ligation relied on two important factors: 
the viability of olefin incorporation at peptide C- and A-termini, and chemoselectivity in 
the CM between these olefin-functionalized peptides. Peptide chemistry is very costly, 
and therefore it is imperative that the reaction is as chemoselective as possible, 
minimising wasteful homodimerization and maintaining the inherent directionality of 
peptides. At this juncture it is worth acknowledging that peptide homodimerization
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products have potential in areas such as the synthesis of unnatural functional peptides, but 
as they will have lost the A—>C directionality, they are therefore not of interest for protein 
semisynthesis, and thus this discussion.
2.1.2 -  Selection o f Appropriate Olefins for Initial Investigation
The selectivity rules defined by Chatteijee et al.49 are based upon the ability of olefins to 
undergo homodimerization, as described in Section 1.4.3. a,p-Unsaturated carbonyls are 
electron poor and hence undergo homodimerization sufficiently slowly to be considered 
as good partners with, for example, allylamines. Thus if two different peptides could be 
functionalized with these groups, one could expect a CM between them to be 
chemoselective (Scheme 2.2).
M etathesis 
- E thene
Scheme 2.2 -  Chemoselective cross metathesis of peptides
Access to the a,|3-unsaturated carbonyl functionalized peptide promised to be compatible 
with peptide chemistry, inasmuch as standard peptide coupling conditions with acrylic 
acid could potentially be used (Scheme 2.3).
HOBt, EDC, DIPEA
Scheme 2.3 -  Functionalization of a peptide A-terminus with acrylic acid
51
This, of course, would generate an acrylamide, which is a type II olefin, at the Af-terminus 
of a peptide. At this point, the easiest way to functionalize the C-terminus with a more 
reactive type I olefin would be to couple it with allylamine using standard peptide 
coupling conditions (Scheme 2.4).
HOBt, EDC, DIPEA
Scheme 2.4 -  Functionalization of a peptide C-terminus with allyl amine
The report by Chatteijee et al.49 of an efficient cross metathesis of acrylamide 1 and a 
terminal olefin moiety (Scheme 2.5) provided good evidence to support the proposed 
cross metathesis. It is important to note that this reaction employed a small excess of the 
type I olefin and yet proceeded in good yield and with good selectivity. These are 
important factors for application of this type of methodology to peptide and protein 
synthesis.
1 equiv. 1.2 equiv.
OTBS 5 mol% Gil,
DCM, reflux
OTBS
71% , >20:1 E/Z
Scheme 2.5 -  Selective CM involving an acrylamido group49
2.2 -  Establishment o f  a CM Ligation Protocol
2.2.1 -  Attempt using an Allyl Amine Functionalized Substrate
Initially the establishment of a successful protocol for metathesis employing single amino 
acids was sought. Such an approach would require appropriate protecting groups at either 
the C-terminus or the jV-terminus, depending on which position was to be functionalized 
/V-acyl protected amino-acids and C-terminal esters were utilised as protecting groups.
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The amino acid chosen for TV-functionalization was glycine ethyl ester 2, and in order to 
emulate as closely as possible the structure of acrylamide 1 in the above example 
(Scheme 2.4), methacrylic acid was used. Functionalization proceeded smoothly giving 
the required derivative 3 in an excellent 97% yield (Scheme 2.6).
OEt HOBt, EDC, DIPEA
OH
OEt
97%
Scheme 2.6 -  Synthesis of 3
Similar conditions were used in the functionalization of N-acyl phenylalanine (4) with 
allylamine to provide a partner for CM, giving 5 in 75% yield (Scheme 2.7).
o
OHN
H
O
4
HOBt, EDC, DIPEA
H2N"
O
75%5
Scheme 2.7 -  Synthesis of 5
CM was now attempted between 3 and 5 (Scheme 2.8). The initial conditions investigated 
were based on those frequently reported in the literature;50 5 mole per cent HG was used 
in refluxing DCM.
o
N
H5 o
Et<
5 mol% HG, DCM, 
reflux, 39  h
*
3 O
Scheme 2.8 -  Attempted CM between 3 and 5
o
N
H
6
OEt
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Unfortunately, 6 was not isolated; starting material 3 was recovered impure, and the 
isomerised product 7 was obtained in 94% (Scheme 2.9) as an inseparable mixture of 
geometric isomers (Cis: trans, 22:25).
5 mol% HG, DCM, 
reflux, 20  h
Scheme 2.9 -  Rearrangement of allyl amide moiety. Cis: trans, 22:25
This phenomenon had been reported45 and this type of ruthenium catalysed isomerisation 
has been used beneficially in certain studies.90,91 Moreover, Steinke and co-workers had 
studied the effect of various additives on the isomerisation, finding that monophenyl 
phosphoester (Figure 2.1) can act as a suppressant.92 An investigation into the application 
of this modified protocol was considered, however it was decided to vary the olefinic 
amine instead, and thus hopefully avoid this rearrangement process.
o
II.^FV-'OH 
Phcr n o h
Figure 2.1 -  Monophenyl phosphoester
More recently a paper had reported a similar rearrangement the allyl amide 8 in a study 
on the homodimerization of amino-acid allyl- and homoallyl-amides using 10 mol% GI 
in DCM at RT (Scheme 2.10).93
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10 mol% Gl, DCM, RT
50%
26%
Scheme 2.10 -  Attempted homodimerization of BocPhe allyl amine derivative by Miller et al
The paper also reports the homodimerization of homoallyl amide 11 (Scheme 2.11) 
which apparently proceeds without rearrangement.
10 mol% Gl, DCM, RT
77%
Scheme 2.11 -  Homodimerization of homoallyl amine derivative by Miller et al
Homoallylamine-functionalized substrates were an attractive prospect as rearrangement 
in subsequent metathesis would be avoided, but we decided first to investigate an 
iV-methyl allylamine functionalized substrate.
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2.2.2 -  Attempts using an N-Methyl Allylamine Functionalized Substrate 
Metathesis reactions involving /V-protected allyl amides have been described in the 
literature and of particular relevance were the RCM reactions of /V-methyl allyl amides. 
An example is given in Scheme 2.12.94~96
10 mol% Gl,
DCM, RT
47%
Scheme 2.12 -  RCM of an /V-methyl allyl amide!
Moreover, an example of successful CM of a /V-methyl allyl carbamate has been 
reported.97 CM of the analogous /V-methyl substrate therefore appeared worthy of 
investigation and so 4 was functionalized with /V-methyl allylamine yielding 13 in 86% 
yield (Scheme 2.13).
o
OHN
H
HOBt, EDC, DIPEA
13
N
H
Scheme 2.13 -  Synthesis of 13
The CM between 3 and 13 was now attempted using a variety of conditions; however no 
identifiable products were isolated (Scheme 2.14).
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HG, DCM 
Reflux for 39  h
+ X OEt
O
-OEt 14 o
Scheme 2.14 -  Attempted CM between 3 and 13
Initially, the metathesis utilized 20 mol% HG. After refluxing in DCM for 39 h, starting 
materials still appeared to be present. Separation of the resultant compounds and NMR 
analysis indicated that neither the cross metathesis nor the homodimerization of 13 had 
occurred. A substantial amount of 3 was recovered in an impure form. NMR spectra of all 
other isolated materials could not be assigned, and were not consistent with a CM product. 
Unfortunately this was the case with all subsequent attempts to generate 14. These 
investigated the effect of higher temperatures using refluxing toluene and microwave 
irradiation, and the use of G II in place of HG. Furthermore, simple homodimerizations 
of 13 were attempted, with no success.
It was clear that 13 underwent no desired metathesis under these various conditions. It is 
possible that one of the ruthenium-13 Alkylidene complexes 15 or 16 is unstable due to 
steric constraints resulting from the A/-methyl group (Figure 2.2).
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15
ci
Figure 2.2 -  Alkylidene intermediates 15 and 16
This explanation is supported by the fact that that 7V-methyl allyl amides have been
Our inability to obtain the homodimer in the absence of 3 was further indicative of this 
argument. In conclusion, a different olefinic amine needed to be used for C-terminal 
olefin-incorporation.
2.2.3 -  Peptidomimetic Considerations
Potential structural implications of introducing metathesis-derived residual atoms into a 
peptide main-chain had to be considered. The product of a successful CM reaction 
between allylamine functionalized AcPhe, 5, or its methylated analogue, 13, with 3 
would comprise a resultant linker one less carbon in length than two amino acid residues 
(Figure 2.3).
shown to undergo metathesis, and yet no such homodimerizations have been reported.94-96
6
R O R O
Peptide.
Peptide
O R  O R
Figure 2.3. -  CM product 6 and native peptide. R = variable side chain.
If the ultimate goal of this methodology is to synthesize functioning peptides, a residual 
group one atom less than the length of two amino acids is potentially unfavourable. This 
is because there is a high probability that lengthening the amino acid chain will have a 
profound effect on the folding of the protein and thus an adverse effect on its function. 
Notwithstanding this, we were hoping such site-specific manipulation of main-chain 
length would provide a valuable tool for structural studies of proteins.
However, from the perspective of the development of a methodology for the ligation of 
peptides in order to produce functional peptides, as opposed to study structure and 
folding, the inclusion of a non-natural resultant linker was a potentially serious problem 
with the methodology. At this point it was decided to pursue a strategy which resulted in 
the replacement of two amino acids. The site of replacement, naturally, would require 
careful consideration so that this replacement itself has minimal effect on the folding of 
the peptide.
In light of this new approach, we were keen to investigate homoallylamine as a means of 
C-terminal olefin-functionalization. The inclusion of the additional CH2 group would 
yield a linker with the same number of bonds as two amino acids in the CM product 
(Scheme 2.15).
R
Peptide
O
HOBt, EDT, DIPEA
Peptide
Peptide
R
O R
Peptide
Peptide
O O R
Scheme 2.15 -  Proposed use of homoallyl amine in peptide ligation
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The linker in the product molecule is a good candidate for a peptidomimetic of two amino 
acids -  it has the same length* and lacks a single amide bond (Figure 2.4). We were 
further encouraged to see very similar peptidomimetic structures in the literature (see 
below) . 98'101
Peptide
Peptide
Peptide"
Mimic
V
O B
Peptide
Figure 2.4 -  Synthetic peptide mimic 17
This methodology therefore had the potential to provide access to much larger peptides, 
introduce a site bearing an olefin moiety which could be subsequently functionalized and 
selectively remove a single amide bond from a peptide chain. This third possibility was 
particularly interesting given recent work at the time by Kelly, who had used the Wittig 
reaction to introduce a trans carbon-carbon double bond into the peptide chain, replacing 
an amide bond.98 This approach was attractive as it mimicked the conformationally 
constrained amide bond by exact substitution with the olefin (Figure 2.5). They went on 
to show how removal of H-bonding ability in a single site of the Ab peptide inhibited the 
formation of fibrils or protofibrils in amyloidogenesis. More recently this inhibition effect 
has been compared to the corresponding ester peptidomimetic, and their toxicities
1 Q2investigated.
* Length of standard dipeptide is 7.27 A. The predicted length of linker based on measured bond lengths of 
simple organic molecules is 7.33 A. Standard bond lengths in peptide (A) -  Ca-C, 1.51; C-N, 1.32; N-Ca,
1.46. C=C bond length is 1.34 (ethene).
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Ph
Peptide''"
H
N. Peptide
Ph'
Mimic
O R
Peptide''"
Peptide
R O
Figure 2.5 -  Peptidomimetic reported by Kelly
Z-Fluoroalkene dipeptide isosteres are another example of a peptidomimetic in which 
there is exact substitution of an amide bond for a carbon-carbon double bond
Figure 2.6 -  Z-fluoroalkene dipeptide isostere"
The fluorine atom forms hydrogen-bonds in a similar manner to the carbonyl oxygen in 
the native structure, and so these structures potentially allow for a more faithful level of 
mimicry. The synthesis of GPR-54-agonistic pentapeptide analogue exhibiting a 
c/s-amide mimetic Zs-fluoroalkene moiety is a good example of the utility of such 
structures. 101 In this study the analogue was shown to have significantly decreased 
activity, and thus the importance of a specific trans amide bond in the native agonist 
could be inferred. The relationship between this isostere and the cis and trans amide 
bonds is shown in Figure 2.7.
(Figure 2.6) . " ' 100
Mimic
Ph
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Peptide' NH
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Figure 2.7 -  Relationship between the £-fluoroalkene and the amide bond
If our CM approach were to be used to generate peptidomimetic 17, it is worth noting that 
the inserted double bond would be shifted with respect to the native amide bond, in 
contrast to these examples. Furthermore the CM approach would yield no side-chain 
functionality. Our methodology however, by virtue of its convergent nature, allows for 
potential access to larger peptides than these examples, in which the modified portion is 
introduced into the peptide chain via simple linear SPPS techniques and are thus subject 
to their inherent restrictions.
Overall, the potential of the linker in 17 (Figure 2.3) to be used as a peptidomimetic 
provided a firm incentive to pursue an approach that utilized homoallyl amine in favour 
of investigating other classes of linkage or rearrangement-suppressing additives as 
described by Steinke et al.
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2 .2 .4 - Successful CM using a Homoallyl Amine Functionalized Substrate
2.2.4.1 -  Ligation o f AcPhe and PheOEt
The CM of homoallylamine functionalized substrates was examined. Homodimerization 
of C-homoallyl amide Boc amino-acids using G l has been reported,93 and does not suffer 
from rearrangement problems that have previously been discussed. Given that 
homodimerization is a key step in CM ,49 this was very encouraging. Furthermore we 
noted an example of successful RCM involving a homoallyl amide in the literature. 103 Of 
note was the ease of synthesis of the precursor, in this case 4 was functionalized with 
homoallylamine, generating 18 in 81% (Scheme 2.16).
o
OH
o4
HOBt, EDC, DIPEA
O
N
H
18
Scheme 2.16 -  Synthesis of 18
In addition to this a new /V-acryloyl amino acid, 19, was prepared in 35% yield by 
subjecting phenylalanine ethyl ester hydrochloride to acrylic acid in a standard peptide 
coupling (Scheme 2.17).
HOBt, EDC, DIPEA
Scheme 2.17 -  Synthesis of 19
Acrylic acid was chosen in place of methacrylic acid as it would simplify the resultant 
linker unit. From a peptidomimetic standpoint the methyl group in compound 3 was 
undesirable. Furthermore some excellent CM yields of acrylamides have been reported 
by the Grubbs group. 104
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18 and 19 were reacted in a 1:1 ratio, in refluxing DCM, with 5 mol% GII, and after 24 h 
a white precipitate had formed. The reaction mixture was purified directly using column 
chromatography on silica gel, yielding the CM product 20 in 61% (Scheme 2.18). This 
simple workup was used for all subsequent CM reactions.
NH
61%
5 mol% GII, 
DCM, reflux
HN
EtO.EtO.
Scheme 2.18 -  First successful CM
We were pleased to observe that the product was obtained as a single isomer, exhibiting a 
vicinal coupling of 15 Hz between olefinic protons, confirming it to be a trans double 
bond. In terms of peptidomimetics this was ideal as it installed a structural motif with a 
conformation closer to that of the native peptide than in the case of the cis isomer.
The reaction was repeated using a 1.2 equivalent excess of 18, and 7 mol% of GII, 
yielding an excellent 90% CM product. Additionally, in this case, a 15% yield1 of 
homodimer 21 was isolated (Figure 2.8), supporting the proposed CM mechanism, i.e. 
the reactive olefin dimerizing first, prior to reaction with the unreactive olefin. It must be 
stressed now, however, that homodimers were generally not isolated.
f Calculated from 1.2 equivalent excess of 18
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oN
H
21
Figure 2.8 -  Isolated homodimer
2.2A.2 -  Synthesis o f Additional Acryloyl Amino-Acid Species
In order to demonstrate the applicability of this reaction to the ligation of various amino 
acids, it was decided to generate a range of iV-acryloyl amino acid esters and attempt the 
CM of each with 18. The coupling of amino-acid esters to acrylic acid under peptide 
coupling conditions proved a very poor method of acryloylation, indeed serine methyl 
ester and cysteine ethyl ester could not be functionalized in this manner.
A paper by Bentolila et a l reports the use of 1.1 equivalents of acryloyl chloride, a 
commercial, stable reagent, as a means to accessing A-acryloyl amino acids. 105 It allowed 
simpler, more economical access to 19 for further studies (Scheme 2.19).
OEt
O
Et3 N, DCM
Cl
O
OEtN
H 78%
Scheme 2.19 -  Improved synthesis of 19
Esters of valine and proline were functionalized in a similar manner to phenylalanine 
ethyl ester generating 22 and 23, in yields of 54% and 72%, respectively (Scheme 2.20).
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Scheme 2.20 -  Synthesis of olefin substrates 22 and 23
2.2.4.3 -  Ligation o f AcPhe and ValOEt
CM between 18 and 22 was performed in refluxing DCM (Scheme 2.21). This reaction 
used a 1.1 excess of 18 and 6  mol% GII and yielded 42% 24 after 24 h.
NH
6  mol% GII, 
DCM, reflux
HN
Scheme 2.21 -  CM between 18 and 21
TLC analysis of limiting reagent, 22, was used to monitor the reaction and after 24 h it 
appeared that a small quantity of 22 persisted. This was attributed to the equilibrium 
between 2 2  and the starting material due to a small amount of ethene remaining in 
solution, and so the reaction was terminated. The CM was repeated using 10 mol% of 
GII. After 72 h 22 was still apparent by TLC, but the reaction was terminated and an 
improved yield of 55% was obtained. One possible explanation is that the catalyst has a 
limited lifespan under these conditions, and hence the prolonged reaction time was not 
beneficial i.e. the increase in yield could be solely attributed to the additional catalyst.
The lower general yield may be tentatively attributed to the steric bulk of the valine side 
chain, as this may lead to a high energetic barrier to complexation to the ruthenium prior 
to metallocycle formation. We noted that one of the requirements for optimal NCL of 
peptides is lack of (3-branching in the C-terminal amino acid . 17,33 Therefore such issues 
associated with the ligation of (3-branched amino acids were anticipated.
At this juncture, two successful CM ligation reactions had been achieved using homoallyl 
amine- and acryloyl chloride-functionalized amino-acids. This approach allows for the 
introduction of a dipeptide isostere in addition to effecting peptide ligation. We were 
keen to perform the reaction in the presence of a range of functional groups, and thus 
demonstrate a wider scope.
2.3 -  Demonstration of the Stereochemical Integrity of Ligated Amino-Acids
Given the initial success of the CM protocol, it was imperative to corroborate the 
stereochemical outcome of these reactions. Stereochemistry is an important factor in 
biological systems and if this methodology is to be applied to generating materials to 
probe biological systems then stereochemical integrity is likely to be an important factor. 
If the stereochemistry of one amino acid in a protein is inverted, it could result in loss of 
function, change of folding pattern, or, at the other extreme, it could have no observable 
effect. This provided a firm incentive to establish the conservation of stereochemistry 
throughout every class of reaction in the protocol.
2.3.1 -  The Issues Associated with Polarimetry
Polarimetry provides information with no use in the assignment of structure, or even the 
determination of whether or not any degree of racemization has occurred -  a zero 
measurement does not necessarily mean racemization has occurred, and any non-zero 
reading could result from any non-equal ratio of enantiomers. Optical rotation 
measurements were obtained for all amino acid derivatives (Table 2.1).
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Compound Solvent
Concentration 
(1  = 1 0  mg/ml)
(Xd
5 MeCN 1 .0 0 -0.47
13 MeCN 0.62 - 1 .2
18 MeCN 0.31 + 5.6
19 CDC13 0.24 + 134
22 CDCI3 1.24 + 19.7
23 MeCN 0.84 -54.0
Table 2.1
Although 5, 13 and 18 exhibited do values with low moduli, as has been stated this by no 
means suggested that the material had racemized, furthermore the higher moduli of the 
other compounds were not indicative of preservation of stereochemistry. Similarly, in the 
case of CM products, do values give no clue as to the diastereotopic weighting of the 
product mixture and if it is even a mixture at all. Interestingly establishing <Xd values for 
20, 21 and 24 proved difficult due to the presence of a red impurity presumably resulting 
from the ruthenium. In a latter case, no value could be obtained due to this impurity 
effectively blocking out light at the path length used. Given the fact the sole use of (Xd 
values is to provide a reference value, it was judged irresponsible to report them. A 
number of protocols for the removal of these highly coloured by-products have been 
published, 106'108 as has the report of a PEG-conjugated catalyst, 109 whose by-products are 
simply removed by aqueous workup, and a polymer immobilized catalyst. 110 These 
procedures were investigated, however were found to be of limited use in the purification 
of our CM products.
Given the fact that the CM of single amino acid derivatives is a model study, it was 
decided that these impurities could reasonably be ignored, especially as the proton and 
carbon NMR spectra were of good quality and exhibited no spurious peaks. It was also 
envisioned that when applied to large peptides there would be a lower concentration of
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ruthenium by-products by weight, as the molecular weight of the peptides involved is 
much greater.
2.3.2 -Analysis o f Stereochemistry o f CM Product 20
As the CM products have two chiral centres, racemization at either centre will result in 
diastereoi somers, which will differ in physical properties and thus be detected by NMR 
analysis. CM product 20 appeared to be a single diastereoisomer by TLC, and there was 
no evidence of diastereoisomers in the !H or 13C NMR spectra when the analysis was 
performed in cfe-DMSO. DMSO is viscous relative to many other common NMR solvents 
and this often results in peak broadening. In light of this NMR spectra were obtained in 
^4-MeOH at 500 MHz, and under these conditions diastereoisomers were very clearly 
visible.
It was necessary to ascertain where racemization had occurred. To this end, R-18 was 
prepared in the same manner as 18 using Ac-D-phenylalanine. Firstly, a mixture of the 
two independently synthesized enantiomers was examined by chiral HLPC in order to 
determine the chiral separation. The individual compounds were analysed, however were 
shown to have undergone, full racemization. In both cases both enantiomers were present 
in approximately equal amounts, determined by UV. Racemization occurred presumably 
via the oxazolone rearrangement discussed in the introduction (Scheme 2.22).
OH.0O
.0N
H
.0
LG
Scheme 2.22 -  Racemization of activated acetyl phenylalanine via the oxazolone
Given that 18 had been shown to have racemized prior to the metathesis step, the effect 
metathesis has on this centre cannot be determined. In order to determine the likelihood 
of racemization induced by the CM conditions, access to the non-racemic amino acid 
derivatives was required.
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2.3.3 -  Model Study Using a Boc-Protected Amino Acid
Boc-protected amino-acids were chosen for investigation as they are less susceptible to 
racemization than acetyl-protected derivatives. Indeed this factor, along with their facile 
deprotection, results in their widespread use in peptide-synthesis. Furthermore, given the 
frequent occurrence of Boc-protected amines in peptide chemistry we were keen to 
investigate their compatibility with metathesis.
Their greater stability to racemization results from two factors, firstly the steric bulk of 
the £Bu group, and secondly the electronics of the carbamate. The steric bulk of the lBu 
group makes the oxazolone formation unfavourable. The overlap between the lone pairs 
of the carbamate oxygen and the C=0 i t *  orbital is not significant due to difference in 
energy. Therefore the oxygen overall has a more inductive effect, polarising the a bond, 
and reducing the electron density around the carbonyl carbon atom. This in turn results in 
a more even distribution of n electrons in the carbonyl and therefore, despite the 
appropriate energy of the nitrogen lone pair for interaction with the C =0 7i* orbitals of 
the acetyl protected amine, it has a far less favourable overlap in the carbamate due to the 
higher energy of its C=0 n* orbital. 7r-Electron density has a much smaller coefficient on 
the oxygen in the carbamate. Therefore carbamates are far less prone to racemization via 
the oxazolone than amides.
Boc-protected phenylalanine was chosen for investigation, as its synthesis had been
QO
reported, and was C-functionalized in the same manner as its acetyl-protected 
counterpart, yielding I I  in 64% (Scheme 2.23).
HOBt, EDC, DIPEA
Scheme 2.23 -  Synthesis of 11
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CM between compounds 11 and 19 was chosen for this model study. The reaction was 
carried out using microwave irradiation (Scheme 2.24). The reaction time was greatly 
reduced, and a full discussion of the employment of microwave irradiation will be given 
in the following section (2.5). From this point on, CM reactions using convection heating 
will be referred to as such, likewise microwave enhanced reactions, to avoid ambiguity.
NH
N
H
O
GII, DCM, MW, 80  °C, 1 h
HN
EtO.-OEtN
H
O
Scheme 2.24 -  Microwave-enhanced CM
To evaluate the stereochemical outcome of the CM process, it was necessary to obtain all 
four diastereoisomers of 25. The appropriate functionalized amino acids were prepared 
from the enantiomerically pure Boc amino-acids and amino-acid esters as described 
previously. Enantiomerically pure Boc R-and 5-phenylalanine and 5-phenylalanine ethyl 
ester were obtained from commercial sources, whereas the /^-phenylalanine ethyl ester 
derivative, R-19 was synthesized in 32% yield by treatment of /^-phenylalanine with 
thionyl chloride in ethanol, and subsequent subjection of this crude product to 
acryloylation conditions as previously described (Scheme 2.25).
ci
.OH
EtOH
OEt
Et3N
crude u
O
N
OEt
32%
Scheme 2.25 -  Synthesis of R - 19
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The remaining diastereoisomers were synthesized by CM. Consistent with there being no 
racemization in the synthesis of the cross-metathesis product, enantiomers exhibited 
identical carbon NMR spectra, (RR identical to SS; SR identical to RS) whereas those of 
the diastereoisomers differed markedly. Figure 2.9 shows the four diastereoisomers, and 
typical 13C NMR shift differences (full 13C data given in Chapter 4).
4 1 . 5  4 1 . 0  4 0 . 5  4 0 . 0  3 9 . 5  3 9 . 5  38 . 5  3 3 . 5  3 7 . 5  3 ~ . 0  3 4 . 5  1 6 . 0  3 5 . 5  ppn
BocHNBocHN S
O O t \ O O * \
Ph Ph
OEt BocHN sBocHN R
§
Figure 2.9 -  Diastereoisomers of 27 and 13C NMR spectra
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It was thus confirmed that stereochemistry is conserved in this case and it is assumed that 
the stereochemical integrity is maintained in all cases.
2.4 -  Extension of Methodology using Convection Heating
2.4.1 -  Synthesis ofBoc Amino-Acid Derivatives
At this point there were two problems to be addressed. Firstly, synthesis of A-acryloyl 
amino acid esters had proved problematic. Secondly, the TV-acetyl phenylalanine 
derivative had been shown to have racemized. However the latter problem could be 
overcome by utilisation of the analogous Boc protected derivatives, and so it was decided 
to generate several Boc-protected C-terminal homoallyl amide substrates. Four 
compounds were synthesized according to Scheme 2.26 (Table 2.2).
HOBt, EDT, DIPEA
Scheme 2.26 -  Synthesis of C-terminal homoallyl amide species 26-29
Compound Amino Acid Yield/%
26 BocHis(Tos) 73
27 BocTyr(Bzl) 61
28 BocArg(diZ) 54
29 BocSer(Bzl) 46
Table 2.2
2 .4 .2 - Scope o f CM Ligation
A variety of CM reactions were now carried out, using a protocol involving refluxing 
DCM and 10 mol% GII (Scheme 2.27). It is fairly common for metathesis reactions to be 
carried out with relatively high catalyst loadings. In all cases a small excess of A-acryloyl 
amino acid was used, and this was monitored by TLC. The results are shown in Table 2.3.
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H II 10 m ol%  Gil,
---------------
BocAAi + AA2 DCM, reflux
Scheme 2.27 -  General CM reaction
Compound AAi a a 2 Yield
30 His(Tos) PheOEt 16
31 Arg(di-Z) PheOEt 70
32 Tyr(Bzl) PheOEt 67
33 Ser(Bzl) ProOMe 49
Table 2.3
NMR spectra of these products were consistent with a trans alkene ( Juans = 15 Hz).
31 and 32 were obtained in acceptable yield of 70% and 67% respectively. 30 and 33, on 
the other hand, were obtained in disappointing yields of 16% and 49% respectively which 
was deemed unacceptable as it falls within the realm of statistical CM reactions.
The synthesis of 30 was curious as both starting materials were still visible by TLC after 
48 h. This was in contrast to the expectation that the more reactive olefin would 
homodimerize rapidly. Indeed in analogous reactions we observed complete consumption 
of 31, 32 and 33 after a few hours, which is assumed to be via homodimerization. In the 
present case one possibility is that the catalyst is being poisoned or its activity 
significantly compromised, possibly by the tosyl-protected histidine moiety.
As both starting materials were present after 48 h, the reaction was terminated, and upon 
purification the CM product 32 was obtained in 16% yield. In order to determine whether 
the reaction was slow, due to the specific side-chain functionality, the reaction was 
carried out at reflux for 6  days. The isolated yield improved to 29% and further 
improvement to 36% was observed with an increase in catalyst loading (16 mol%) and a 
change to dichloromethane as solvent. It is hard to ascertain the nature of this apparent
BocAA
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deactivation process. It is possible that the His(Tos) side chain permanently deactivates 
the catalyst or competitively binds to ruthenium. It is interesting to note, however, that 
there is a literature report which describes the lack of reactivity of 26 with GI.93 Further 
investigation was judged unnecessary as this phenomenon was not observed in any other 
examples; on no occasion was any other reactive olefin isolated.
2.5 -  Microwave Enhancement and Optimization
2.5.1 -  Microwave-Enhanced Cross-Metathesis
Microwaves has been widely used in modem synthetic chemistry and in many cases has 
been reported to produce dramatic increases in the rate of reactions. 111 We noted that it 
has been reported to greatly increase the rate of both self cross-metathesis, 112 and 
selective cross-metathesis. 113
The effectiveness of a solvent in converting microwaves to heat can be measured by 
considering the ratio of the amount of input microwave energy that is lost to the sample 
as dissipated heat to the molecules ability to store electric charge. 114 Thus polar solvents 
such as dimethylformamide (DMF) and water heat rapidly under microwave conditions 
whereas solvents such as DCM interact very little with microwaves. The idea of a 
‘microwave effect’ is hotly contested, 115 and attempts have been made to rationalize 
unusual experimental observations. 116,117 It is possible that the rapidity of the reaction 
simply results from a combination of increased pressure and heat dissipated to the system 
by the irradiated solvent. Indeed, in the field of microwave-promoted metathesis, studies 
have both supported118 and contradicted119 this idea.
However irrespective of the detailed nature of the observed affects we decided to embark 
upon a study to determine the impact of microwave radiation on our metathesis protocol. 
Various conditions were attempted across a range of substrates in an effort to determine 
the effect of microwave irradiation and thus establish a good starting point for 
optimization (Scheme 2.28). Results are given in Table 2.4.
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Power 150 W
1.1 -1 .3  equiv. O
Scheme 2.28 -  Initial conditions for microwave-enhanced CM
Compound AAi AA2 T/°C Time Mol% GII Yield/%
25 BocPhe PheOEt 80 1 h 19 8 6
24 AcPhe ValOEt 90 2 x 15 min 9 55
20 AcPhe PheOEt 90 1 h 19 71
30 BocHis(Tos) PheOEt 90 2 x 15 min 19 41
32 BocTyr(Bzl) PheOEt 90 4 x 15 min 19 57
31 BocArg(diZ) PheOEt 90 1 h 17 43
33 BocSer(Bzl) ProOMe 60 2  h 11 35
Table 2.4
From these results, it appears that in most examples the yield has been diminished upon 
use of microwave conditions. It does, predictably, increase reaction rates significantly in 
all cases, and this alone was enough to prompt us to investigate the use of microwave 
irradiation further.
2.5.2 - Optimization
It was clear that a specific optimization study was required. The synthesis of 32 
(Scheme 2.29) was chosen for this as the yield under microwave irradiation was 10%, 
which gave plenty of opportunity for optimization. Results are shown in Table 2.5.
HN
NH
Gil, DCM, MW 1 h
MeO-
EtO
NH
Scheme 2.29 -  Optimized CM reaction
Mol(27)/
Mol(19)
Mol% GII
Temp
(°C)
Power
(W)
Yield
(%)
i 1.3 19 90 150 57
ii 1.3 18 80 150 55
iii 1.3 18 90 300 6 6
iv 0.83 26 90 300 61
V 1.3 18fl 90 300 36
vi 2 .1 2 0 90 300 52
vii 0.83 18* 90 300 58
viii 1.3 18 1 0 0 300 82
ix 1.3 18 1 1 0 300 59
X 1.3 18 1 0 0 n/ac 58
xi 1.3 18 95 n/ac 77
a  HG used. Catalyst added in 2 x 9 nmol portions. °  Used a different microwave unit without adjustable power.
Table 2.5
CM reactions were carried out for 30 minutes then degassed by bubbling argon through 
the reaction mixture for 30 seconds before further irradiation for 30 minutes. Degassing 
was employed to remove the ethene, which would otherwise remain in the sealed 
microwave vessel. For entry (ii), the experiment was monitored at 30 minute intervals
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and TLC analysis indicated that 19 persisted in the reaction mixture. From this study we 
decided on a protocol involving two periods of 30 minutes irradiation interjected with a 
brief period (30 seconds) of ‘degassing’ with argon.
This study showed that microwave power and the stoichiometric ratio of olefins had an 
effect on the yields. An increase in yield was obtained by increasing the power to 300 W, 
this was apparent from comparison of the results from entries (i) and (iii). The power 
should merely affect the rate at which the solvent attains the desired temperature, and 
therefore this effect on yield was unexpected. Given this observed increase in yield, 
however, 300 W was chosen for all subsequent microwave reactions. It was concluded 
that 1.3 equivalent excess of 19 gave generally better yields, an observation that was 
pleasing from the point of view of application to peptides.
Entry (v) showed that the use of HG in place of G II results in a considerably lower yield 
compared to the other examples. Hence we elected to utilise G II in all further 
experiments.
The variation of temperature had the greatest effect on the outcome of the reaction. 
Initially, temperatures above 90°C were avoided as r-butyl carbamates are prone to 
thermal degradation. 120 However when the temperature was increased to 100°C a 
significant increase in yield was obtained, (compare entries (iii, 6 6 %) and (viii, 82%)). 
This suggests that one of the key steps in the reaction mechanism of this particular 
metathesis has a high energy-barrier. Indicative of the threshold of the compounds’ 
thermal stabilities is entry (ix), which shows a significant drop in yield to 59% resulted 
from a 10°C increase to 110°C.
A satisfactory optimization had therefore been completed. The high-yielding example 
was repeated, however at the time the usual microwave unit was unavailable. 
Disappointingly, the use of a different microwave unit (Biotage Initiator 60) yielded 58%, 
entry (x). It was believed that this difference may reflect the inferior temperature control 
and in the early phases of the reaction a higher temperature may be operating. In this new
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apparatus, another attempt was made this time utilising 95°C and, gratifyingly, 77% CM 
product was obtained. Whilst the results were not directly comparable, this demonstrated 
that under optimized conditions acceptable yields could be attained.
2.6 -  Application of Optimized Conditions
2.6.1 -  Preparation o f Additional Substrates
Prior to the application of the optimized conditions to all substrates, some additional 
compounds were prepared. A-Acryloyl- serine and threonine derivatives 34 and 35 were 
synthesized from the Boc-protected amino acids according to Scheme 2.30.
Scheme 2.30 -  Synthesis of 34 and 35
Additionally, Boc leucine and Boc S-4-methylbenzyl cysteine were C-functionalized 
according to the reaction conditions described in Scheme 2.31, in yields of 89% and 84%, 
respectively.
MeOH, T oluene
BocHN'BocHN
crude1 equiv.
O
35 R = Me, 99%
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HBTU, HOBt, DIPEA
O 37 o 84%
Scheme 2.31 -  Synthesis of 36 and 37
2.6.2 -  Application o f Optimized Conditions
The optimized conditions were applied to the full range of substrates with one 
modification. We opted to use 1.1 equivalents as opposed to 1.3 of the A-acryloyl 
amino-acid esters in most cases, as we wanted to the protocol to be as economical as 
possible for application to large peptides. Additionally, as an excess of 1.3 had given 
good results in the optimization studies, it was assumed that 1.1 equivalents would be 
similarly successful. The results for the CM reactions (Scheme 2.32) are shown in
Table 2.6.
o
BocAA{BocAA-f
1.1 equiv. MW 300 W 
2 x 30 min
O
Scheme 2.32 -  Optimized CM conditions
Compound AAi a a 2 Yield/%
i SS-25 S-Phe S-PheOEt 63
ii 38 Phe ValOEt 34
iii 38 Phe ValOEt 30"
iv 31 Arg(di-Z) PheOEt 43
V 31 Arg(di-Z) PheOEt 40
vi 31 Arg(di-Z) PheOEt 55*
vii 33 Ser(Bzl) ProOMe 50
viii 39 Ser(Bzl) PheOEt 73
ix 40 Leu Thr(Bzl)OMe 61"
X 41 Leu Ser(Bzl)OMe 75"
xi 42 Cys(4-MeBzl) PheOEt 51
" Used a different microwave unit without adjustable power. 1.5 equivalent excess of A'-acryloyl amino-acid used
Table 2.6
It is apparent from these results that individual optimization may be necessary in order to 
maximise individual yields. However for the purposes of this study this was deemed 
unnecessary and we decided to focus attention on exploration of the wider scope of the 
methodology. It should be noted that 41 existed as two diastereoisomers (approximately 
15:3, by 13C NMR), visible by NMR. This is presumably due to partial racemization of 
serine during coupling to homoallyl amine via the oxazolone. The high propensity of 
serine to racemize has been reported.121
This model study has demonstrated the wide applicability of the technique in generating 
peptidomimetic structures of equivalent length to four amino acids from functionalized 
single amino acids. It must be highlighted that such structure could potentially be 
incorporated into peptide sequences using existing SPPS protocols, much the same as 
Kelly’s peptidomimetic.98
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2.7 -  Application to a Larger Peptide
As encouraging as these results were, single amino acids are not sufficiently 
representative of larger peptides for us to infer applicability to large peptides or proteins. 
Therefore, before attempting the synthesis of a protein using this novel ligation, it was 
decided to attempt the ligation with larger peptides. Thus olefin-derivatized dipeptide 43 
was synthesized from 36 using solution-phase procedures, according to Scheme 2.33. 
33% of pure material was obtained.
Scheme 2.33 -  Synthesis of functionalized dipeptide 43
The choice of amino acids was not arbitrary -  they correspond to those found on the 
A-terminal side of the linkage site proposed in the retrosynthesis analysis of Crambin. 
The choice of linkage site is discussed in Chapter 3. An appropriately functionalized 
tripeptide corresponding to the residues found on the C-terminal side of Crambin was 
also synthesized. This was prepared using a solution-phase Boc-protection approach, 
according to Scheme 2.34.
BocHN
HATU, DIPEA
BocHN
BocHN
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MeOH, Toluene OMeOH
BocHNBocHN
TMS-
(i) TFA
(ii) HATU, DIPEA,
BocSer(Bzl)OH
BocHN,
BocHN(ii) HATU, DIPEA, 
BocThr(Bzl)OH
(i) TFA
(ii) Acryloyl Cl, EtsN
Scheme 2.34 -  Synthesis of functionalized tripeptide 47
Compounds 43 and 47 were subjected to the optimized metathesis conditions. LCMS and 
evaporative light-scattering detection analysis of the crude mixture suggested the CM 
product 48 (Figure 2.10) had been produced in 67% yield, however only 38% was 
isolated using flash column chromatography on silica gel.
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OMe
BocHN.
NH
Figure 2.10 -  CM product 48
This result was the first example of CM performed on peptides of this size, and also 
served as a very encouraging demonstration of the methodology in the presence of a host 
of functional groups. Interestingly, in this case the product was obtained as an inseparable 
1:8 mixture of cis and trans isomers. It is difficult to say why in this case alone geometric 
isomers were obtained; perhaps some secondary structural effects decrease the relative 
free energy of the cis configuration.
2.8 -  Conclusion
From these studies,122 it can be concluded that this cross metathesis protocol is effective 
in the presence of a variety of amino acids and can be assumed to result in no appreciable 
racemization. It does appear, however, to require optimization in each case, and some 
specific amino acids give very poor CM yields, for example with valine, proline and 
tosyl-protected histidine. As for application of this methodology, it can be viewed, 
variously, as a new ligation technique, a method of inserting a peptidomimetic which 
lacks a main chain amide bond, similar to the work of Kelly, and a way by which a site 
capable of further functionalization and manipulation may be incorporated into a peptide. 
The employment of this methodology will involve several considerations, chiefly the 
effect that replacement of two amino acids with a peptidomimetic will have on protein 
structure and function. Furthermore, the peptide fragments must be synthetically 
accessible, a factor which may influence the division of the protein. We shall now turn to 
the application of this new methodology in the synthesis of the plant protein, Crambin.
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Chapter 3 -  Towards the Total Synthesis of Crambin
3.1 -  Introduction
The Plant protein Crambin was an ideal candidate for application of the metathesis 
ligation described in Chapter 2. This is because it is small, and therefore the segments
88 89should be reasonably accessible by SPPS. Indeed such syntheses have been reported. ’ 
Moreover, in terms of structure and folding, Crambin is one of the most studied of all 
proteins (See section 1.6).
3.1.1 -  Choice o f Ligation Site
The choice of ligation site in the application of metathesis ligation to the chemical 
synthesis of a protein requires the consideration of two factors. These are availability of 
fragments and the likely effect that insertion of the peptidomimetic linker would have on 
the structure. The latter is hard to predict, however substitution in regions of defined 
secondary stmcture is likely to cause severe perturbations resulting from loss of an amide 
bond and thus hydrogen bonding ability. The peptidomimetic generated upon ligation 
lacks analogous side-chains, and thus most closely resembles two glycine residues 
(Figure 3.1). Any Gly-Gly unit has potential for ligation.
o
H
H
O
N. ^ P ep tid e
Peptide N
Peptide
Peptide
O
Figure 3.1 -  Gly-Gly and resultant linker, for comparison
In most cases a Gly-Gly unit at an appropriate site will not be available, and so in each 
case the structural involvement of side chains in the native protein will have to be 
examined. In the long term it is not unreasonable for any ‘retrosynthetic analysis’ of a 
protein to require this type of strategic planning.
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Crambin has a size accessible by traditional SPPS, and so the question of fragment size 
did not have a bearing on the choice of ligation site. Ideally, however, we wanted to 
divide the protein approximately in half, so that the two different methods of peptide 
functionalization, C-terminal and TV-terminal, could be attempted on reasonably sized 
peptides. There are no adjacent glycine residues in the amino-acid sequence of Crambin, 
and so it was necessary to consider replacement of different residues.
Even if the ligation site is located outside a region of secondary structure, the replacement 
of two amino acids with the peptidomimetic has the potential to interfere with non- 
covalent interactions in the protein’s tertiary structure. Therefore, it was necessary to 
consider specific examples and make a qualitative prediction of the likely impact of our 
proposed ‘synthetic mutation’.
Figure 3.2 shows a cartoon of the tertiary structure of PL-form Crambin, based on the 
high-resolution crystal-structure at 150 K.75 Two possible ligation sites were considered -  
both falling outside well-defined secondary-structure, and dividing the protein into 
suitably large segments. These are shown in yellow.
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Figure 3.2 -  Cartoon of PL-from Crambin
The first is located in the region between an a-helix and a p-sheet, replacing Gly[31] and 
either Thr[30] or Cys[32]. All cysteine residues form disulfide bridges in folded Crambin, 
and so replacement of Cys[32] was not considered due to the importance of these 
moieties in maintaining the structural integrity of the protein. From analysis of the 
high-resolution crystal-structure it could be seen that both the Thr[30] side-chain and the 
Gly[31] are involved in hydrogen bonding. Figure 3.3 shows the hydrogen bonds in the 
region in yellow. The bond lengths are given in Angstroms.
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Figure 3.3 -  Hydrogen bonds in Cram[27-32] shown in yellow
Although we were attempting to introduce the non-native linker in unstructured regions, 
it was clear that it would be hard to avoid their disruption altogether -  clearly in this 
region hydrogen bonding is supporting the turn-like structure.
The second potential ligation site occurs between two a-helices, potentially replacing 
Gly[20] and either Pro[19] or Thr[21]. Once again, hydrogen bonding would be disrupted. 
In the native peptide Thr[21] side-chain is involved in hydrogen bonding, as is Gly[20] in 
a p-tum-like structure (Figure 3.4).
Figure 3.4 -  Hydrogen bonds in Cram[ 16-21]
The Pro[19]-Gly[20] junction was chosen for ligation, as there were fewer hydrogen 
bonds in this region. It was acknowledged that such a replacement would remove a 
hydrogen bond in a (3-turn-like structure, and that the conformational constraints effected 
by Pro[19] would be lost. Such a modification, however, could in itself produce 
interesting results -  it would be possible to assess the importance of these features in 
dictating the overall tertiary structure of Crambin. Indeed as only a single hydrogen bond 
is removed if the Pro[19]-Gly[20] unit is replaced, it may be possible to attribute any 
structural perturbations to this alone, making this linkage site the more attractive option.
3.2 Synthetic Strategy
It was reasoned that SPPS should allow easy access to Cram[l-18] and Cram[21-46]. 
Previous reports of the synthesis of Crambin by NCL utilize a Boc protection, however 
this relies on the use of hydrofluoric acid for resin cleavage and so the Fmoc protection 
strategy was chosen for its practicability. Furthermore Fmoc chemistry on chlorotrityl
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resins allows for the generation of fully protected peptide fragments via cleavage with 
acetic acid20"23 (Section 1.2.3). The ligation of peptides via CM requires full protection; 
firstly to prevent catalyst deactivation interactions with thiol and amine functionality, and 
secondly to render the fragments soluble in DCM. Once synthesized, it was hoped the 
peptide fragments could be appropriately functionalized. Deprotection could occur after 
ligation and the synthetic protein subsequently folded (Scheme 3.1).
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PGHN—( Cram[1 -18] PGHN^YN
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'Nf  Cram[22-46]
(i) C leavage
(ii) Functionalization
PGHN— [ Cram[1-18]
(i) C leavage
(ii) Functionalization
0PHa  f  o
N x f~ :ra m [2 2 -4 6 ] ^
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N j f  N "C ~Cram [22-46]
Deprotection
lC r a m [2 2 -4 6 1
Folding
PGHN— ( Cram[1 -18]
H2 N—{ Cram[1-18]
Synthetic Crambin 
Scheme 3 .1- Proposed route to synthetic Crambin
Despite the fact it is possible to cleave peptide fragments fully protected with subsequent 
solution-phase functionalization,20'23 there were far more attractive approaches to
90
generating the functionalized peptides. These approaches -  on-resin acryloylation for 
iV-functionalization and a safety-catch linker strategy for C-functionalization -  avoided 
solution phase manipulation.
In the case of ^-functionalization, solution-phase steps could potentially be avoided by 
direct acryloylation, i.e. bypassing Boc protection, cleavage and Boc deprotection. 
Cleavage with acetic acid, which leaves protecting groups intact, then yields the desired 
protected peptide (Scheme 3.2).
PG R
y — f Peptide V^ ^ N H F m o c
O
(i) Piperidine, DMF
(ii) Et3N, DCM, 
Acrytoyl chloride
y — [ Peptide
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AcOH, TFE, DCM C
HO
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y — ( Peptide
Scheme 3.2 -  On-resin acryloylation of A -^terminus
Similarly, with the use of a sulfonamide safety-catch linker,123 C-terminal 
functionalization and cleavage in theory could be achieved in a single step according to 
Scheme 3.3.
i c h 2 c n ,  d ip e a
PG
J  Peptide ]— NHBoc
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R PG
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O
Scheme 3.3 -  Simultaneous cleavage and C-functionalization
In summary, it was hoped that the appropriately functionalized Crambin segments would 
be accessible via simple SPPS steps and on-resin manipulations. It was decided to 
investigate the synthesis of both fragments on chlorotrityl resin prior to functionalization 
in the case of Cram[21-46] or switching to a safety catch approach in the case of 
Cram[l-18].
3.3 -  Synthesis of Fragments
3.3.1 -  Introduction
Figure 3.5 shows the proposed ligation site in PL form Crambin. This exhibits Pro[22] as 
opposed to Ser[22], found in the SI form. Proline residues are favourable in SPPS, indeed 
‘pseudoprolines’124 have been shown to facilitate access to difficult sequences by 
disrupting hydrogen bonding.125 As the choice was arbitrary, PL form was chosen due to 
the fact it contains an extra proline residue.
T h r - T h r - C y s - C y s - P r o - S e r - I l e - V a l - A l a - A r g - S e r - A s n - P h e - A s n - V a l -  
C y s - A r g - L e u - P r o - G l y - T h r - P r o - G l u - A l a - L e u - C y s - A l a - T h r - T y r - T h r -  
G l y - C y s -  l i e  -  I l e - I l e - P r o - G l y - A l a - T h r - C y s - P r o - G l y - A s p - T y r - A l a -  
A s n
Figure 3.5 -  PL form Crambin. The proposed ligation site is shown in bold
All syntheses utilized a Microwave Peptide-Synthesizer (MWPS), which has been shown 
to be superior to traditional automated peptide synthesizers in terms of minimisation of 
side reactions, length of coupling times and ability of access difficult sequences.126 From 
the outset, methods were set to subject the deprotected amine to two rounds of microwave 
couplings for proline residues, and any residue being coupled to proline, leucine, 
isoleucine and valine. This was in anticipation of potentially poor couplings. These could 
result from steric hindrance caused by a high degree of side-chain branching in the case 
of leucine, isoleucine and valine, and the conformational inflexibility of proline. 
Additionally, two rounds of coupling were used in the case of proline residues due to 
their associated steric issues. In order to examine the peptide purity in each case, a small 
amount was cleaved from the chlorotrityl resin using TFA:EDT:H20:TIS (94:2.5:2.5:1), 
conditions which simultaneously effect full deprotection. The crude mixtures were 
precipitated in cold ether, and the washed with cold ether three times. When it was 
necessary to leave protecting groups intact the milder acetic acid cleavage was used 
(AcOH:TFE:DCM, 1:1:8).
3 .3 .2 - Linear Syntheses
3.3.2.1 -  Cram[21-46]
The synthesis of Cram[21-46] was attempted. HPLC analysis of the TFA-cleaved 
material showed it to be impure (Figure 3.6) and no detectable mass peak could be seen 
in the ES+ mass spectrum.
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Figure 3.6 -  Chromatogram of crude Cram[21-46]
Sequence: TPEALCATYTGCIIIPGATCPGDYAN
The sequence was attempted two further times, firstly by a simple repetition, secondly by 
modifying the coupling protocols to double the coupling of each residue with the aim of 
improving the purity of the product. Unfortunately, with double coupling of each residue, 
the chromatogram still exhibited several peaks (Figure 3.7), and no detectable mass peak 
could be seen in the ES+ mass spectrum.
Figure 3.7 -  Chromatogram of crude Cram[21-46]
Sequence: TPEALCATYTGCIIIPGATCPGDYAN
It appeared that the undesirable product was not a simple deletion sequence, and that 
there were multiple coupling issues. The Ile[33]-Ile[34]-Ile[35] segment was considered 
to be a potential cause of the problems. Hydrophobic residues tend to associate through 
hydrophobic interactions, and this can render the amino terminus inaccessible to coupling.
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This effect would be particularly pronounced in the case of three adjacent isoleucines, 
and this would affect the coupling of all subsequent residues.
The poor quality of both HPLC and ES+ mass spectrum results made it very difficult to 
ascertain the nature of the problem associated with the synthesis of Cram[21-46]. It was 
possible, however, to test whether the De[33]-De[34]-Ile[35] portion was problematic and 
to this end both Cram[32-46] and Cram[35-46] were synthesized. TFA-cleavage of the 
former was poor, yielding an impure peptide (Figure 3.8). No mass peaks corresponding 
to Cram[32-46] were visible in the ES+ mass spectrum.
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Figure 3.8 -  Chromatogram of crude Cram[32-46]
Sequence: CIIIPGATCPGDYAN
The TFA-cleavage of Cram[35-46], on the other hand, proceeded smoothly, yielding the 
peptide in excellent purity (Figure 3.9) without resort to preparative HPLC. The material 
was characterised by ES+ mass spectrometry.
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Figure 3.9a -  Chromatogram of crude Cram[35-46]
Sequence: IPGATCPGDYAN
2 6 3  3  (0 .2 8 1 ) C m  (3 :2 4 ) S c a n  E S +
H JU .SJ79 2 .1 6 e 6100i
IC ram  |35-46]+H +Na]
[C ram  [35-46]+2H]589.8840
[C ram [35-46]+ H]
1178.8485
 ....  ■> I ■ U i ■
1 0 0 0  1 1 0 0  1200  1 3 0 0  1 4 0 0
m /z
400 5 0 0 6 0 0 7 0 0 8 0 0 9 0 0
Figure 3.9b -  MS spectrum of crude Cram[35-46] 
Calculated m/e for [(IPGATCPGDYAN)+H]+: 1178.515
This gave good evidence that the difficulties were associated with isoleucine couplings. 
Coupling of the next isoleucine was carried out manually, without microwave irradiation. 
The completeness of coupling was being assessed by Kaiser test127 (Section 4.2.2.3).
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After 3 h a sample of the resin tested negative for free amine. TFA-cleavage yielded the 
product in acceptable purity (Figure 3.10), confirmed by ES+ mass spectrometry.
i» ■
Figure 3.10a -  Chromatogram of crude Cram[34-46] 
Sequence: IIPGATCPGDYAN
2 5 3 + i 10  (0 .8 7 6 ) C m  (7 :3 7 ) 
100n 646.5005
S c a n  E S +  
2 .7 0  e5
[Cram  [34-46]+
657.8992V
C rnm[34-46]+H+NaT
470 5062
589.9462
600.9703522.0022
695.1487
40 0  4 2 5  4 5 0  4 7 5  5 0 0  5 2 5  " 5 5 0  ' 5 7 5  "  6 0 0  ' 6 2 5  ' 6 5 0  ’ 6 7 5  ' '7 0 0  "7 2 5  ” 7 5 0  "  7 7 5  8 0 0
Figure 3.10b -  MS Spectrum of crude Cram[34-46] 
Calculated m/e for [(HPGATCPGDYAN)+2H]2+: 646.304
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The coupling of De[33] and Cys[32] were carried out manually in a similar manner to the 
coupling of Ile[34]. TFA-cleavage afforded Cram[32-46] in excellent purity, confirmed 
by ES+ mass spectrometry (Figure 3.11).
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Figure 3.1 la -  Chromatogram of crude Cram[32-46] 
Sequence: CniPGATCPGDYAN
2 6 8  11 (0 .9 6 1 )  C m  (4 :33 ) 
100-1
783.1091
[C ram [32-46]+fB u+2H 12+
548.9046
1
802.6086
/
*LL,l
C i nm [32-46]+?Bu+H+K]-i2+
811.1434
/
S c a n  E S +  
4 .6 4  e5
rrI'1' " i1 ■1 1 I" " I " " I" "  iJ" 11" ■11" 11111 ■ w1 w       ■ ■ ■, ■ i ■ ■ " 11
4 0 0  5 0 0  6 0 0  7 0 0  8 0 0  9 0 0  1 0 0 0  1 1 0 0  1 2 0 0  1 3 0 0  1 4 0 0
m /z
Figure 3.1 lb -  MS spectrum of crude Cram[32-46] 
Calculated m/e for [(CIIIPGATCPGDYAN)+H]+: 1507.692
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The fact that effective coupling of the Ile[34]-Ile[33]-Cys[32] portion proceeded without 
the MWPS was counter-intuitive as we had anticipated that microwave irradiation would 
reduce hydrophobic interactions and hence improve the coupling efficiency.
Notwithstanding this the synthesis of the remainder of the sequence was attempted, using 
microwave enhancement and double coupling for each residue. Cleavage from of the 
resultant peptide in TFA proceeded very well; however the chromatogram of the product 
was broad, indicating closely eluting impurities (Figure 3.12).
Figure 3.12 -  Chromatogram of crude Cram[21-46]
Sequence: TPEALCATYTGCIIIPGATCPGDYAN
Preparative HPLC failed to achieve good peak separation; however ES+ mass 
spectrometry applied to the different fractions in the product peak showed only two 
impurities -  Cram[21-46] plus a rBu group (not shown), and Cram[21-46], minus Thr[21], 
Thr[28] or Thr[30] (Figure 3.13).
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2 8 8  18  (2 .1 5 6 )  C m  (2 :2 6 ) 
100n 872.7144
1308.5382
Scan ES+
3.09e5
[ C  r am[21-46]+ 2H^*
[ C  r  n m  [21  - 4 6 ] +  3 H
551.5309
1258.1366
[Cram[21-46]-Thr+2Hf+
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40 0  5 0 0  6 0 0  7 0 0  8 0 0  9 0 0  1 0 0 0  1 1 0 0  1 2 0 0  1 3 0 0  14 0 0
Figure 3.13 -  MS spectrum of crude Cram[21-46]
Calculated m/e for [(TPEALCATYTGCIIIPGATCPGDYAN)+2H]2+: 1308.095
These impurities, however, both had low intensities relative to the product peak. The fBu- 
Cram[21-46] impurity observed in the ES+ mass spectrum could result from several 
different compounds with different rBu points of attachment. This could account for the 
broadness of the chromatogram.
33.2.2 -N-Acryloyl Cram[21-46]
A portion of Cram[21-46] was acryloylated according to Scheme 3.4.
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Scheme 3.4 -  Acryloylation of Cram[21-46]
Similar to its non-acryloylated counterpart, the chromatogram of TFA-cleaved A-acryloyl 
Cram[21-46] was broad and various impurities were present (Figure 3.14).
Figure 3.14a -  Chromatagram of crude A-acryloyl Cram[21-46]
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28 9  2  (0 2 6 2 )  C m  (2 :2 8 )
605.3386
427.2838
/
[JV-Acryloyl Cram[21-46]+:
W -A cryloyl C ram [21-46]+3H ]
\  890.2924
4 0 0  5 0 0  6 0 0  7 0 0  8 0 0  9 0 0  1 0 0 0  1 1 0 0  1 2 0 0  1 3 0 0  1 4 0 0
Figure 3.14b -  Chromatagram and MS spectrum of crude /V-acryloyl Cram[21-46] 
Calculated m/e for [N-acryloyl Cram[21-46]+2H]2+: 1334.605
Preparative HPLC did not effect good separation, however mass spectrometry confirmed 
acryloylation had taken place (Figure 3.14); both by presence of the /V-acryloyl 
Cram[21-46] in several fractions, and total absence of the Cram[21-46] peak in any 
fraction.
In conclusion, despite the ambiguously broad chromatogram peaks, we observed no 
evidence for deletion sequences in the ES+ mass spectrum. ES+ mass spectrometry, 
furthermore, provides definitive evidence that /V-acryloyl Cram[21-46] has been made. 
We therefore believe with optimization /V-acryloyl Cram[21-46] can be produced in high 
purity. The efficiency of the acetic acid cleavage was not addressed and this will be of 
, key importance to the future application of the methodology.
Scan ES+
2.42e5
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3 .3 .2 3 -C ram [l-18]
Although our intention was to synthesize Cram[l-18] on a sulfonamide safety catch 
linker, the sequence was first attempted on chlorotrityl resins in order to investigate its 
ease of synthesis. All couplings from this point on made use of the MWPS.
It was decided to synthesize different length portions of Cram[l-18], building up to the 
full peptide length, so that any problematic couplings could be more accurately identified 
and to this end Cram[9-18] was synthesized first. A sample was cleaved with TFA and 
the crude assessed by ES+ mass spectrometry. No deletion sequences were apparent, and 
so we continued with the synthesis of Cram[6-18]. TFA-cleavage of the product yielded a 
product that was pure by HPLC and ES+ mass spectrometry (Figure 3.15).
05106J2007 16_06_41 SCI PI_03 CttTA [290XX) i
Figure 3 .1 5 a -  Chromatogram o f crude Cram[6-18] 
Sequence: SIVARSNFNVCRL
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2 5 5 * 1 9  (1 .6 4 1 )  C m  (3 :2 5 ) S c a n  EES+
2 .2 6  e6740.038010Ch
Cram[6-18]+2H]
5 0 04 0 0 6 0 0 7 0 0 8 0 0 9 0 0 1 0 0 0  1 1 0 0  1 2 0 0  1 3 0 0 14 0 0
Figure 3.15b -  MS spectrum of crude Cram[6-18] 
Calculated m/e for [(SIVARSNFNVCRL)+2H]2+: 739.899
The synthesis of Cram[4-18] was then attempted and at the end of the coupling sequence 
the product was cleaved using the TFA-cleavage protocol. Assessment of the purity of 
the product using HPLC indicated that the desired product was present but it was impure 
(Figure 3.16). ES+ mass spectrometry seemed to indicate that the peptide was present but 
it was contaminated with a residual trityl-bearing peptide. In order to obtain pure material 
we carried out preparative HPLC, and were able to obtain a pure sample of the desired 
peptide.
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Figure 3.16a -  Chromatogram of crude Cram[4-18]
Sequence: CPSIVARSNFNVCRL
262'1 (5.474) Cm (1) Scan ES+
84U.1/5U 8 .6 1 e 710CH
;Cram[4-18]+2H]
961.7883
560.6749 [Cram[4-18]+Trt+2H]
8 0 0 9 0 0 12004 0 0 5 0 0 6 0 0 7 0 0 1000 1100 1 3 0 0 14 0 0
Figure 3.16b -  MS spectrum of crude Cram[4-18]
Calculated m/e for [(CPSIVARSNFNVCRL)+2H]2+: 839.930
Finally, both Cram[2-18] and Cram[l-18] were synthesized. HPLC analysis of 
TFA-cleaved Cram[2-18] revealed that there were two peptides present (Figure 3.17),
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unfortunately, however ES+ mass spectrometry suggested only the desired peptide was 
present.
•20
Figure 3.17a -  Chromatogram of crude Cram[2-18] 
Sequence: TCCPSIVARSNFNYCRL
2 6 7  5  (0 .4 5 1 )  C m  (5 :3 2 ) 
10CH
942.7237
S c a n  E S +  
2 .7 0  e5
628.5621
C ram [2-18]+3H T
[Cram [2-18]+2H] 2+
li,. ii
1 1 I 11 "  I '  I 1 ' I '  ' ’ 1 I "  I ' I "  "  I "  '  I I 'T T - n - n  I r j i T i  i - p - r  i i /  • r n  , i . i 1 7 < i  n  11
8 0 0  9 0 0  1 0 0 0  1 1 0 0  1 2 0 0  1 3 0 0  14 0 0
m /z
4 0 0
I ' ' 1 1 I 1 '
5 0 0
Figure 3.17b -  MS spectmm of cmde Cram[2-18]
Calculated m/e for [(TCCPSIVARSNFNVCRL)+2H]2+: 941.958
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Cram[l-18] appeared to be significantly less pure upon examination (Figure 3.18). 
Moreover, the TFA-cleavage was poor yielding, furnishing very small quantities of the 
desired material. The ES+ mass spectrum indicated the presence of Cram[l-18], although 
the indicative peaks were of low resolution. After repeated attempts we were not able to 
resolve this. We suspect that it would have been easier to isolate and purify high quality 
material if we had been able to improve the yield of the cleavage reaction.
R T [m in ]
Figure 3 .1 8 a -  Chromatogram o f crude Cram [l-18] 
Sequence: TTCCPSIVARSNFNVCRL
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271conc’ 12 (1.445) Cm (2 1 2 )  Scan ES+
bbi  , 4 / a a 1 .0 9 e 6100—I
991.6779
;Cram[l-18]+3H] ;Crnm[l-18]+2H]
m/z
4 0 0 5 0 0 6 0 0 7 0 0 8 0 0 9 0 0 1000 1100 1200 1 3 0 0 1 4 0 0
Figure 3.18b -  MS spectrum of crude Cram[l-18]
Calculated m/e for [(TTCCPSIVARSNFNVCRL)+2H]2+: 992.482
Despite the potential limitations of our cleavage protocol and its apparent deterioration 
with increasingly complex peptides, we decided not to attempt to optimize this protocol 
but rather to work with the safety-catch linker as this had always been envisaged for the 
total chemical synthesis.
3.3.2.4 -  Synthesis o f C-functionalized Cram[9-18]
It was decided to first explore the synthesis and cleavage of Cram[9-18] on a safety catch 
linker. SPPS, with double coupling of appropriate residues (see Section 3.3.1) was carried 
out, and the sulfonamide activated using iodoacetonitrile. Cleavage and 
C-functionalization was then achieved in one step using homoallylamine, and TFA 
deprotection of the cleaved peptide afforded the functionalized peptide product. HPLC 
analysis, however, showed there to be several peptide products with similar retention
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times (Figure 3.19). This and subsequent cleavages using this safety-catch linker 
approach proceeded very well in terms of the quantities of material obtained.
ms'
Figure 3.19 -  MS spectrum of crude C-functionalized Cram[9-18]
The ES+ mass spectrum revealed three deletion sequences, and these were assumed to be 
responsible for the additional HPLC peaks. The deletion sequences either lacked (a) a 
cysteine residue, (b) a valine residue or (c), both cysteine and a valine. It therefore 
seemed sensible to repeat the SPPS of this sequence, doubling the coupling of the valine 
and cysteine residues. Hence we repeated the sequence but with this modified coupling 
regime, however once again, the cleaved, C-functionalized and deprotected material was 
impure by HPLC (Figure 3.20).
l_03_4iOMA [290.001
N0(
Figure 3.19 -  Chromatogram of crude C-functionalized Cram[9-18]
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m * » 3  22 (TO 388) Cm (11:124) 
100
616.92
: C-H omo a lly 1C r am [21 -46]+ 2H]
JC-Homonllyl 
Ci am[21-46]-Cvs+H]
690.39
962.60
m /z
2 0 0  3 0 0  4 0 0  5 0 0  6 0 0  7 0 0  8 0 0  9 0 0
Figure 3.20 -  MS spectrum of crude C-functionalized Cram[9-18]
Calculated m/e for [C-Homoallyl Cram[9-18]+2H]2+: 616.834
The ES+ mass spectrum indicated that doubling of the valine and cysteine residues did 
eliminate the previous deletion sequences, inasmuch as they were not visible. 
Interestingly, however, a new impurity exhibiting a mass which corresponds to the 
sequence without cysteine and without homoallyl amine functionalization was now 
visible. One explanation is that water is selectively cleaving the deletion sequence, as 
neither the C-functionalized deletion sequence and non-functionalized Cram[9-18] were 
observed. Synthesis of the sequence was attempted once again, this time coupling every 
residue twice, and the cysteine residue three times. Simultaneous functionalization and 
cleavage, followed by deprotection yielded a peptide with a broad HPLC peak 
(Figure 3.21).
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Figure 3.21a -  Chromatogram of crude C-functionalized Cram[9-18]
T*M »6 CRUDE 114(2.003) Cm 0»:12S) 
100
616.90
C-Homoa Uyl C ram[21-46]+ 2H]
C-Homoallyl C 1 am[2 l-46]-Cy s+H]
1076.79
m /z7 0 0 9 0 0 1 0 0 0  1 1 0 0  1 2 0 0  130 0  1 4 0 03 00 4 00 5 0 0 6 0 0
Figure 3.21b -  MS spectrum of crude C-functionalized Cram[9-18]
Examination of the ES+ mass spectrum showed the desired functionalized sequence as 
the dominant peak. The peak corresponding to the sequence lacking cysteine and the 
homoallyl amine functionalization was still visible, but was significantly less intense. 
This indicated the triple coupling of the cysteine residue had mostly resolved this 
problem.
I l l
Overall, this was a promising result. Time constraints prevented extending the 
methodology to the synthesis of functionalized Cram[l-18].
3.3.3 -  Convergent Approach -  Towards a Native Chemical Ligation Synthesis 
The initial difficulties in synthesizing pure /V-acryloyl Cram[21-46] led us concurrently to 
consider NCL and propose a new approach for the synthesis of this fragment. The 
Gly[31]-Cys[32] junction was the obvious choice for NCL as it divided the segment into 
a 10-mer and a 14-mer. Furthermore there are no racemization or steric issues associated 
with glycine. The proposed application of NCL to the synthesis of Crambin is illustrated 
in Scheme 3.5.
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Scheme 3.5 -  Proposed use of native chemical ligation
We had already synthesized Cram[32-46] pure (Section 3.3.2.1), and so all that was 
needed was the N-acryloyl Cram[21-31] thioester.
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3.3.3.1 -  Synthesis o f Cram[21-31 ]
Cram[21-31] was synthesized on chlorotrityl resins to gain an idea of the accessibility of 
this sequence. This proceeded excellently with double coupling of each residue, and 
cleavage with TFA yielded a product visibly clean by HPLC (Figure 3.22).
Figure 3.22a -  Chromatogram of crude Cram[21-31] 
Sequence: TPEALCATYTG
2 5 6 p  17  (2 .0 3 7 ) C m  (7 :2 1 ) S c a n  E S +
1 1 2 eb1126.4751100n
;Cram[21-31]+H]
563.9194
;Cram[21-31]+2H]
800 900
0
400 500
m/z
600 700 1000 1100 1200 1300 1400
Figure 3.22b -  MS spectrum o f crude Cram[21-31] 
Calculated m/e for [(TPEALCATYTG)+H]+: 1126.509
A portion of the resins were deprotected and acryloylated as described previously 
(Scheme 3.4). Cleavage with TFA yielded the impure product (Figure 3.22), preparative 
HPLC afforded the pure acryloylated product (Figure 3.23).
1,
Figure 3.22 -  Chromatogram o f crude /V-acryloyl Cram[21-31]
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Figure 3.23a -  Chromatogram o f purified /V-acryloyl Cram[21-31]
2 8 0  2  (0 .2 6 2 ) C m  (2 :12) S c a n  E S +
644.5482 2 .4 8 e 6100-1
610.0087 -A cryloyl C rnm [21-31]+K +H ]
1202.9187
[N -A cryloyl C ram [21-31]+N a
1180.8330
[N -A ciy loy l C iam [21-31 ]+ H l+ 1265.9659
1000 1100 1200 1300 1400400 500 600 7 0 0 800 900
Figure 3.23b -  MS spectrum o f purified /V-acryloyl Cram[21-31] 
Calculated m/e for [/V-acryloyl Cram[21-31]+H]+: 1181.535
As we had synthesized both /V-acryloyl Cram[21-31] and C-homoallyl Cram[9-18] 
successfully, and had limited time, we were keen to attempt a model cross metathesis on 
these segments. In order for/V-acryloyl Cram[21-31] to be cleaved with protecting groups 
intact, it was necessary to investigate the efficiency of an acetic acid cleavage.
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Quantitative investigation, however, showed these cleavage conditions to afford the 
protected /V-acryloyl Cram[21-31] in -2.5% yield. This was judged to be prohibitively 
low to perform this model study.
The acetic acid cleavage would have only been relevant to a model study, and the TFA 
cleavage was non-applicable to our methodology as it removed all protecting groups. The 
use of a safety-catch linker and cleavage with a thiol, as has been proposed (Scheme 3.5, 
above), would be required, however this approach was not explored.
3.4 -  Conclusion and further work
Ultimately, we had synthesized Cram[31-46], /V-acryloyl Cram[21-46], /V-acryloyl 
Cram[21-31], Cram[l-18] and C-functionalized Cram[9-18]. There were, however, 
problems with the synthesis of some these peptides that could be addressed with more 
time.
The original proposed synthesis, via the CM between /V-acryloyl Cram[21-46] and 
C-functionalized Cram[l-18], would require successful synthesis of Cram[l-18] on a 
safety-catch linker and improvement of the synthesis of /V-acryloyl Cram[21-46]. The 
latter appeared to be impure by HPLC and so the synthesis is in need of optimization. 
Moreover an acetic acid cleavage has not yet been attempted. If this turns out to be 
prohibitively low yielding, as was the case with the equivalent cleavage of /V-acryloyl 
Cram[21-31], the NCL approach (Scheme 3.5, above) may prove a better option.
In order for NCL to be employed successfully, Cram[32-46] is required, unprotected. 
This has been successfully achieved. Furthermore, the synthesis of /V-acryloyl 
Cram[21-31], has been achieved. Its synthesis on and thiol cleavage from the 
sulfonamide safety catch linker, however, needs to be explored. Given our previous 
success with safety catch linkers in the synthesis of C-functionalized Cram[9-18] we are 
hopeful this approach will prove fruitful.
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Both proposed syntheses require C-functionalized Cram[l-18]. Although 
C-functionalized Cram[9-18] exhibited a broad peak by HPLC, ES+ evidence suggests it 
is of reasonable purity. Given the broadness of the peak, however, and the difficulties 
encountered in the synthesis of Cram [1-18] on chlorotrityl resins, it is very likely 
synthesis of C-functionalized Cram[l-18] will be non-trivial.
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Chapter 4  -  Experimental
4 .1 -  Synthetic Organic Chemistry
4.1.1 — General information
All reactions were carried out under an argon atmosphere, using oven-dried glassware. 
All chemicals were purchased from commercial sources and were used as received. 
Peptide coupling reactions were monitored in some cases using a Micromass Platform LC 
instrument. Acryloylations and thermal cross metathesis reactions were monitored by 
thin-layer chromatography (TLC) on pre-coated silica gel plates (254 mm) and in some 
cases using a using a Micromass Platform LC instrument. Microwave reactions utilized a 
CEM Discover instrument unless otherwise stated. All yields quoted are isolated yields. 
lH NMR spectra were recorded at 300 MHz and 13C at 75 MHz on a Bruker AMX 300 at 
ambient temperature unless otherwise stated. The chemical shifts for *H and 13C are 
quoted in ppm relative to residual protiated signals of the solvent. Coupling constants (7) 
are given in Hertz. Mass spectra were obtained using electrospray ionization on a VG70- 
SE or a MAT 900 XP mass spectrometer using a triple quadrupole mass analyser. 
Infrared spectra were obtained using a solution cell on a Shimadzu FTIR 8700 
Spectrophotometer or using a Perkin Elmer Spectrum 100 (solid). Optical rotations were 
measured using monochromatic light at 589 nm with a 1 dm cell and either a model AA- 
1000 polarimeter, at 294 K or a Polaar 2000 polarimeter at ambient temperatures. Melting 
points were measured, where appropriate, with a Gallenkamp apparatus and are 
uncorrected.
A note on the assignment of *H NMR -  Superscript a and b distinguish between 
diastereotopic protons on the same carbon and thus are not intended to uniquely define 
protons within the same molecule.
Abbreviations br broad
s singlet q quartet
d doublet app apparent
t triplet obsc obscured
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4.1.2 -  General procedures
Protocol I -  C-functionalization of amino acids with homoallyl amine 
Protected amino acid (3.4 mmol) and HOBt (455 mg, 3.4 mmol) were dissolved in DCM 
(15 mL) and the mixture stirred vigorously. EDC.HC1 (1.2 g, 6 .8  mmol) and DIPEA 
(1.18 mL, 6 .8  mmol) were added and the mixture stirred for 10 minutes. Homoallyl 
amine or the corresponding HC1 salt (3.4 mmol) was added and the resultant mixture 
stirred for 4 h. The mixture was then diluted with DCM (15 mL), and washed with HC1 
(2x10 mL, 0.5 M), NaHCC>3 (2x10 mL, 0.5 M), water (2x10 mL) and saturated brine (10 
mL) and dried with anhydrous MgSC>4. The MgSCL was removed by filtration and the 
solvent removed in vacuo. The resultant material was dissolved in a small amount of 
DCM and purified by silica-gel chromatography (petroleum ether and ethyl acetate, 
initial 3:1 v:v, final 100% ethyl acetate).
Protocol II -  /V-Acryloylation of amino acid with acryloyl chloride 
To a stirred solution of amino acid ester (1.7 mmol) and Et3N (0.5 mL, 3.7 mmol) in 
DCM (10 mL) was added acryloyl chloride (2 mmol, as a 1 M solution in DCM) was 
over 1 h. The resultant mixture was allowed to warm to RT and stirred for a further 18 h. 
The DCM was removed in vacuo, and ethyl acetate added (80 mL). The solid was filtered 
off and the filtrate was washed with HC1 (1x10 mL, 0.5 M), NaHCC>3 (2x10 mL, 0.5 M), 
water (1x10 mL) and saturated brine (1x10 mL), dried with anhydrous MgSC>4. The 
MgSCL was removed by filtration and the solvent removed in vacuo. The resultant 
material was dissolved in a small amount of DCM and purified by silica-gel 
chromatography (petroleum ether and ethyl acetate, initial 3:1 v:v, final 100% ethyl 
acetate).
Protocol III -  Thermal CM between /V-acryloyl and C-homoallyl amine functionalized 
amino acids
To a stirred solution of /V-acryloyl amino acid (0.2 mmol) and C-homoallyl amine 
functionalized amino acid (1.3 equivalents) in DCM (3 mL) was added G II (7-19 mol% 
in 2 mL DCM). The resultant mixture was heated to reflux and stirred until the N- 
acryloyl amino acid was no longer visible by TLC. The reaction mixture was allowed to
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cool to RT, and the solvent removed in vacuo. The resultant material was dissolved in a 
small amount of DCM and purified by silica-gel chromatography (petroleum ether and 
ethyl acetate, initial 3:1 v:v, final 100% ethyl acetate).
Protocol IV -  Optimized microwave cross metathesis
A solution of A-acryloyl amino acid (0.1 mmol), C-homoallyl amine functionalized 
amino acid (1.3 equivalents) and GII (18 mol%) in DCM (0.5 mL) was sealed in a 
microwave vial. The solution was then subjected to microwave irradiation (300 W, 
100 °C) for 30 mins. The reaction mixture was then degassed with argon for 
approximately 30 seconds, and the mixture and subjected to microwave irradiation (300 
W, 100 °C) for a further 30 mins. The reaction mixture was allowed to cool to RT, and 
the solvent removed in vacuo. The resultant material was dissolved in a small amount of 
DCM and purified by silica-gel chromatography (petroleum ether and ethyl acetate, 
initial 3:1 v:v, final 100% ethyl acetate).
4.1.3 -  Synthesis o f Compounds in Number Order 
3 -  (2-Methyl-acryloylamino)-acetic acid ethyl ester
To a stirred solution of methacrylic acid (2.5 mL, 29 mmol) in dichloromethane (100 mL) 
was added HOBt (4.0 g, 30 mmol), EDC.HC1 (5.2 g, 29 mmol), DIPEA (5.3 mL, 29 
mmol) and glycine ethyl ester hydrochloride, 2, (2.13 g, 15.2 mmol). The reaction 
mixture was stirred at RT for 6Vi h. The reaction mixture was washed with HC1 (1x20 
mL, 0.5 M), sodium bicarbonate solution (1x20 mL, 0.5 M) and once with saturated brine 
(1x20 mL) and dried with anhydrous MgSCL. The MgSCL was removed by filtration and 
the solvent removed in vacuo. The resultant material was dissolved in a small amount of 
DCM and purified by silica-gel chromatography (petroleum ether and ethyl acetate, 
initial 3:1 v:v, final 100% ethyl acetate). The product was obtained as a colourless 
viscous liquid (2.52 g, 97 %).
o
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'H NMR (DMSO d6): 8.34 (t, J = 6.0, 1 H, NH); 5.72 (s, 1 H, C=CH cis); 5.46 (s, 1 H, 
C=CH trans); 4.08 (q, J  = 7.0, 2 H, O C//2CH3); 3.83 (d, J  = 6.0, 2 H, N O /2); 1.86 (s, 3 
H, C=CCff3); 1.81 (t, J  = 7.0, 3 H, OCH2Cff3). 13C NMR (DMSO d6) : 169.7 (C=0);
167.7 (C=0); 139.2 (C); 119.7 (CH2); 60.2 (CH2); 40.9 (CH2); 18.3 (CH3); 13.9 (CH3).
IR, solution cell, DCM (cm'1): 3348 (N-H stretch); 2984; 2937; 1749 (C=0 stretch); 1666 
(C=0 stretch); 1622; 1531.
HRMS calc. fo rC 8H13N 0 3: 194.0788 [M+Na]+; Found 194.0793.
5 — (S)-2-Acetylainino-.V-allyl-3-phenyl-propionamidel s
To a stirred solution of 4 (1.0 g, 4.8 mmol) in DCM was added HOBt (0.65 g, 4.8 mmol), 
DIPEA (0.88 mL, 4.8 mmol) and EDC.HC1 (1.7 g, 4.8 mmol), and the mixture stirred at 
RT for 10 minutes. Allyl amine (1.42 mL, 19.2 mmol) was added and the resultant 
mixture stirred at RT for 6  h. The reaction mixture was washed once with HC1 (20 mL, 
0.5 M), once with sodium bicarbonate solution (20 mL, 0.5 M) and once with saturated 
brine (20 mL) and dried with anhydrous MgSC>4. The MgSCL was removed by filtration 
and the solvent removed in vacuo affording 5 as a white solid (0.88 g, 75%).
l¥L NMR (DMSO d6): 8.15 (t, /  = 6.0, 1 H, NIT); 8.13 (d, J  = 8.5, 1 H, NH); 7.15-7.28 (m, 
5 H, Ar-H); 5.72 (ddt, J  = 5.0, J  = 17.0, J  = 10.5, 1 H, NHCH2C#); 4.98-5.08 (m, 2  H, 
C=CH2); 4.47 (ddd, J  = 9.5, J = 8.5, J  = 5.0, 1 H, NCtfCO); 3.66 (m, 2 H, NCtf2); 2.95 
(dd, J  = 5.0, J  = 13.5, 1 H, NCHCHb7f); 2.74 (dd, J  = 9.5, J  = 13.5, 1 H, NCHCH3/^ );
1.75 (s, 3 H, COCH3). 13C NMR (DMSO d6): 171.0 (C=0); 169.0 (C=0); 138.0 (C);
135.0 (CH); 129.0 (CH); 128.0 (CH); 126.1 (CH); 114.9 (CH2); 54.1 (CH); 40.7 (CH2);
37.8 (CH2); 22.4 (CH3).
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IR, solid disc (cm 1): 3251 (N-H stretch); 3061; 1670 (C=0 stretch); 1635; 1551. 
(a) D -4.7° (c = 1.0, MeCN).
HRMS calc, for C 14Hi8N20 2 : 269.1266 [M+Na]+; Found 269.1263.
Mp: 136-139 °C. Lit. 160-161 °C.
7 -  (S)-2-Acetylamino-3-phenyl-iV-prop-2-enyI-propionamide
To a stirred solution of 5 (100 mg, 0.41 mmol) and 3 (70 mg, 0.40 mmol) in DCM (12 
mL) was added HG (14 mg, 5 mol%). The mixture refluxed for 20 h, by which time 5 
was no longer visible by TLC. The reaction mixture was allowed to cool to RT, and the 
solvent removed in vacuo. The resultant material was dissolved in a small amount of 
DCM and purified by silica-gel chromatography chromatography (petroleum ether and 
ethyl acetate, initial 3:1 v:v, final 100% ethyl acetate) yielding 7 (94 mg, 94%) as a 
mixture of isomers (Cis: trans, 22:25).
Cis product -
■h NMR (DMSO d,:y. 9.45 (d, J  = 10.5, 1 H, NH)\ 8.21 (d, J  = 8.0, 1 H, NH); 7.18-7.27 
(m, 5 H, Ar-H); 6.50 (dq, J  = 10.5, J = 1.5, 1 H, NCH=C); 4.65-4.75 (m, 2 H, NCT/CO, 
C=CWMe superimposed); 2.91 (dd, J  = 5.0, J  = 13.5, 1 H, NCHCH V ); 2.76 (dd, J =
10.0, J  = 13.5, 1 H, NCHCH3/ /1’); 1.76 (s, 3 H, COC//3); 1.60 (dd, J  = 7.0, J = 1.5, 1 H, 
C=CCH<). ,3C NMR (DMSO d6) -  169.7 (C=0); 169.2 (0=0); 137.7 (C); 129.1 (CH); 
127.9 (CH); 126.2 (CH); 122.0 (CH); 105.7 (CH); 53.6 (CH); 37.6 (CH2); 22.3 (CH3);
11.3 (CH3).
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Trans product -
‘H NMR (DMSO d6): 9.83 (d, J  = 10.0, 1 H, N//CH=CH); 8.19 (d, J = 8.5, 1 H, NH)\ 
7.14-7.29 (m, 5 H, Ar-H); 6.54 (ddd, J  = 14.0, J  = 10.0, J = 2.0, 1 H, NC//=C); 5.18 (dq, 
J  = 14.0, J  = 6.5, 1 H, C=CHMe); 4.41-4.49 (m, 1 H, NC7/CO); 2.92 (dd, J  = 5.0, J  =
13.5, 1 H, N C H C H V ); 2.73 (dd, J  = 9.5, J  = 13.5, 1 H, NCHCHa/7b); 1.75 (s, 3 H, 
COC//3); 1.60 (dd, J  = 6.5, J = 2.0, 1 H, C=CCH,). 13C NMR (DMSO d6): 169.1 (0=0);
168.6 (C=0); 137.7 (C); 129.0 (CH); 128.0 (CH); 126.2 (CH); 123.6 (CH); 107.1 (CH);
54.0 (CH); 37.5 (CH2); 22.3 (CH3); 14.8 (CH3).
IR, solid disc (c m 1); 3266 (N-H stretch); 3065; 1666 (C=0 stretch); 1636; 1528; 1549. 
HRMS calc, for C i4H lsN20 2 : 269.1266 [M+Na]+; Found 269.1274.
11 -  (S)-(l-but-3-enylcarbamoyl-2-phenyl-ethyl)-carbamic acid tert-butyl ester
BocPheOH (1.7g, 6.4 mmol) was C-functionalized with homoallyl amine hydrochloride 
according to protocol I yielding 11 as a waxy solid (1.3g, 64%).
lH NMR (CDC13): 7.17-7.29 (m, 5 H, Ar-H); 5.99 (br, 1 H, NH); 5.61 (app ddt, J  = 17.0, 
J  = 10.5, J  = 6.5, 1 H, H2CC//=CH2); 5.20 (br, 1 H, NH); 4.91-4.98 (m, 2 H, 
H2CCH =CH2); 4.29 (app q, /  = 7.0, 1 H, NHCH); 3.13 (m, 2 H, NUCH2); 3.01 (m, 2 H, 
CHCH2); 2.02-2.16 (m, 2 H, 0 7 2CH=CH2); 1.38 (s, 9 H, C(CH3)3). 13C NMR (CDC13):
171.1 (C=0); 155.4 (C=0); 136.9 (C); 134.9 (CH); 129.3 (CH); 128.6 (CH); 126.9 (CH);
117.1 (CH2); 80.0 (C); 56.0 (CH); 38.9 (CH2); 38.4 (CH2); 33.4 (CH2); 28.3 (CH3).
HRMS calc, for Ci9H26N20 3: 319.2022 [M+H]+; found 319.2027.
IR, solution cell, DCM (cm 1): 3427 (N-H stretch); 2978; 2934; 1709 (C=0 stretch); 1676 
(C=0 stretch).
( o ) 25d  +4.9 ( c  0.50, CHC13)
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13 -  (S)-2>AcetyIamino-iV-allyl-iV-methyl-3-phenyl-propionamide
To a stirred solution of 4 (0.60 g, 2.9 mmol) in DCM (20 mL) was added Af-Methyl 
allylamine (0.41 mL, 4.4 mmol), HOBt (0.39 g, 2.9 mmol), DIPEA (0.96 mL, 5.8 mmol) 
and EDC.HC1 (1.0 g, 5.8 mmol), and the mixture stirred at RT for 1 h. The reaction 
mixture was washed with HC1 (2x10 mL, 0.5 M), sodium bicarbonate solution (2x10 mL, 
0.5 M) and saturated brine (2x10 mL) and dried with anhydrous MgSCL. The MgSCL was 
removed by filtration and the solvent removed in vacuo yielding 13 as a viscous, 
colourless liquid (0.65 g, 8 6 %).
‘H NMR, 400 MHz, 383 K (DMSO d6): 7.7 (br, NH); 7.18-7.27 (m, Ar-H); 5.61-5.71 (m, 
CH20 /= C ); 5.03-5.10 (m, C=CH2); 4.94 (q, NHCfl); 2.98 (m, NCHC//aHb); 2.82 (m, 
NCHCHaH1’), 2.80 (s, NCH:i); 1.80 (s, COCH,). 13C NMR (DMSO d6): 171.5, 171.2 
(C=0); 169.1 (C=0); 138.1, 137.9 (CH); 133.9, 133.3 (CH); 129.6 (CH); 128.6 (CH);
126.8 (CH); 116.9, 116.7 (CH2); 51.5, 50.4 (CH); 50.2, 49.7 (CH3); 38.6, 38.0 (CH2); 
34.7, 33.6 (CH2); 22.8 (CH3).
IR, solution cell, DCM (c m 1); 3296 (N-H stretch); 3061; 3032; 2982; 2930; 1636 (C=0 
stretch); 1541.
HRMS calc, for C 15H20N2O2: 283.1417 [M+Na]+; Found 283.1417.
(a) d - 1. 2°  (c = 0.62, MeCN).
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18 -  (S)-2-Acetylamino-iV-but-3-enyl-3-phenyl-propionamide
4 (0.70 g, 3.4 mmol) was C-functionalized with homoallyl amine HC1 according to 
protocol I. The crude product was recrystallized from ethyl acetate and petroleum ether 
yielding 18 as white crystals (0.82 g, 93%).
‘H NMR (DMSO df,): 8 .1 1 (d, J  = 9.0, 1 H, NtfCH); 7.98 (t, J  = 5.5, 1 H, NHCH2); 7.14- 
7.27 (m, 5 H, Ar-H)\ 5.70 (app ddt, J  = 10.5, J  = 17.0, J = 7.0, 1 H, H2C07=CH2); 4.95-
5.05 (m, 2 H, CH=C//2); 4.43 (app dt, J  = 9.0, J  = 5.5, 1 H, NHCfl); 2.95-3.17 (m, 2 H, 
N H Cft); 2.92 (dd, J = 5.5, J  = 13.5, CHaHbPh); 2.72 (dd, J  = 9.0, J  = 13.5, C H ^ P h );
2.08 (app q, J  = 7.0, 2 H, t f 2CCH=CH2); 1.75 (s, 3 H COCH3). 13C NMR (MeOH d4):
173.5 (C=0); 173.0 (C=0); 138.5 (C); 136.5 (CH); 130.3 (CH); 129.4 (CH); 127.8 (CH);
117.0 (CH2); 56.3 (CH); 39.8 (CH2); 39.2 (CH2); 34.6 (CH2); 22.4 (CH3).
IR, solution cell, DCM (c m 1): 3423 (N-H stretch); 3310 (N-H stretch); 2932; 1665 (C=0 
stretch); 1504.
HRMS calc, for C 15H20N2O2: 283.1422 [M+Na]+; found 283.1423.
(a) d + 5 .6°  (c =  0.31, MeCN).
Mp: 127-128 °C.
19 -  (S)-2-Acryloylamino-3-phenyl-propionic acid ethyl ester129
-OEt
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PheOEt HC1 (3.0 g, 13 mmol) was TV-acryloylated according to protocol II. The product 
was purified by two recrystallizations from ethyl acetate and petroleum ether yielding 19 
as white, needle-like crystals (78%).
‘H NMR (MeOH eUY 7.17-7.29 (m, 5 H, Ar-ff); 6.26 (dd, J  = 9.5, J = 17.0,1 H, H2CCH)\
6.17 (dd, J  = 2.5, J  = 17.0, 1 H, HC=CHH trans); 5.64 (dd, J  = 2.5, J  = 9.5, 1 H, 
HC=C/7H cis); 4.70 (dd, J  = 6.0, J  = 8.5, 1 H, HNC/f); 4.12 (app q, J  = 7.0,2 H, OCH2); 
3.15 (dd, J  = 6.0, J  = 14.0, 1 H, CflaHbPh); 2.99 (dd, J  = 8.5, /  = 14.0, 1 H, CHa/ / JPh);
1.18 (app t, J  = 7.0, 3 H, CH2CH3). 13C NMR (MeOH dt): 173.0 (C=0); 167.9 (C=0);
138.1 (C); 131.4 (CH); 130.2 (CH); 129.5 (CH); 127.9 (CH); 127.4 (CH2); 62.4 (CH2);
55.5 (CH); 38.5 (CH2); 14.4 (CH3).
IR, solution cell, DCM (c m 1): 3420 (N-H stretch); 2986; 2359; 1735 (C=0 stretch); 1676 
(C=0 stretch); 1632; 1506.
HRMS calc, for Ci4H n NOj: 270.1106 [M+Na]+; found 270.1112.
(a)25u +133.6 (c 0.24, CHCI3). Lit. (a)20D 121.7° (c = 3.0, C6H6).
Mp: 64-66 °C. Lit. 6 6 °C
(R)-2-Acryloylamino-3-phenyl-propionic acid ethyl ester
.OEt
R-19
To a stirred solution of D-Phe (1.0 g, 6.1 mmol) in ethanol at -5°C was added thionyl 
chloride (0.50 mL, 6.7 mmol). This was allowed to warm to RT and the mixture stirred 
for a further 18 h. The solvent was removed in vacuo and the crude mixture N- 
acryloylated according to protocol II. R-19 was obtained as a white solid (0.48 g, 32%). 
NMR and IR data analogous to 19 
(a)2SD -132.0 (c 0.27, CHCI3)
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20 -  (S)-2- [5-((S)-2- Acety lamino-3-pheny 1-propiony lamino)-pent-2-enoy lamino] -3- 
phenyl-propionic acid ethyl ester
‘OEt
Method 7: To a stirred solution of 18 (240 mg, 0.92 mmol) and 19 (230 mg, 0.40 mmol) 
in DCM (3 mL) was added GII (40 mg, 5 mol%). The mixture was refluxed for 24 h, by 
which time a white precipitate had formed. DCM (5 mL) was added and the mixture 
refluxed for a further hour to achieve dissolution. The solution was allowed to cool to RT, 
silica gel (5 g) added and the solvent removed in vacuo. Purification of the dry-loaded 
product mixture using silica-gel chromatography (ethyl acetate, then 5% MeOH in ethyl 
acetate) afforded 20 as a light brown solid (269 mg, 61%). Repetition using 18 (120 mg, 
0.46 mmol), 19 (100 mg, 0.40 mmol) and GII (23 mg, 7 mol%) afforded 174 mg 20 
(90%) and the homodimer, 21 (33 mg, 15%).
Method 2: A solution of 18 (33 mg, 1.3 mmol), 19 (25 mg, 0.10 mmol) and GII (16 mg, 
19 mol%) in DCM (1.0 mL) was sealed in a microwave vial. The solution was subjected 
to microwave irradiation (150 W, 90°C) for 1 h. The solution was allowed to cool to RT, 
silica gel (1.5 g) added and the solvent removed in vacuo. Purification of the dry-loaded 
product mixture using silica-gel chromatography (ethyl acetate, then 5% MeOH in ethyl 
acetate) gave 32 as a pale brown solid (34 mg, 71%).
*H NMR (DMSO d6): 8.37 (d, J  = 6.0, 1 H, NTT); 8.11 (d, J  = 9.0, 1 H, NTT); 8.06 (br, 1 
H, NTT); 7.14-7.28 (m, 10 H, Ar-TT); 6.61 (app d t , ./ = 15.5, /  = 7.0, 1 H, CH2C77=CH); 
5.95 (d, J  = 15.5, 1 H, CH2CH=CT7); 4.49 (app dt, J = 8.0, J  = 6.0, 1 H, NHCT7); 4.41 
(app dt, J  = 9.0, J  = 5.0, 1 H, NHCH); 4.02 (app q, /  = 7.0, 2 H, OC772); 2.86-3.20 (m, 4 
H, CHCT72Ph, NHCT72 superimposed); 2.91 (dd, J  = 5.0, J  = 13.5, 1 H, CTfH^h); 2.71
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(dd, J = 9.0, J  = 13.5, 1 H, CHaflbPh); 2.19 (app q, J  = 7.0, 2 H, ff2CCH=CH); 1.74 (s, 3 
H, COCH3); 1.08 (app t, 3 H, J  = 7.0, CH2CH,).
13C NMR (DMSO d6): 171.6 (C=0); 171.1 (C=0); 168.9 (C=0); 164.6 (C=0); 140.6 
(CH); 138.0 (C); 137.1 (C); 129.0 (CH); 128.95 (CH); 128.2 (CH); 127.9 (CH); 126.5 
(CH); 126.1 (CH); 124.9 (CH); 60.4 (CH2); 54.0 (CH); 53.6 (CH); 37.8 (CH2); 37.5 
(CH2); 36.8 (CH2); 31.4 (CH2); 22.4 (CH3); 13.9 (CH3).
IR, solution cell, DCM (cm 1): 3424 (N-H stretch); 2963; 2358; 1734 (C=0 stretch); 
1674 (C=0 stretch); 1506.
HRMS calc, for C27H33N30 5: 502.2318 [M +Naf; found 502.2325.
( a ) 16D -4.6 (c 0.33, CHC13).
21 -  (S)-2-AcetyIamino-N-[6-((S)2-acetylamino-3-phenyl-propionylamino)-hex-3- 
eny 1] -3-pheny 1-propionamide
'H NMR (DMSO d6): 8.10 (d, J  = 9.0, 2 H, NtfCH); 7.93 (t, J  = 5.5, 2 H, N#CH2); 7.13-
7.26 (m, 10 H, Ar-Hy, 5.26-5.33 (m, 2 H, CH=CH): 4.43 (app dt, J  = 5.5, J = 9.0, 2 H, 
NHC/f); 2.95-3.14 (m, 4 H, NHCtf2); 2.91 (dd J = 5.5, J  = 13.5, 2 H, C/T'H'TPh); 2.71 (dd, 
]=  13.5, J  = 9.0, 2 H, C H ^ P h ) ;  1.95-2.03 (m, 4 H, C/72CH=CH); 1.74 (s, 6  H, COCHi). 
13C NMR (DMSO d6): 171.0 (C=0); 169.0 (C=0); 138.0 (C); 129.1 (CH); 128.7 (CH);
128.0 (CH); 126.2 (CH); 54.1 (CH); 38.4 (CH2); 38.0 (CH2); 32.2 (CH2); 22.5 (CH2).
IR, solid disc (cm'1): 3279 (N-H stretch); 2929; 1639 (C=0 stretch); 1533.
HRMS calc, for C28H36N40 4: 515.2629 [M+Na]+; found 515.2636.
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22 -  (S)-2-Acryloylamino-3-methyl-butyric acid ethyl ester
ValOEt HC1 (1.7 g, 9.4 mmol) was acryloylated according to protocol II, yielding 22 as a 
pale yellow liquid (1.0 g, 54%).
‘H NMR (MeOH d*): 6.40 (dd, J  = 10.0, J  = 17.0, 1 H, H2CCtf); 6.24 (dd, J  = 2.0, J  =
17.0, 1 H, HC=C//H trans); 5.68 (dd, J  = 2.0, J  = 10.0, 1 H, HC=CHH trans)-, 4.37 (d, J 
= 6.5,1 H, HNC//); 4.14-4.23 (m, 2 H, OCH2): 2.16 (app octet, J  = 6.5,1 H, Ctf(CH3)2);
1.26 (app t, J = 7.0, OCH2CH3); 0.96 (d, J  = 6.5, 6  H, CH(C//3)2). 13C NMR (MeOH d4):
173.0 (C=0); 168.2 (C=0); 131.5 (CH); 127.5 (CH2); 62.2 (CH2); 59.4 (CH); 31.8 (CH);
19.5 (CH3); 18.5 (CH3); 14.5 (CH3).
IR, solution cell, DCM (cm 1): 3678; 3425 (N-H stretch); 2972; 1732 (C=0 stretch); 1678 
(C=0 stretch); 1626; 1510.
HRMS calc, for CioHi7N 0 3: 222.1106 [M+Na]*; found 222.1104.
(a)16D +19.7 (c 1.24, CHC13). Lit. (a)20D -9.9 (c 9.9, C6H6).
23 -  (S)-l-acryloyl-pyrrolidine-2-carboxylic acid methyl ester
•OMe
ProOMe HC1 (415 mg, 2.5 mmol) was acryloylated according to protocol II yielding 23 
as a colourless liquid (340 mg, 72%). This consisted of a 3:1 mix of rotamers, clearly 
visible by NMR. Heating did not result in coalescence of peaks and thus the spectmm for 
each conformation is reported separately.
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Conformation 1 (75%)
'H NMR (CDCI3, 400 MHz): 6.44 (dd, J  = 10.0, J  = 17.0, 1 H, Ctf=CH2); 6.35 (dd, J =
2.0, J  = 17.0, 1 H, CH=CH2); 5.67 (dd, J  = 10.0, J  = 2.0, 1 H, CH=Ctf2); 4.51 (dd, J  =
4.0, J  = 8.5, 1 H, NC/7); 3.69 (s, 3 H, OMe); 3.55-3.77 (m, 2 H, NCT/2); 1.91-2.27 (m, 4 
H, NCH2C//2C //2). 13C NMR (CDC13, 100 MHz): 172.6 (C=0); 164.4 (C=0); 128.4 
(CH2); 128.0 (CH); 58.8 (CH3); 52.1 (CH); 46.9 (CH2); 29.1 (CH2); 24.7 (CH2). 
Conformation 2 (25%)
‘H NMR (CDCI3, 400 MHz): 6.33 (dd, J  = 2.0, J  = 17.0, 1 H, CH=CH2); 6.20 (dd, J  =
10.5, J  = 17.0, 1 H, CH=CH2); 5.62 (dd, J  = 2.0, J = 10.5, 1 H, CH=Ctf2); 4.48 (dd, J  =
3.0, J  = 8.5, 1 H, NCtf); 3.70 (s, 3 H, OMe); 3.55-3.77 (m, 2 H, NC//2); 1.91-2.27 (m, 4 
H, NCH2CH2CH2). 13C NMR (CDC13, 100 MHz): 172.5 (C=0); 164.8 (C=0); 128.1 
(CH2); 128.0 (CH); 59.2 (CH3); 52.5 (CH); 46.4 (CH2); 31.3 (CH2); 22.5 (CH2).
IR, solution cell, DCM (c m 1): 3476; 2959; 2883; 1744 (C=0 stretch); 1649 (C=0 
stretch); 1609.
HRMS calc, for C9H 13N0 3: 206.0793 [M+Na]+; found 206.0793.
(a)14D -54.0 (c 0.84, MeCN). Lit (a)20D -110.0 (c 1.00, CHCI3).
24 -  (S)-2-[5-((S)-2-Acetylamino-3-phenyl-propionylamino)-pent-2-enoylamino]-3- 
methyl-butyric acid ethyl ester
'OEt
Method 7: To a stirred solution of 18 (110 mg, 0.42 mmol) and 22 (80 mg, 0.40 mmol) in 
DCM (3 mL) was added G II (19 mg, 6  mol%). The resultant mixture was refluxed for 24 
h, by which time a white precipitate had formed. DCM (5 mL) was added and the mixture 
refluxed until complete dissolution had occurred. The solution was allowed to cool to RT, 
silica gel (5 g) added and the solvent removed in vacuo. Purification the dry-loaded
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product mixture by silica-gel chromatography (ethyl acetate, then 5% MeOH in ethyl 
acetate) yielded 24 as a pale brown solid (72 mg, 42%).
Method 2: To a stirred solution of 18 (74 mg, 0.28 mmol) and 21 (50 mg, 0.25 mmol) in 
DCM (3 mL) was added GEE (21 mg, 10 mol%). The resultant mixture was refluxed for 
72 h, by which time a white precipitate had formed. DCM (5 mL) was added and the 
mixture refluxed until complete dissolution had occurred. The solution was allowed to 
cool to RT, silica gel (5 g) added and the solvent removed in vacuo. Purification the dry- 
loaded product mixture by silica-gel chromatography (ethyl acetate, then 5% MeOH in 
ethyl acetate) yielded 25 as a pale brown solid (59 mg, 55%).
Method 3: A solution of 18 (75 mg, 0.28 mmol), 21 (52 mg, 0.25 mmol) and G II (16 mg, 
9 mol%) in DCM (2.0 mL) and DMF (3 drops) was sealed in a microwave vial. The 
solution was subjected to microwave irradiation (150 W, 90°C) for 15 min. After cooling, 
the mixture was irradiated for a further 15 min. The solution was allowed to cool to RT, 
silica gel (5 g) added and the solvent removed in vacuo. Purification the dry-loaded 
product mixture by silica-gel chromatography yielded 25 as a pale brown solid (47 mg, 
55%).
*H NMR (MeOH d4): 7.16-7.32 (m, 5 H, Ar-H); 6 .6 8  (app dt, J  = 15.5, J  = 7.0, 1 H, 
CH2C//=CH); 6.07 (d, J  = 15.5, 1 H, CH2CH=C//); 4.52 (ddd, J  = 2.0, J  = 6.5, J  = 9.0, 1 
H, C//CH2Ph); 4.35 (d, J  = 6.5, 1 H, C//CH(CH3)2); 4.16 (app q, J  = 7.0, 2 H, OCH2); 
3.21-3.31 (m, 2 H, NCH2); 3.06 (dd, J  = 6.5, J  = 13.5, 1 H, C /^H bPh); 2.85 (dd, J  = 9.0, 
J = 13.5, 1 H C H V P h); 2.29 (app q, J  = 7.0, 2 H, NCH2C//2CH); 2.32 (app octet, J  =
6.5, 1 H, a / (C H 3)2); 1.89 (s, 3 H, COC//3); 1.27 (t, J  = 7.0, 3 H, CH2CH3); 0.94 (d, J  =
6.5, 6  H, CH(C//3)2). 13C NMR (MeOH d4): 173.7 (C=0); 173.1 (C=0); 173.05 (C=0);
168.3 (C=0); 142.8 (CH); 138.5 (C); 130.3 (CH); 129.4 (CH); 127.8 (CH); 126.0 (CH);
62.2 (CH2); 59.4 (CH); 56.4 (CH); 39.2 (CH2); 39.1 (CH2); 32.8 (CH2); 31.9 (CH3); 22.5 
(CH3); 19.5 (CH3); 18.6 (CH3); 14.6 (CH).
IR, solution cell, DCM (cm'1): 3425 (N-H stretch); 3308 (N-H stretch); 2969; 2936; 1731 
(C=0 stretch); 1647 (C=0 stretch); 1507.
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HRMS calc, for C23H33N3O5: 454.2312 [M+Na]+; found 454.2315.
25 -  (S)-2-[(E)-5-((S)-2-terf-Butoxycarbonylamino-3-phenyl-propionylamino)-pent- 
2-enoylamino]-3-phenyl-propionic acid ethyl ester
SS-product: A solution of 11 (80 mg, 0.25 mmol), 19 (50 mg, 0.20 mmol) and GII (32 
mg, 19 mol%) in DCM (1 mL) was sealed in a microwave vial. The solution was 
subjected to microwave irradiation (150 W, 80 °C) for 1 h. The solution was allowed to 
cool to RT and the solvent removed in vacuo. The resultant material was dissolved in a 
small amount of DCM and purified by silica-gel chromatography (petroleum ether and 
ethyl acetate, initial 3:1 v:v, final 100% ethyl acetate) affording 25 as a brown waxy solid 
(92 mg, 8 6 %).
RS-product: A solution of R-11 (80 mg, 0.25 mmol), 19 (50 mg, 0.20 mmol) and GII (32 
mg, 19 mol%) in DCM (1 mL) was sealed in a microwave vial. The solution was 
subjected to microwave irradiation (150 W, 80 °C) for 2 h. The solution was allowed to 
cool to RT and the solvent removed in vacuo. The resultant material was dissolved in a 
small amount of DCM and purified by silica-gel chromatography (petroleum ether and 
ethyl acetate, initial 3:1 v:v, final 100% ethyl acetate) yielding RS-25 as a brown waxy 
solid (71 mg, 61%).
SR-product: A solution of 11 ( 8 6  mg, 0.27 mmol), R-19 (52 mg, 0.21 mmol) and GII (28 
mg, 17 mol%) was sealed in a microwave vial. The solution was subjected to microwave 
irradiation (300 W, 90 °C) for 30 mins. The reaction mixture was then degassed with 
argon for approximately 1 min, and the mixture stirred and subjected to microwave
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irradiation (300 W, 90 °C) for a further 30 mins. The resultant material was dissolved in a 
small amount of DCM and purified by silica-gel chromatography (petroleum ether and 
ethyl acetate, initial 3:1 v:v, final 100% ethyl acetate) giving SR-25 as a brown waxy 
solid (52 mg, 48%).
RR-product: 11 and 19 were reacted according to protocol IV yielding RR-25 as a red 
waxy solid (34 mg, 63%).
SS product
lH NMR (CDC13, 400 MHz): 7.14-7.28 (m, 5 H, Ph-tf); 6 .6 8  (br, 1 H, NH); 6.62 (app dt, 
J  = 15.6, J  = 7.9, 1 H, CH2C//=CH); 6.45 (br, 1 H, NH); 5.64 (d, J  = 15.6, 1 H, 
CH2CH=CH); 5.53 (br, 1 H, NH)\ 4.90 (app td, J  = 6.3, J  = 7.6, 1 H, NCtfCOOEt); 4.48 
(br m, 1 H, BocNCH); 4.16 (app q, J  = 7.5, 2 H, OC//2CH3); 3.17-3.25 (br m, 2 H, 
NHCH2); 3.06-3.17 (m, 2 H, E t0 2CHCH2); 2.99 (d, J  = 7.3, 2 H, BocNHCHCtf2); 2.10- 
2.30 (br m, 2 H, NHCH2C //2); 1.36 (s, 9 H, C(C//3)3); 1-22 (app t, J  = 7.5, 3 H, 
OCH2C //3). 13C NMR (CDC13): 172.2 (C=0); 171.8 (C=0); 165.1 (C=0); 155.7 (C=0);
141.1 (CH); 137.0 (C); 136.1 (C); 129.5 (CH); 129.3 (CH); 128.5 (2CH); 127.0 (CH);
126.8 (CH); 124.9 (CH); 80.0 (C); 61.5 (CH2); 55.8 (CH); 53.9 (CH); 39.2 (CH2); 38.1 
(CH2); 37.6 (CH2); 31.9 (CH2); 28.3 (CH3); 14.1 (CH3). Superimposable on 13C NMR of 
RR product.
IR, solution cell, DCM (c m 1): 3425 (N-H stretch); 2980; 2936; 1726 (C=0 stretch); 1678 
(C=0 stretch); 1501.
HRMS calc, for C30H39N3O6: 538.2917 [M+H]+; found 538.2918.
RS product
13C NMR (CDC13): 171.7 (C=0); 171.3 (C=0); 164.9 (C=0); 155.4 (C=0); 141.2 (CH);
136.8 (C); 136.0 (C); 129.4 (CH); 129.3 (CH); 128.6 (CH); 128.5 (CH); 127.1 (CH);
126.9 (CH); 125.2 (CH); 80.2 (CH); 61.42 (CH2); 56.0 (CH); 53.3 (CH); 38.8 (CH2); 38.0 
(CH2); 37.8 (CH2); 31.9 (CH2); 28.3 (CH3); 14.1 (CH3). Superimposable on 13C NMR of 
SR product.
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26 -  (S)-{ l-but-3-enyIcarbamoyl-2-[3-(toluene-4-sulfonyl)-3H-imidazol-4-yl]-ethyl}-
carbamic acid tert-butyl ester93
, N —
BocHis(Tos)OH (654 mg, 0.48 mmol) was C-functionalized with homoallyl amine 
according to protocol I yielding 26 as a viscous colourless liquid (537 mg, 73%).
‘H NMR (CDCls): 8.00 (br s, 1 H, Im-//); 7.92 (d, J  = 8.0, 2 H, Ts-H)\ 7.35 (d, J  = 8.0, 2 
H, Ts-H); 7.09 (s, 1 H, Im-H); 6.61 (br s, 1 H, NH); 5.86 (br, 1 H, NH); 5.63 (app ddt, 1 
H, J  = 17.5, J  = 10.5, J  = 6.5, H2CCH=CH2); 4.96-5.02 (m, 2 H, CH=Ctf2); 4.40 (br s, 1 
H, HNCH); 3.17 (app q, /  = 6.5, 2 H, NHCH2); 3.03 (dd, J  = 5.5, /  = 14.5, 1 H, 
C tfH bIm); 2.90 (dd, J  = 4.5, J  = 14.5, 1 H, C H ^ Im ); 2.34 (s, 3 H, ArCH3); 2.09 (app q, 
J  = 6.5, 2 H, CH2CH2CH); 1.40 (s, 9 H, C(C//3)3). 13C NMR (MeOH dA): 173.7 (C=0);
157.5 (C=0); 148.0 (C); 141.7 (C); 138.1 (CH); 136.5 (CH); 136.2 (CH); 131.7 (CH);
128.7 (CH); 117.5 (CH2); 116.4 (CH); 80.6 (C); 55.5 (CH); 39.8 (CH2); 34.6 (CH2); 31.7 
(CH2); 30.7 (CH2); 28.7 (CH2); 21.7 (CH3).
IR, solution cell, DCM (cm’1): 3423 (N-H stretch); 2978; 2934; 1711 (C=0 stretch); 1672 
(C=0 stretch); 1593.
HRMS calc, for C22H3oN40 5S: 463.2010 [M+H]+; found 463.2005.
(a)'4c +21.2 (c 0.62, CHC13)
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27 -  [(S)-2-(4-Benzyloxy-phenyl)-l-but-3-enylcarbamoyI-ethyl]-carbamic acid tert- 
butyl ester
BocTyr(Bzl)OH (594 mg, 1.6 mmol) C-functionalized with homoallyl amine according 
to protocol I affording 27 as a waxy solid (417 mg, 61%).
*H NMR (DMSO d6): 7.86 (app t, 7 = 5.5, 1 H, N//CH2); 7.30-7.43 (m, 5 H, CH2Ar-//); 
7.13 (d, J = 8.5, 2 H, H  meta to O); 6.89 (d, J  = 8.5, 2 H, H  ortho to O); 6.82 (d, 7 = 9.0, 
1 H, N//CH); 5.73 (app ddt, 1 H, 7 = 17.0, J  = 10.5, J  = 7.0, H2CC//=CH2); 5.04 (s, 2 H, 
OCtf2Ph); 4.96-5.02 (m, 2 H, CH=C//2); 4.02 (app dt, J  = 4.5, J  = 9.0, 1 H, NHCH); 
3.00-3.20 (m, 2 H, NHC//2); 2.79 (dd, J  = 9.0, 7 = 13.5, 1 H, CHC/fHbAr); 2.64 (dd, J  =
9.0, 7 = 13.5, 1 H C H C H ^A r); 2.10 (app q, 7 = 7.0, 2 H, CH2C //2CH=CH2); 1.29 (s, 9 
H, C(CH3)3). 13C NMR (DMSO <&): 171.4 (C=0); 156.8 (C=0); 155.1 (C); 137.2 (C);
135.9 (CH); 130.2 (C); 130.1 (CH); 128.3 (CH); 127.7 (CH); 127.5 (CH); 116.1 (CH2);
114.3 (CH); 77.9 (C); 69.0 (CH2); 55.9 (CH); 37.9 (CH2); 36.8 (CH2); 33.3 (CH2); 28.1 
(CH3).
IR, solution cell, DCM (cm'1): 3427 (N-H stretch); 2977; 2934; 1711 (C=0 stretch); 1676 
(C=0 stretch); 1611; 1506.
HRMS calc, for C25H32N20 4: 425.2440 [M+H]+; found 425.2448.
(a)16D +14.7 (c 0.63, CHC1,)
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28 -  ll-Oxa-2,4,9-triazatridec-3-enoic acid, 8-[(3-buten-l-ylamino)carbonyl]-12,12- 
dimethyl-10-oxo-3-[[(phenyImethoxy)carbonyl]amino]-, phenylmethyl ester, (8 S)
CY
BocArg(diZ)OH (869 mg, 1.6 mmol) C-functionalized with homoallyl amine according 
to protocol I yielding 28 as a waxy solid (520 mg, 54%).
lU NMR (DMSO d6): 9.18 (br s, (HN)2C=N); 7.78 (app t, J  = 5.5, HNCH2); 7.26-7.43 (m, 
10 H, Ar-H); 6.77 (d, J  = 8.1, 1 H, N//CH); 5.71 (app ddt, J  = 17.0, J  = 10.0, J  = 6.5, 1 
H, H2CC/7=CH2); 5.23 (s, 2 H, CH2Ph); 5.05 (s, 2 H, C //2Ph); 4.99 (d, J  = 17.0, 1 H, 
C H = C /W ); 4.95 (d, 7 = 10.0, 1 H, CH=CHcis); 3.85 (br m, 3 H,
NHC//CH2CH2C //2NH); 2.95-3.20 (m, 2 H, CONHCH2); 2.10 (app q, J  = 6.5, 2 H, 
CH2CH=CH2); 1.4-1.7 (m, 4 H, NHCHC//2C/72CH2N); 1.35 (s, 9 H, C(C//3)3). 13C NMR 
(DMSO 76): 171.6 (C=0); 162.8 (C=0); 159.5 (app t, C=N); 155.1 (C=0); 154.9 (C=0);
137.0 (C); 135.8 (CH); 135.2 (CH); 128.4 (CH); 128.2 (CH); 128.19 (CH); 127.8 (CH); 
127.78 (CH); 127.6 (CH); 116.1 (CH2); 77.9 (C); 68.1 (CH2); 66.0 (CH2); 54.0 (CH);
44.3 (CH2); 37.8 (CH2); 33.3 (CH2); 29.3 (CH2); 28.1 (CH3); 25.1 (CH2).
IR, solution cell, DCM (cm 1): 3665 (N-H stretch); 3391 (N-H stretch); 3281 (N-H 
stretch); 3038; 2974; 2941; 1715 (C=0 stretch); 1668 (C=0 stretch); 1612; 1506.
HRMS calc, for C3iH4iN50 7: 596.3079 [M+H]+; found 596.3085.
(a)25D+15.1 (c 0.29, CHC13).
Y“rY
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29 -  ((S)-2-Benzyloxy-l-but-3-enyIcarbamoyl-ethyl)-carbamic acid tert-butyl ester
BocSer(Bzl)OH (1.0 g, 3.4 mmol) was C-functionalized with homoallyl amine according 
to protocol I. Purification gave 29 as a colourless liquid (541 mg, 46%).
'H NMR (CDCla): 7.26-7.40 (m, 5 H, Ar-H); 6.49 (br t, J  = 5.5, 1 H, N#CH2); 5.71 (ddt, 
J  = 17.0, J  = 10.0, J  = 6.5, 1 H, H2CC7/=CH2); 5.41 (br, 1 H, NH); 4.92-5.00 (m, 2 H, 
H2CCH=072); 4.48 (d, J = 12.0, 1 H, OC77aHbPh); 4.42 (d, J  = 12.0, 1 H, O C H ^ P h );
4.19 (br, 1 H, NHCfl); 3.81 (dd, J  = 4.0, J  = 9.0, 1 H, NHCHC//aHb); 3.50 (dd, J  = 9.0, J  
= 6.5, 1 H, NHCHCH2* 1’); 3.17-3.34 (m, 2 H, NHC//2); 2.16 (app q, J = 6.5, 2 H, 
CH2C//2CHCH2); 1.39 (s, 9 H, C(CH,h). 13C NMR (MeOH d4): 172.8 (C=0); 157.6 
(C=0); 139.2 (C); 136.6 (CH); 129.4 (CH); 128.9 (CH); 128.8 (CH); 117.1 (CH2); 80.9 
(C); 74.1 (CH2); 71.1 (CH2); 56.2 (CH); 39.9 (CH2); 34.6 (CH2); 28.7 (CH3).
HRMS calc. forC 22H3oN40 5 S: 371.1941 [M+Na]+; found 371.1930.
IR, solution cell, DCM (cm 1): 3425 (N-H stretch); 2978; 2872; 1713 (C=0 stretch); 1674 
(C=0 stretch).
(a)I9D +9.4 (c 0.64, CHC13).
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3 0 -  (S)-2-((E)-5-{(S)-2-ter£-Butoxycarbonylaimno-3-[l-(toluene-4-sulfonyl)-lH- 
imidazol-4-yl]-propionylamino}-pent-2-enoylamino)-3-phenyl-propionic acid ethyl 
ester
“OEt
Method 1: 26 (200 mg, 0.43 mmol), 19 (100 mg, 0.40 mmol) and GII (33 mg, 10 mol%) 
were reacted according to protocol III. After 48 h 26 and 19 were still visible by TLC, 
however the reaction was terminated. 30 was obtained as a red solid (45 mg, 16%). 
Starting materials 26 (124 mg) and 19 (59 mg) were recovered, exhibiting red colouration.
Method 2: 26 (125 mg, 0.27 mmol), 19 (56 mg, 0.23 mmol) and GII (18 mg, 9 mol%) 
were reacted according to protocol III. After 6 days 26 and 19 were still visible by TLC, 
however the reaction was terminated. 30 was obtained as a red solid (45 mg, 29%).
Method 3: 26 (116 mg, 0.25 mmol), 19 (50 mg, 0.20 mmol) and GII (28 mg, 17 mol%) 
were reacted according to protocol III, except chloroform was used in place of DCM. 
After 6  days 26 and 19 were still visible by TLC, however the reaction was terminated. 
30 was obtained as a red solid (49 mg, 36%).
Method 4: A solution of 26 (58 mg, 0.13 mmol), 19 (25 mg, 0.10 mmol) and GII (16 mg, 
19 mol%), in DCM (1.4 mL) and DMF (3 drops) was sealed in a microwave vial, the 
solution was subjected to microwave irradiation (150 W, 90°C) for 15 min. After cooling, 
the mixture was irradiated for a further 15 min and allowed to cool to RT. The solvent 
was removed in vacuo, a small amount of DCM added to the resultant material and this 
was purified using silica-gel chromatography (petroleum ether and ethyl acetate, initial 
3:1 v:v, final 100% ethyl acetate), giving 30 as a red waxy solid (28 mg, 41%).
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‘H NMR (DMSO <4, 353 K, 400 MHz): 8.02 (d, 7 = 7.5, 1 H, NH); 7.75 (app t, 7 = 5.8, 1 
H, N//); 7.27 (d, 7 = 8.0, 2 H, Ts-//); 7.19-7.27 (m, 5 H, Phe-H); 7.09 (d, 7 = 8.0, 5 H, 
Ts-//); 6.65 (br, 1 H, NH); 6.57 (app dt, 7 = 15.5,7 = 7.0, 1 H, CH2C//=CH); 6.00 (d, 7 =
15.5, 1 H, CH2CH=C//); 4.57 (app dt, 7 = 6 .5 ,7 = 8.0, 1 H, NHC//CH2Ph); 4.24 (app dt, 
7 = 5.5,7 = 8.5, 1 H, NHC//CH2Im); 4.05 (app q, 7 = 7.0, 2 H, OC//2CH3); 3.10-3.22 (m, 
2 H, CONHC//2); 3.10 (dd, 7 = 15.0,7 = 5.5, 1 H, C/TT^Im); 3.05 (dd, 7 = 14.0,7 = 6.5, 
1 H, C //aHbPh); 2.95 (dd, 7 = 14.0, 7 = 8.5, 1 H, CHa//*Ph); 2.90 (dd, 7 = 15.0,7 = 8.5, 1 
H, C H ^ Im ); 2.29 (s, 3 H, ArCH}): 2.23 (app q, 7 = 6.5, 2 H, NHCH2C //2); 1.34 (s, 9 H, 
C(C//3)3); 1.12 (app t, 7 = 7.0, 3 H, OCH2C //3). 13C NMR (CDC13): 171.9 (C=0); 171.2 
(C=0); 165.1 (C=0); 155.6 (C=0); 146.5; 141.4; 140.5; 136.4; 136.1; 134.7; 130.5 (CH);
129.3 (CH); 128.5 (CH); 127.5 (CH); 127.0 (CH); 125.2 (CH); 114.9; 80.2 (C); 61.5 
(CH2); 54.1 (CH); 53.3 (CH); 38.0 (CH2); 37.9 (CH2); 32.1 (CH2); 30.3 (CH2); 28.3 
(CH3); 21.7 (CH3); 14.1 (CH3).
IR, solution cell, DCM (cm 1): 3422 (N-H stretch); 3296 (N-H stretch); 2932; 1762 (C=0 
stretch); 1674 (C=0 stretch); 1501.
HRMS calc, for C34H43N5O8S: 682.2905 [M+H]+; found 682.2920.
31 -  2,4,10,16-Tetraazaoctadeca-3,13-dienedioic acid, 8-[[(l,l- 
dimethylethoxy)carbonyl]amino]-9,15-dioxo-3-[[(phenylmethoxy)carbonyl]amino]- 
17-(phenylmethyl)-, 18-ethyl l-(phenylmethyl) ester, (8S,13E,17S)
.OEt
NH
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Method 1: 28 (134 mg, 0.23 mmol), 19 (52 mg, 0.21 mmol) and GII (21 mg, 12 mol%) 
were reacted according to protocol III affording 31 as a red waxy solid (120 mg, 70%).
Method 2: 28 ( 6 6  mg, 0.11 mmol) and 19 (25 mg, 0.10 mmol) were reacted according to 
protocol IV yielding 31 as a red waxy solid (32 mg, 40%). Repetition afforded 43%.
Method 3: 28 (89 mg, 0.15 mmol) and 19 (25 mg, 0.10 mmol) were reacted according to 
protocol IV yielding 31 as a red waxy solid (45 mg, 55%).
lH NMR (400 MHz, 353 K) (DMSO d6): 8.98 (s, 2 H, (//N)2C=N); 7.93 (br d, 1 H, 
N7/CHCH2Ph); 7.56 (br t, 1 H, NHC//2); 7.19-7.40 (m, 15 H, Ar-H); 6.57 (app dt, 1 H, J  
= 15.5, /  = 7.0, CH2C//=CH); 6.23 (br m, 1 H, NtfCHCH2CH2); 5.98 (d, J  = 15.5, 1 H, 
CH2CH=C//); 5.25 (app s, 2 H, OCtf2Ph); 5.07 (app s, 2 H, OC//2Ph); 4.58 (ddd, J  = 8.5, 
J  = 8.0, J  = 6.0, 1 H, NHC//CH2Ph); 4.05 (app q, J  = 7.0, 2 H, OCH2); 3.87 (m, 3 H, 
NHC//CH2CH2C/72N=C); 3.12 (m, 2 H, CONCH2); 3.05 (dd, J  = 6.0, J  = 13.5, 1 H, 
C /fH ^ h ); 2.98 (dd, J  = 8.5, J  = 13.5, 1 H, CHV^Ph); 2.23 (app q, 2 H, /  = 7.0, 
H2CCH=C); 1.45-1.65 (m, 4 H, NHCHC//2C //2CH2N=C); 1.36 (s, 9 H, C(CH3)3); 1.12 
(app t, J  = 7.0, 3 H, OCH2C //3). 13C NMR (CDC13): 172.0 (C=0); 171.7 (C=0); 165.1 
(C=0); 163.4 (C=0); 160.9 (C=N); 155.8 (C=0); 155.5 (C=0); 141.3 (CH); 136.4 (C);
136.0 (C); 134.6 (C); 129.3 (CH); 128.8 (CH); 128.6 (CH); 128.5 (CH); 128.3 (CH);
128.2 (CH); 127.0 (CH); 124.9 (CH); 79.6 (C); 69.0 (CH2); 67.2 (CH2); 61.5 (CH2); 53.5 
(CH); 53.2 (CH); 44.1 (CH2); 37.9 (CH2); 37.7 (CH2); 31.9 (CH2); 29.0 (CH2); 28.4 
(CH3); 24.5 (CH2); 14.1 (CH3).
IR, solution cell, DCM (cm'1): 3391 (N-H stretch); 2976; 2939; 1719 (C=0 stretch); 1676 
(C=0 stretch); 1611; 1504.
HRMS calc, for C43H54N6Oio: 815.3974 [M+H]+; found 815.3979.
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32 -  (S)-2-{ (E)-5- [(S)-3-(4-Benzyloxy-phenyl)-2-tert-butoxycarbonylamino- 
propionylamino]-pent-2-enoylamino}-3-phenyl-propionic acid ethyl ester
Method 1: 27 (95 mg, 0.23 mmol), 19 (52 mg, 0.21 mmol) and GII (19 mg, 11 mol%) 
were reacted according to protocol III yielding a 32 as a pale brown waxy solid (120 mg, 
70%).
Method 2: A solution of 27 (53 mg, 1.3 mmol), 19 (25 mg, 0.10 mmol) and GII (16 mg, 
19 mol%) in DCM (1.4 mL) was sealed in a microwave vial. The solution was subjected 
to microwave irradiation (150 W, 90°C) for 15 min. The mixture was irradiated for a 
further three periods of 15 min, after which time 27 was no longer visible by TLC. The 
reaction mixture was allowed to cool to RT, and the solvent removed in vacuo. The 
resultant material was dissolved in a small amount of DCM and purified by silica-gel 
chromatography (petroleum ether and ethyl acetate, initial 3:1 v:v, final 100% ethyl 
acetate) affording 32 as a pale brown waxy solid (37 mg, 57%).
Optimization: A solution of 27 and 19 in DCM (0.5 mL) was added to a microwave vial. 
Molar ratios are shown in Table 1. The smallest molarity used was 0.1 mmol in every 
case. A Grubbs catalyst was added, the vial sealed, and the mixture subjected to 
microwave irradiation for 30 mins. The reaction mixture was then degassed with argon 
for approximately 30 seconds, and the mixture subjected to microwave irradiation for a 
further 30 mins. The reaction mixture was allowed to cool to RT, and the solvent 
removed in vacuo. The resultant material was dissolved in a small amount of DCM and
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purified by silica-gel chromatography (petroleum ether and ethyl acetate, initial 3:1 v:v, 
final 100% ethyl acetate). All conditions and yields are reported in Table 1.
Table 1
Mol(27)/
Mol(19)
Mol% G II Catalyst
Temp
(°C)
Power
(W)
Yield
(%)
1.3 18 G II 80 150 55
1.3 18 G II 90 300 66
0.83 26 G II 90 300 61
1.3 18 HG 90 300 36
2.1 20 G II 90 300 52
0.83 18 § G II 90 300 58
1.3 18 G II 100 300 82
1.3 18 G II 110 300 59
1.3 18 G II 100 n/a* 58
1.3 18 G II 95 n/a* 77
§ Catalyst added in 2 x 9 ^imol portions, one initially, the second after 30 min 
* Used a Biotage Initiator 60 microwave unit
lH NMR (MeOH dA, 400 MHz, 333 K): 7.16-7.39 (m, 10 H, Ar-H); 7.10 (d, J  = 8.5, 2 H, 
H  meta to O); 6.89 (d, J  = 8.5, 2 H, H  ortho to O); 6.64 (app dt, J  = 15.5, J  = 7.0, 1 H, 
CH2C//=CH); 5.94 (d, J  = 15.5, 1 H, CH2CH=Cfl); 5.03 (s, 2 H, OC//2Ph); 4.71 (dd, 1 H, 
J  = 6.5, J  = 8.0, NHC//CH2Ar); 4.18 (app t, J  = 7.0, BocNHC//CH2Ar); 4.10 (app q, 7 =
7.0, 2 H, OC//2CH3); 3.15-3.24 (m, 2 H, CONHC//2); 3.11 (dd, 7 = 6.5, J  = 14.0, 1 H, 
C /fH bPh); 2.99 (dd, J  = 8.0, J  = 14.0, 1 H, C H ^ P h ); 2.95 (dd, J  = 6.5, J  = 13.8, 1 H, 
C /fH bAr); 2.67 (dd, J  = 8.0, J  = 13.8, 1 H, C H ^ A r); 2.27 (app q, 7 = 7.0, 2 H, 
H2CCH=C); 1.35 (s, 9 H, C(Ctf3)3); 1.18 (app t, 7 = 7.0, 3 H, OCH20 7 3). 13C NMR 
(CDCI3): 172.0 (C=0); 171.7 (C=0); 165.1 (C=0); 157.7 (C=0); 155.6 (C); 141.1 (CH);
137.0 (C); 136.1 (C); 130.4 (C); 130.4 (CH); 129.3 (CH); 128.6 (CH); 128.5 (CH); 128.0 
(CH); 127.5 (CH); 127.0 (CH); 125.0 (CH); 115.0 (CH2); 80.0 (C); 70.1 (CH2); 61.5
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(CH2); 53.4 (CH2); 56.0 (CH); 53.4 (CH); 38.2 (CH2); 38.0 (CH2); 37.6 (CH2); 32.0 
(CH2); 28.3 (CH3); 14.1 (CH3).
IR, solution cell, DCM (c m 1); 3425 (N-H stretch); 2979; 2933; 1726 (C=0 stretch); 1678 
(C=0 stretch); 1506.
HRMS calc, for C37H45N3O7: 666.3150 [M+Na]+; found 666.3142.
32hd- ((S)-2-(4-Benzyloxy-phenyl)-l-{6-[(S)-3-(4-benzyloxy-phenyl)-2-tert- 
butoxycarbonylamino-propionylamino]-hex-3-enylcarbamoyl}-ethyl)-carbamic acid 
tert-butyl ester (Homodimer)
!H NMR (CDCI3): 7.23-7.60 (m, 10 H, Ar-H); 7.10 (d, J  = 8.5, 4 H, H  ortho to O); 6.89 
(d, J  = 8.5, 4 H, H  meta to O); 6.75 (br, 2 H, N//CH2); 5.51 (d, J = 8.5, 2 H, NHCR);
5.26 (br m, 2 H, CH=CH); 4.99 (s, 4 H, O C//2Ph); 4.38 (br m, 2 H, NUCH); 3.50 (br m, 2 
H, NHC/fflhCH^); 2.97 (dd, J  = 7.0, J  = 14.0, 2 H, C tfU bAr); 2.85 (dd, J  = 7.5, J =
14.0, 2 H, C H ^ A r); 2.81-3.16 (obsc, 2 H, NHCHa/^C H 2); 2.13 (br m, 2 H, 
C /^H bCH=CH); 2.04 (br, 2 H, C H ^ C H ^ H ) ;  1.36 (s, 6 H, COC//3). 13C NMR 
(CDCI3): 172.1 (C=0); 157.6 (C=0); 155.8 (C); 137.0 (C); 130.3 (CH); 129.8 (CH);
129.5 (CH); 128.6 (CH); 127.9 (CH); 127.4 (CH); 114.8 (CH); 79.8 (C); 70.0 (CH2); 56.3 
(CH); 38.6 (CH2); 38.1 (CH2); 32.6 (CH2); 28.3 (CH3).
IR, solution cell, DCM (cm'1): 3427 (N-H stretch); 3352; 2932; 1668 (C=0 stretch); 1508. 
HRMS calc, for C48H60N4O8: 843.4303 [M+Na]+; found 843.4320.
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33 -  (S)-l-[(E)-5-((S)-3-Benzyloxy-2-te/f-butoxycarbonylamino-propionylamino)-
pent-2-enoyl]-pyrrolidine-2-carboxylic acid methyl ester
OEt
Method 7: 29 (104 mg, 0.30 mmol) and 23 (42 mg, 0.23 mmol) were reacted according to 
protocol III, using chloroform in place of DCM. Purification yielded 33 as a brown waxy 
solid (56 mg, 49%)
Method 2: A solution of 29 (88 mg, 1.3 mmol) and 23 (25 mg, 0.10 mmol) and GII (16 
mg, 10 mol%) in DCM (1.4 mL) was sealed in a microwave vial. The solution was 
subjected to microwave irradiation (150 W, 60°C) for 2 h. Purification of the product 
mixture using silica-gel chromatography (petroleum ether and ethyl acetate, initial 3:1 v:v, 
final 100% ethyl acetate) yielded 33 as a brown waxy solid (35 mg, 35%).
Method 3: 29 (35 mg, 0.12 mmol) and 23 (19 mg, 0.10 mmol) were reacted according to 
protocol IV. Purification yielded 33 as a brown waxy solid (25 mg, 50%).
*H NMR (CDC13, 400 MHz): 7.23-7.33 (m, 5 H, Ph-77); 6.81 (app dt, J  = 14.0, J = 6.5, 1
H, CH2C7/=CH); 6.51 (br, 1 H, N77); 6.15 (d, J = 15.2, 1 H, CH2CH=C/7); 5.29 (d, J =
5.5, 1 H, N77CH); 4.51 (AB q, /  = 11.8, 2 H, OC772Ph); 4.41-4.52 (br, 1 H, C77C02Me);
4.20 (app dt, J  = 4.5, J  = 6.5, 1 H, NHC77CH20); 3.84 (dd, J  = 9.5, J  = 4.5, 1 H, 
C H C /f^ O ); 3.68 (s, 3 H, OMe); 3.64 (br t, 1 H, NC77aHbCH2CH2); 3.56 (dd, J = 6.5, J  
= 9.5, 1 H, C H C H ^ O ); 3.51-3.57 (obsc, 1 H, N C H ^ O L C H ^ ; 3.32-3.42 (m, 2 H, 
NHC7/2); 2.37 (app q, J  = 6.5, 2 H, NHCH2C7/2); 1.86-2.20 (m, 4 H, NCH2C772C772);
I.41 (s, 9 H, C(C773)3). 13C NMR (CDC13): 172.7 (C=0); 170.3 (C=0); 164.4 (C=0);
155.5 (C=0); 142.6 (CH); 137.5 (C); 128.5 (CH); 127.9 (CH); 127.7 (CH); 123.0 (CH);
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80.2 (C); 73.4 (CH2); 69.9 (CH2); 59.2s; 58.9 (CH3); 52.6s; 54.0 (CH); 52.2 (CH); 46.8 
(CH2); 46.5s; 38.2 (CH2); 32.3 (CH2); 31.3s; 29.1 (CH2); 28.3 (CH3); 24.8 (CH2); 22.5s. 
IR, solution cell, DCM (cm 1): 3886; 3425 (N-H stretch); 2978; 2949; 2878; 1715 (C=0 
stretch); 1672 (C=0 stretch); 1616.
HRMS calc, for C26H36N3O7: 504.2710 [M+H]+; found 504.2714.
34 -  (S)-2-Acryloylamino-3-benzyIoxy-propionic acid methyl ester
>Me
To a stirred solution of BocSer(Bzl)OH (1.8 g, 6.1 mmol) in methanol (10 mL) and 
toluene (10 mL) was added 2 M TMS diazomethane in hexanes (3.1 mL, 6.2 mmol). 
Acetic acid was added dropwise until the yellow colour disappeared. The solvent was 
removed in vacuo, and a further 20 mL of toluene added. This was removed in vacuo in 
order to azeotrope off impurities. TFA (5 mL) and DCM (12 mL) were added and the 
mixture monitored by LCMS until the Boc protected material could no longer be seen. 
Toluene (10 mL) was added and the solvents removed in vacuo. This was repeated once. 
The resultant material was dissolved in DCM (40 mL) and triethylamine (0.12 mL, 0.76 
mmol) added. Acryloyl chloride in DCM (0.17 mmol per mL) was slowly added until the 
starting free amine was no longer visible by LCMS. The solvent was removed in vacuo 
and the material worked up as described in protocol II, yielding 34 as a colourless viscous 
liquid (1.24 g, 77%).
*H NMR (CDC13) 400 MHz): 7.25-7.36 (m, 5 H, Ph-//); 6.47 (d, J  = 8.0, 1 H, NH)\ 6.34 
(dd, J  = 1.5, J = 17.0, 1 H, trans //HC=CH); 6.16 (dd, J  = 10.0, J  = 17.0, 1 H, H2C=CH);
§ Smaller peaks corresponding to a different conformation of the proline portion of the compound. 
Analogous to those seen in 22.
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5.69 (dd, J  = 1.5, J  = 10.0, 1 H, cis HffC=CH); 4.84 (app dt, J  = 3.0, J  = 8.0, 1 H, 
NHCtf); 4.51 (AB q, J = 12.0, 2 H, CH2OC7/2Ph); 3.93 (dd, J  = 3.0, J  = 9.5, 1 H, 
CHCWaHbO); 3.94 (s, 3 H, OMe); 3.93 (dd, J  = 3.0, J  = 9.5, 1 H, CHCH’i / ’O). 13C NMR 
(CDC13, 100 MHz): 171.1 (C=0); 165.6 (0=0); 137.9 (C); 130.7 (CH); 128.9 (CH);
128.3 (CH); 128.0 (CH); 127.7 (CH2); 73.7 (CH2); 70.1 (CH2); 53.1 (CH); 53.0 (CH3).
IR, solution cell, DCM (cm 1): 3427 (N-H stretch); 3071; 3034; 2951; 2872; 1747 (C=0 
stretch); 1678 (C=0 stretch); 1626; 1506.
HRMS calc, for C 14H 17NO4: 264.12360 [M+H]+; found 264.12230.
( o ) 2Sd  +47.2 (c0.46 CHCI3)
35 -  (2S,3R)-2-Acryloylamino-3-benzyloxy-butyric acid methyl ester
-OMe
BocThr(Bzl)OH (472 mg, 1.5 mmol) was treated with a series of reagents, as described 
for Compound 34. 35 was obtained as a colourless viscous liquid (414 mg, 99%).
‘H NMR (CDC13, 400 MHz): 7.20-7.32 (m, 5 H, Ph-H): 6.30 (dd, J  = 1.5, J  = 17.0, 1 H, 
/ / “H t ^ H ) ;  6.25 (br s, 1 H, NH)\ 6.16 (dd, J  = 10.0, J  = 17.0, 1 H, H2C=C17); 5.66 (dd, 
J = 1.5, 7 = 10.0, 1 H, H ^ C C H ) ;  4.66 (dd, J  = 2.5, J =  9.5, 1 H, NHCfl); 4.54 (d, J  =
12.0, 1 H, C tf 'rf’Ph); 4.34 (d, J  = 12.0, 1 H, CHa/rtPh); 4.13 (dq, J  = 2.5, J = 6.5, 1 H, 
C//(CH3)OCH2); 3.63 (s, 3 H, OMe); 1.19 (d, J  = 6.5, 3 H, Cff,CHOCH2). 13C NMR 
(CDC13, 100 MHz): 171.4 (C=0); 166.1 (C=0); 138.1 (C); 130.7 (CH); 128.8 (CH);
128.3 (CH); 128.2 (CH); 127.8 (CH2); 74.8 (CH); 71.3 (CH2); 57.0 (CH3); 52.7 (CH3);
16.7 (CH3).
IR, solution cell, DCM (c m 1): 3427 (N-H stretch); 3069; 3034; 2984; 2947; 2874; 1746 
(C=0 stretch); 1678 (C=0 stretch); 1628; 1508.
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HRMS calc, for C 15H 19NO4: 278.1392 [M+H]+; found 278.13840.
(a)25D+13.0 (c 0.70, CHCI3)
36 -  (S)-(l-but-3-enylcarbamoyl-3-methyl-butyl)-carbamic acid tert-butyl ester93
To as stirred solution of BocLeuOH (1.0 g, 4.0 mmol) in DMF (5 mL) and DCM (10 mL) 
was added HATU (1.5 g, 3.9 mmol) and DIPEA (2 mL, 11.5 mmol) and the resultant 
mixture stirred for 10 minutes. A solution of homoallyl amine hydrochloride (395 mg, 
3.66 mmol) and DIPEA (0.5 mL, 2.9 mmol) in DCM (2 mL) was added and the mixture 
monitored by LCMS. After 2 h successive LCMS readings showed the relative intensities 
of the peaks to be constant. The solvent was removed in vacuo, DCM (15 mL) was added 
and worked up as described in Protocol I yielding 36 as a white waxy solid (940 mg, 
89%).
!H NMR (MeOH dA, 400 MHz): 5.81 (app ddt, J  = 17.0, J  = 10.5, J  = 7.0, 1 H, 
H2CCH=CH2); 5.10 (app dd, J  = 17.0, J  = 1.5, 1 H, #HC=CH); 5.05 (d, J  = 10.5, 1 H, 
HHC=CH); 4.05 (dd, J = 9.0, J  = 6.0, 1 H, NHCH); 3.15: 3.33 (m, 2 H, NHCH2); 2.26 
(app q, J  = 7.0, 2 H, NHCH2CH 2y, 1.61-1.72 (m, 1 H, C//(CH3)2); 1.46-1.52 (m, 2 H, 
CHCtf2CH); 1.52 (s, 9 H, C(C//3)3); 0.93-0.97 (m, 6  H, CH(C//3)2). 13C NMR (MeOH d4, 
100 MHz): 176.1 (C=0); 137.0 (CH); 117.5 (CH2); 81.0(C); 55.1 (CH); 42.9 (CH2); 40.2 
(CH2); 35.1 (CH2); 29.1 (CH3); 26.3 (CH); 23.8 (CH3); 22.4 (CH3).
IR, solution cell, DCM (cm'1): 3431 (N-H stretch); 3342 (N-H stretch); 3055; 2966; 2876; 
1707 (C=0 stretch); 1676 (C=0 stretch); 1501.
HRMS calc, for Ci5H28N20 3: 285.2178 [M+H]+; found 285.21730.
(a)25D -39.2 (c 0.47, CHC13).
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37 -  [(R)-l-But-3-enylcarbamoyl-2-(4-methyl-benzylsulfanyl)-ethyl]-carbamic acid
tert-butyl ester
To a stirred solution of BocCys(4-MeBzl)OH (2.0 g, 6.2 mmol) in DCM (5 mL) and 
DMF (5 mL) was added HOBt (873 mg, 6.5 mmol), HBTU (2.3 g, 6.1 mmol) and DIPEA 
(1.1 mL, 6.2 mmol), and the resultant mixture stirred for 20 min. A solution of homoallyl 
amine hydrochloride (335 mg, 3.1 mmol) and DIPEA (0.6 mL, 3.4 mmol) in DCM (2 mL) 
was added, and the resultant solution stirred for 3 h. The majority of the solvent was 
removed in vacuo. DCM (20 mL) was then added, and the mixture washed with HC1 
(2x10 mL, 1 M), LiCl (2x10ml, 10%), NaHCC>3 (2x10 mL, 0.5 M), water (2x10 mL) and 
saturated brine (10 mL) and dried with anhydrous MgSCL. The MgSC>4 was removed by 
filtration and the solvent removed in vacuo. The resultant material was dissolved in a 
small amount of DCM and purified by silica-gel chromatography (petroleum ether and 
ethyl acetate, initial 3:1 v:v, final 100% ethyl acetate), affording 37 as a waxy solid (989 
mg, 84%).
NMR (CDC13): 7.22 (d, J  = 8.0, 2 H, Ph-//); 7.12 (d, J = 8.0, 2 H, Ph-H); 6.26 (br t, 1 
H, N//CH2); 5.75 (app ddt, J  = 17.0, J  = 10.5, J  = 7.0, 1 H, H2CC//=CH2); 5.26 (br m, 1 
H, N//CH); 5.06-5.13 (m, 2 H, / / 2C=CH); 4.18 (br app q, /  = 6.0, 1 H, NHCH); 3.71 (s, 2 
H, S 0 7 2Ar); 3.29-3.36 (m, 2 H, NHCH2); 2.86 (dd, J  = 5.5, J  = 14.0, 1 H, C H C /fH ^);
2.70 (dd, J  = 9.5, J  = 14.0, 1 H, C H C H ^ S ); 2.32 (s, 3 H, ArCH3); 2.22-2.29 (m, 2 H, 
NUCH2CH2); 1.45 (s, 9 H, C(CH3)3). 13C NMR (CDC13): 170.5 (C=0); 155.4 (C=0);
136.9 (C); 135.0 (CH); 134.9 (C); 129.3 (CH); 128.9 (CH); 117.4 (CH2); 80.3 (C); 53.8 
(CH); 38.6 (CH2); 36.2 (CH2); 33.8 (CH2); 33.6 (CH2); 28.3 (CH3); 21.1 (CH3).
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IR, solution cell, DCM (cm 1): 3423 (N-H stretch); 2974; 2930; 2330; 1713 (C=0 stretch); 
1676 (C=0 stretch); 1489.
HRMS calc, for C20H30N2O3S: 379.2055 [M+H]+; found 379.20450.
(a)19D +3.9 (c 0.42, CHCI3)
38 -  (S)-2-[(E)-5-((S)-2-te/?-Butoxycarbonylamino-3-phenyl-propionylamino)-pent- 
2-enoyIamino]-3-methyl-butyric acid ethyl ester
.OEt
11 (70 mg, 0.22 mmol) and 22 (40 mg, 0.20 mmol) were reacted according to protocol IV 
yielding 38 as a brown waxy solid (33 mg, 34%). Repetition with 11 (35 mg, 0.11 mmol) 
and 22 (20 mg, 0.0.10 mmol) in the Biotage Initiator 60 microwave unit afforded 14.9 mg 
(30%) material.
NMR (CDC13, 400 MHz): 7.22-7.32 (m, 5 H, Ph-//); 6 .6 8  (dt, J  = 15.0, J  = 6.5, 1 H, 
CH2C//=CH); 6.52 (br d, 1 H, N//(Phe)); 6.29 (br t, 1 H, N//CH2); 5.93 (d, J  = 15.0, 1 H, 
CH2CH=C//); 4.65 (dd, J  = 5.0, J  = 9.0, 1 H, NHC//(Val)); 4.42 (br m, 1 H, 
NHC//(Phe)); 4.18-4.42 (m, 2 H, O C//2CH3); 3.20-3.40 (m, 2 H, NHC//2); 3.04 (d, J =
7.0, 2 H, CHCH2); 2.15-2.35 (m, 3 H, NHCH2C/ / 2 and C//(CH3) 2 superimposed); 1.40 (s, 
9 H, C(C//3)3); 1.32 (app t, J  = 7.0, OCH2C //3); 0.98 (app t, /  = 7.0, CH(C//3)2). 13C 
NMR (MeOH dA, 100 MHz): 174.8 (C=0); 173.5 (C=0); 168.8 (C=0); 158.0 (C=0); 
143.26 (CH); 139.0 (C); 130.8 (CH); 129.8 (CH); 128.1 (CH); 126.4 (CH); 81.0 (C); 62.6 
(CH2); 59.7 (CH); 58.0 (CH); 40.0 (CH2); 39.5 (CH2); 33.2 (CH2); 32.3 (CH); 29.1 (CH3);
19.9 (CH3); 19.0 (CH3); 15.0 (CH3).
IR, solution cell, DCM (cm 1): 3427 (N-H stretch); 3329 (N-H stretch); 3057; 2974; 2936; 
1726 (C=0 stretch); 1678 (C=0 stretch); 1504.
HRMS calc, for C26H39N30 6: 490.2917 [M+H]+; found 490.2925.
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39 -  (S)-2- [(E)-5-((S)-3-Benzyloxy-2-teft-butoxycarbonylamino-propionylamino)-
pent-2-enoylamino]-3-phenyl-propionic acid ethyl ester
33 (39 mg, 0.11 mmol) and 19 (25 mg, 0.10 mmol) were reacted according to protocol IV 
yielding 39 as a brown waxy solid (43 mg, 73%).
lH NMR (MeOH d4, 400 MHz): 7.21-7.36 (m, 10 H, Ph-//); 6.72 (app dt, J  = 15.5, J  =
7.0, 1 H, CH2C//=CH); 6.01 (d, J = 15.5, 1 H, CH2CH=C/Z); 4.71 (dd, J  = 8.5, J  = 6.0, 1 
H, NC/ZCOOEt); 4.47-4.57 (m, 2 H, CH2OC//2Ph); 4.26 (m, 1 H, BocNHC//); 4.13 (app 
q, /  = 7.0, 2 H, OC//2CH3); 3.63-3.72 (m, 2 H, CHC//20); 3.23-3.35 (m, 2 H, NHC//2); 
3.15 (dd, J  = 6.0, J  = 14.0, 1 H, C /Z ^ P h ); 3.01 (dd, J  = 8.5, J = 14.0, 1 H, C H ^ P h ); 
2.38 (app q, J  = 7.0, 2 H, NHCH2CZZ2); 1.45 (s, 9 H, C(CZZ3)3); 1.17 (app t, /  = 7.0, 
OCH2C/Z3). 13C NMR (MeOH d4, 100 MHz): 173.5 (C=0); 173.4 (C=0); 168.5 (C=0);
158.1 (C=0); 143.3 (CH); 139.7 (C); 138.5 (C); 130.7 (CH); 130.0 (CH); 129.8 (CH);
129.3 (CH); 129.2 (CH); 128.3 (CH); 126.3 (CH); 81.3 (C); 74.5 (CH2); 71.5 (CH2); 62.8 
(CH2); 56.5 (CH); 55.9 (CH); 39.7 (CH2); 39.0 (CH2); 31.1 (CH2); 29.1 (CH3); 14.8 
(CH3).
IR, solution cell, DCM (cm 1): 3423 (N-H stretch); 3059; 2980; 2936; 2870; 1722 (C=0 
stretch); 1678 (C=0 stretch); 1499.
HRMS calc, for C3iH4iN30 7: 568.30230 [M+H]+; found 568.3013.
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4 0 -  (2S3R)-3-Benzyloxy-2-[(E)-5-((S)-2-terf-butoxycarbonylamino-4-methyl-
pentanoylamino)-pent-2-enoylamino]-butyric acid methyl ester
-OMe
36 (32 mg, 0.11 mmol) and 35 (28 mg, 0.10 mmol) were reacted according to protocol IV. 
Purification yielded 40 as a pale brown waxy solid (33 mg, 61%).
NMR (CDC13) 400 MHz): 7.16-7.29 (m, 5 H, Ph-//); 6.72 (app dt, J  = 15.0, J  = 7.0, 1 
H, CH2CZ/=CH); 6.45 (br s, 1 H, NH); 6.40 (br d, J  = 8.5, 1 H, NH); 5.88 (d, /  = 15.0, 1 
H, CH2CH=C//); 5.05 (br s, 1 H, NH); 4.69 (dd, J  = 2.5, J = 9.5, 1 H, N H C//C02Me); 
4.51 (d, J  = 12.0, 1 H, C /^H bPh); 4.32 (d, J  = 12.0, 1 H, CHa/^Ph); 4.09 (dq, J  = 2.5, J  
= 6.5, 1 H, C//(CH3)OCH2); 4.06 (br s, 1 H, N//CHCH2); 3.60 (s, 3 H, OMe); 3.23-3.38 
(m, 2 H, NHCH2); 2.32 (app q, J  = 7.0, 2 H, NHCH2C //2); 1.51-1.60 (m, 2 H, 
CHC//2CH); 1.37-1.44 (m, 1 H, C//(CH3)2); 1.36 (s, 9 H, C(CH3)3); 1.16 (d, J = 6.3, 3 H, 
CZ/3CHOCH2); 0.83-0.86 (m, 6  H, CH(C//3)2). 13C NMR (CDC13, 100 MHz): 173.3 
(C=0); 171.6 (C=0); 166.3 (C=0); 156.3 (C=0); 141.9 (CH); 138.2 (C); 128.8 (CH);
128.2 (CH); 128.2 (CH); 125.6 (CH); 80.4 (C); 74.7 (CH); 71.2 (CH2); 57.0 (CH3); 53.4 
(CH); 52.8 (CH); 41.7 (CH2); 38.2 (CH2); 32.6 (CH2); 28.7 (CH3); 25.2 (CH); 23.3 (CH3);
22.4 (CH3); 16.7 (CH3).
IR, solution cell, DCM (cm'1): 3429 (N-H stretch); 2959; 2874; 1744 (C=0 stretch); 1680 
(C=0 stretch); 1504.
HRMS calc, for C28H43N30 7: 534.3179 [M+H]+; found 534.3187.
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41 -(S)-3-Benzyloxy-2-[(E)-5-((S)-2-terf-butoxycarbonylamino-4-methyl-
pentanoylamino)-pent-2-enoylamino]-propionic acid methyl ester
-OMe
36 (32 mg, 0.11 mmol) and 34 (26 mg, 0.10 mmol) were reacted according to protocol IV 
yielding 41 as a pale brown waxy solid (39 mg, 75%).
‘H NMR (CDC13, 400 MHz): 7.19-7.29 (m, 5 H, Ph-//); 6.70 (app dt, J = 15.5, J  = 6.5, 1 
H, CH2C//=CH); 6.70 (br, 1 H, N//(Ser)); 6.59 (br s, 1 H, N//CH2); 5.84 (d, J = 15.5, 1
H, CH2CH=CH); 5.14 (br d, J  = 6.0, 1 H, N//(Leu)); 4.77 (app dt, J = 5.0, J  = 3.5, 1 H, 
NHC//(Ser)); 4.48 (d, J  = 12.0, 1 H, C tfV ’Ph); 4.41 (d, J  = 12.0, 1 H, CH^Ph); 4.08 
(br s, NHC//(Leu)); 3.84 (dd, J  = 3.5, J  = 9.5, 1 H, CHC//aHbO); 3.67 (s, 3 H, OMe); 
3.64 (dd, J  = 3.5, J  = 9.5, 1 H, CHCHVO); 3.24-3.37 (m, 2 H, NHC//2); 2.31 (app q, J 
= 6.5, 2 H, NHCH2C//2); 1.51-1.60 (m, 2 H, CHC//2CH); 1.35-1.45 (m, 1 H, C//(CH3)2);
I.35 (s, 9 H, C(CH3)3); 0.83-0.86 (m, 6  H, CH(C//3)2). 13C NMR (CDC13, 100 MHz):
173.4 (C=0); 171.4 (C=0); 170.7f (C=0); 165.7 (C=0); 164.2} (C=0); 141.8 (CH);
137.9 (C); 137.8* (C); 133.5" (CH); 128.9f (CH); 128.8 (CH); 128.4* (CH); 128.3 (CH); 
138.1* (CH); 128.0 (CH); 125.6 (CH); 80.4 (C); 73.74* (CH2); 73.66 (CH2); 70.1 (CH2); 
69.8* (CH2); 53.3 (CH); 53.04 (CH); 52.96 (CH3); 42.5* (CH2); 41.8 (CH2); 38.2 (CH2);
32.5 (CH2); 28.7 (CH3); 25.2 (CH); 23.3 (CH3); 22.4 (CH3).
IR, solution cell, DCM (cm 1): 3429 (N-H stretch); 2957; 2873; 1746 (C=0 stretch); 1678 
(C=0 stretch); 1504.
HRMS calc, for C27H41N3O7: 520.3023 [M+H]+; found 520.3010.
fMinor peaks resulting from diastereoisomer impurity
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42-(S)-2-{(E)-5-[(R)-2-te/f-Butoxycarbonylamino-3-(4-methyl-benzylsulfanyl)- 
propionylamino]-pent-2-enoylamino}-3-phenyl-propionic acid ethyl ester
37 and 19 were reacted according to protocol IV affording 42 as a pale brown waxy solid 
(31 mg, 51%).
!H NMR (CDC13): 7.09-7.30 (m, 9 H, Ar-tf); 6.74 (dt, J  = 15.0, J  = 6.5, 1 H, 
CH20/= C H ); 6.55 (br t, 1 H, NHCH2); 6.34 (br d, /  = 7.0, 1 H, N//(Phe)); 5.82 (d, J  =
15.5, 1 H, CH2CH=C//): 5.45 (br, 1 H, Ntf(Cys)); 4.91 (dt, J  = 7.5, 7 = 6.0, 1 H, 
NHC//(Phe)); 4.27 (br m, 1 H, NHC//(Cys); 4.14 (app q, J  = 7.0, 2 H, OCf/2CH3); 3.30- 
3.40 (m, 2 H, CHC//2S); 3.10-3.14 (m, 2 H, CHC//2Ph); 2.80 (dd, J  = 6.0, J  = 14.0, 1 H, 
C H C tf^ S ); 2.70 (dd, J  = 7.0, /  = 14.0, 1 H, CHCHa/^S); 2.36 (app q, J  = 6.5, 2 H, 
NHCH2C //2); 2.35 (s, 3 H, PheMe); 1.44 (s, 9 H, C(CH3)3); 1.22 (app t, /  = 7.0, 
OCH2C //3). 13C NMR (CDC13): 171.9 (C=0); 171.0 (C=0); 165.1 (C=0); 155.6 (C=0);
141.1 (CH); 136.9 (C); 136.0 (C); 134.9 (C); 129.33 (CH); 129.29 (CH); 128.9 (CH);
128.5 (CH); 127.1 (CH); 125.2 (CH); 80.3 (C); 61.6 (CH2); 53.8 (CH); 53.3 (CH); 38.0 
(CH2); 36.1 (CH2); 33.9 (CH2); 32.0 (CH2); 30.3 (CH2); 28.3 (CH3); 21.1 (CH3); 14.1 
(CH3).
IR, solution cell, DCM (cm'1): 3422 (N-H stretch); 2980; 2932; 2332; 1726 (C=0 stretch); 
1678 (C=0 stretch); 1504.
HRMS calc, for C32H43N30 6S: 598.2951 [M+H]+; found 598.2937.
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43 -  L-Leucinamide, N5-[bis[[(phenylmethoxy)carbonyl]amino]methylene]-N2- 
[(l,l-dimethylethoxy)carbonyl]-L-ornithyl-N-3-buten-l-yl
36 (500 mg, 1.76 mmol) was dissolved in DCM (10 mL) and TFA (10 mL). The mixture 
was monitored by LCMS until the Boc protected material could no longer be seen. 
Toluene (20 mL) was added and the solvents removed in vacuo. This was repeated once 
and the crude deprotected product was dissolved in DCM (4 mL) and DMF ( 8  mL). To a 
stirred solution of BocArg(diZ)OH (1.0 g, 2.0 mmol) in DMF (5 mL) was added HATU 
(760 mg, 2.0 mmol) and DIPEA (1 mL, 4 mmol) and the resultant solution stirred for 10 
minutes The solution of crude deprotected product was added to the activated 
BocArg(diZ)OH solution, stirred and monitored by LCMS. The free amine was 
consumed after 35 min. The solvent was removed in vacuo, DCM (15 mL) was added 
and the mixture worked up as described in Protocol I yielding a cream-coloured waxy 
solid. The compound was triturated in ether to remove residual tetramethyl urea, y ielding 
43 as a cream-coloured waxy solid (413 mg, 33%).
‘H NMR (CDCI3, 400 MHz): 9.96 (br s, (WN)C=N); 9.31 (br s, («N)C=N); 7.30-1.45 (m, 
10  H, Ph-7/); 6.60 (d, J  = 8 .0 , N//(Leu)); 6.28 (br s, 1 H, NO); 5.73 (app ddt, J  = 17.0, J  
= 10.5, J  = 7.0, 1 H, H2CCO=CH2); 5.58 (br s, 1 H, NO(Arg)); 5.27 (s, 2 H, (O f2Ph)2); 
5.18 (AB q, J = 12.5, 2 H, C //2Ph); 5.04-5.09 (m, 2 H, W2C=CH); 4.32 (app clt,-/= 9.0, J  
= 7.0, 1 H, NHCO(Leu)); 4.15 (app q, J  = 6.5, 1 H, NHCO(Arg)); 3.90-4.05 (n , 2 H, 
C7/2NCN2); 3.16-3.37 (m, 2  H, NHCH2CH2CH=CH2); 2.22 (m, 2  H, NHC//2CH2I; 1.60-
1.70 (m, 4 H, CHC//2a / 2CH2); 1.45 (s, 9 H, C (C ft)3); 1.50-1.60 (m, 1 H, CW(CH,)2);
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1.30-1.40 (m, 2 H, CHC//2CH); 0.80-0.90 (m, 6  H, CH(C//3)2). 13C NMR (CDC13, 100 
MHz): 172.5 (C=0); 171.9 (C=0); 164.0 (C=0); 161.0 (C=0); 156.3 (C=N); 137.1 (C);
135.5 (CH); 135.0 (C); 129.32 (CH); 129.26 (CH); 128.9 (CH); 128.8 (CH); 128.4 (CH);
128.3 (CH); 117.4 (CH2); 80.6 (C); 69.4 (CH2); 67.5 (CH2); 55.0 (CH); 52.3 (CH); 44.5 
(CH2); 40.8 (CH2); 39.0 (CH2); 34.0 (CH2); 28.7 (CH3); 28.4 (CH2); 25.4 (CH2); 25.1 
(CH); 23.3 (CH3); 22.2 (CH3).
IR, solution cell, DCM (cm'1): 3391 (N-H stretch); 3281 (N-H stretch); 3072; 3036; 2961; 
2875; 2330; 1717 (C=0 stretch); 1672 (C=0 stretch); 1612; 1508.
HRMS calc, for C37H52N60 8: 425.2440 [M+H]*; found 425.2448.
(a)25D-22.5 (c0.18CHCl3)
45 -  (S)-2-((S)-3-Benzyloxy-2-tert-butoxycarbonylamino-propionylamino)- 
pentanedioic acid 5-cycIohexyl ester 1-methyl ester
-OMe
To a stirred solution of BocGlu(OcHex)OH (2.0 g, 6.2 mmol) in methanol (10 mL) and 
toluene (10 mL) was added 2 M TMS diazomethane in hexanes (3.1 mL, 6.2 mmol). 
Acetic acid was added dropwise in until the yellow colour disappeared. The solvent was 
removed in vacuo, and a further 20 mL of toluene added and removed in vacuo. TFA (8  
mL) and DCM (11 mL) were added and the mixture monitored by LCMS until the Boc 
protected material could no longer be seen. Toluene (10 mL) was added and the solvents 
removed in vacuo. This was repeated once and the crude deprotected product was 
dissolved in DCM (4 mL) and DMF (8  mL). To a stirred solution of BocSer(Bzl)OH (502 
mg, 1.7 mmol) in DCM (4 mL) and DMF (8  mL) was added HATU (646 mg, 1.7 mmol) 
and DIPEA (1 mL, 4 mmol) and the resultant solution stirred for 10 min. The solution of
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crude deprotected product was added to the activated BocSer(Bzl)OH solution. The 
resultant mixture was monitored by LCMS, and the starting material (GluOcHexOMe) 
was consumed after 0.5 h. The solvent was removed in vacuo, DCM (25 mL) was added 
and worked up as described in Protocol I yielding 45 as a viscous colourless liquid (717 
mg, 89%).
!H NMR (CDC13, 400 MHz): 7.29-7.38 (m, 5 H, Ph-H)\ 7.15 (br d, J  = 5.0, 1 H, 
N//(Glu)); 5.42 (br s, 1 H, N//(Ser)); 4.75 (m, 1 H, OCtf(CH2)2); 4.67 (dt, J  -  5.0, J =
8.5, 1 H, NHC//(Glu)); 4.55-4.61 (m, 2 H, CH2OC//2Ph); 3.74 (br m, 1 H, NHC/f(Ser)); 
3.93 (dd, J  = 3.0, J  = 9.5, 1 H, CHC/^HbO); 3.74 (s, 3 H, OMe); 3.59 (dd, J  = 6.5, J  =
9.5, 1 H, C H C H ^O ); 2.17-2.42 (m, 3 H, C /fflhC/^CO^Hex); 1.96 (app ddt, J  = 14.0, 
J  = 6.0, J = 8.5, 1 H, CHa7/bCH2C 0 2cHex); 1.80-1.87 (br m, 2 H, OcHex); 1.67-1.76 (br 
m, 2 H, OcHex); 1.50-1.59 (br m, 1 H, OcHex); 1.47 (s, 9 H, C(C//3)3); 1-38 (br m, 2 H, 
OcHex); 1.21-1.32 (br m, 1 H, OcHex). 13C NMR (CDC13) 100 MHz): 172.4 (C=0); 172.3 
(C=0); 170.7 (C=0); 155.8 (C=0); 137.8 (C); 128.9 (CH); 128.9 (CH); 128.3 (CH); 
128.25 (CH); 80.7 (C); 72.9 (CH2); 73.4 (CH); 70.2 (CH2); 54.4 (CH); 52.9 (CH); 52.1 
(CH3); 32.0 (CH2); 30.9 (CH2); 28.7 (CH3); 28.0 (CH2); 25.7 (CH2); 24.1 (CH2).
IR, solution cell, DCM (cm 1): 3425 (N-H stretch); 2941; 2864; 1719 (C=0 stretch); 1680 
(C=0 stretch); 1493.
HRMS calc, for C27H4oN20 8 : 521.2863 [M+H]+; found 521.2875.
(a)25D+l 1.2 (c 0.59 CHC13)
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46 -  (S)-2- [(S)-2-((2S,3R)-3-Benzyloxy-2-(3-benzyloxy-2-tert-butoxycarbonylamino-
butyrylamino)-propionylamino]-pentanedioic acid 5-cyclohexyl ester 1-methyl ester
>Me
45 (808 mg, 1.6 mmol) was dissolved in DCM (7 mL) and TFA (5 mL). The mixture was 
monitored by LCMS until the Boc protected material could no longer be seen. Toluene 
(10 mL) was added and the solvents removed in vacuo. This was repeated once. The 
resultant material was dissolved in DCM (20 mL). To astrirred solution of 
BocThr(Bzl)OH (525 mg, 1.7 mmol) in DMF (2 mL) was added HATU (646 mg, 1.7 
mmol) and DIPEA (1 mL, 4 mmol), and the resultant solution stirred for 10 min. The 
solution of crude deprotected product was added to the activated BocThr(Bzl)OH 
solution. The resultant mixture was monitored by LCMS, and the starting material 
(Ser(Bzl)GluOcHexOMe) was consumed after 20 min. The solvent was removed in vacuo, 
DCM (25 mL) was added and the resultant mixture worked up as described in Protocol I 
giving 46 as a white waxy solid (644 mg, 58%).
'H NMR (CDC13, 400 MHz): 7.24-7.37 (m, 10 H, Ph-//); 7.20 (d, J  = 7.2, 1 H, NH); 7.18 
(d, J  = 8.0, 1 H, NH); 5.49 (d, J  = 6.5, 1 H, NH); 4.71-4.79 (m, 1 H, OCH(CH2)2); 4.64 
(d, J  = 11.5, 1 H, OCHaHbPh); 4.16 (app dt, J  = 3.0, J  = 7.5, 1 H, NHCH); 4.58-4.66 
(obsc, 1 H, NHCH); 4.55 (d, J  = 12.0, 1 H, O C H ^P h); 4.51 (d, J  = 11.5, 1 H, 
OCHaHbPh); 4.45 (d, J  = 12.0, 1 H, O C H ^ P h ); 4.30 (br m, 1 H, NHCH(Thr)); 4.20 (br 
m, 1 H, NHCHCH(Thr)); 3.94 (dd, 1 H, J  = 2.5, J  = 9.0, CHCHaHbO); 3.27 (s, 3 H, 
OMe); 3.50 (dd, 1 H, J = 6.0, J  = 9.0, C H C H ^O ); 2.08-2.39 (m, 3 H, 
CHaHbCH2C 0 2cHex); 1.67-1.89 (brm , 5 H, CH,HbCH2C 0 2cHex, OcHex superimposed);
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1.50-1.60 (br m, 1 H, OcHex); 1.44 (s, 9 H, C(C//3)3); 1.30-1.41 (m, 4 H, OcHex); 1.25- 
1.30 (obsc, 1 H, OcHex); 1.25 (d, J  = 6.5, 3 H, C //3CHOCH2). 13C NMR (CDC13, 100 
MHz): 171.9 (C=0); 171.7 (C=0); 169.81 (C=0); 169.75 (C=0); 155.8 (C=0); 137.8 (C);
137.3 (C); 128.5 (CH);128.4 (CH); 128.0 (CH); 127.9 (CH); 127.8 (CH); 127.6 (CH);
80.3 (C); 74.8 (CH); 73.5 (CH2); 72.9 (CH); 71.7 (CH2); 69.3 (CH2); 58.2 (CH); 52.9 
(CH); 52.4 (CH); 51.7 (CH3); 31.6 (CH2); 30.5 (CH2); 28.3 (CH3); 27.3 (CH2); 25.3 
(CH2); 23.7 (CH2); 15.6 (CH3).
IR, solution cell, DCM (cm 1): 3422 (N-H stretch); 3360 (N-H stretch); 2939; 2894; 1719 
(C=0 stretch); 1680 (C=0 stretch); 1495.
HRMS calc, for C38H53N3Oi0: 712.3809 [M+H]+; found 712.3814.
( o ) 2Sd  +11.3 (c 0.23 CHCI3)
47 -  (S)-2-[(S)-2-((2S,3R)-2-Acryloylamino-3-benzyloxy-butyrylamino)-3-benzyIoxy- 
propionylaminoj-pentanedioic acid 5-cyclohexyl ester 1-methyl ester
O M e
46 (490 mg, 0.69 mmol) was dissolved in DCM ( 8  mL) and TFA ( 6  mL). The mixture 
was monitored by LCMS until the Boc protected material could no longer be seen. 
Toluene (10 mL) was added and the solvents removed in vacuo. This was repeated once. 
The resultant material was dissolved in DCM (40 mL) and triethylamine (0.12 mL, 0.76 
mmol) added. Acryloyl chloride in DCM (0.17 mmol per mL) was slowly added until the 
starting free amine was no longer visible by LCMS. The solvent was removed in vacuo 
and the material worked up as described in protocol II, affording 47 as a white waxy solid 
(359 mg, 78%).
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!H NMR (CDCI3, 400 MHz): 7.27-7.38 (m, 10 H, Ph-fl); 7.20 (d, 7 = 7.5, 1 H, NH); 7.18 
(d, 7 = 8.0, 1 H, NH); 6.64 (d, 7 = 6.5, 1 H, NH); 6.34 (dd, 7 = 1.0, 7 = 17.0, 1 H, 
H U bC=CU); 6.19 (dd, 7 = 10.0, 7 = 17.0, 1 H, H2C=CH); 5.71 (dd, 7 = 1.0, 7 = 10.0, 1 
H, HPtf’CsCH); 4.72-4.79 (m, 1 H, OC//(CH2)2); 4.73 (d, 7 = 11.5, OCtfaHbPh); 4.69 
(dd, 7 = 3.5, 7 = 6.5, 1 H, NHC/7(Thr)); 4.59-4.66 (obsc, 1 H, NHCH); 4.63 (dt, J  = 2.5, 
/  = 7.5, 1 H, NHCH); 4.60 (d, J  = 11.5, 1 H, OC/^HbPh); 4.49-4.57 (m, 2 H, OCtf2Ph); 
4.23 (dq, J  = 3.5, J  = 6.5, 1 H, NHCHC//(Thr)); 3.95 (dd, 7 = 3.5, 7 = 9.0, 1 H, 
CUCHHbO); 3.23 (s, 3 H, OMe); 3.53 (dd, 7 = 6.0,7 = 9.0, 1 H, C H C H ^O ); 2.08-2.35 
(m, 3 H, C //aHbC //2C 0 2cHex); 1.65-1.90 (br m, 5 H, CHa/^C H 2C 0 2cHex, OcHex 
superimposed); 1.50-1.65 (br m, 1 H, OcHex); 1.30-1.45 (br m, 4 H, OcHex); 1.23-1.30 
(obsc, 1 H, OcHex); 1.23 (d, 7 = 6.5, 3 H, C/73CHOCH2). 13C NMR (CDC13, 100 MHz): 
172.22 (C=0); 172.17 (C=0); 170.1 (C=0); 169.6 (C=0); 166.0 (C=0); 138.1 (C); 137.8 
(C); 130.6 (CH); 128.83 (CH); 128.78 (CH); 128.23 (CH); 128.21 (CH); 128.11 (CH);
128.09 (CH); 127.8 (CH2); 75.0 (CH); 73.8 (CH2); 73.3 (CH); 72.1 (CH2); 69.9 (CH2);
56.9 (CH); 53.4 (CH); 52.7 (CH); 52.1 (CH3); 32.0 (CH2); 30.9 (CH2); 27.6 (CH2); 25.7 
(CH2); 24.1 (CH2); 15.7 (CH3).
IR, solution cell, DCM (cm*1): 3406 (N-H stretch); 2939; 2864; 1734 (C=0 stretch); 1674 
(C=0 stretch); 1497.
HRMS calc, for C36H47N3O9: 666.3390 [M+H]+; found 666.3370.
(a)25D +11.9 (c 0.25 CHCI3)
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L-Glutamie acid, N5-[bis[[(phenylmethoxy)carbonyl]amino]methylene]-N2-[(l,l- 
dimethylethoxy)carbonyl]-L-ornithyI-L-leucyI-(2E)-5-amino-2-pentenoyl-0- 
(phenylmethyl)-L-threonyI-0-(phenylmethyl)-L-seryl-, 65-cyclohexyl 61-methyl 
ester
hn .
'Me
43 (78 mg, 0.11 mmol) and 47 (67 mg, 0.10 mmol) were reacted according to protocol IV 
in the Biotage Initiator 60 microwave unit yielding 48 as a pale brown waxy solid (51 mg, 
38%). The HPLC yield had been determined to be 67% by ELSD.
'H NMR (CDCI3, 500 MHz): 9.46 (br s, 1 H, HNC=N): 9.29 (br s, 1 H, HNC=N); 7.69 (d, 
J  = 8.0, 1 H, NWSer)); 7.55 (br d, 1 H, NMThr)); 7.38 (obsc, 1 H, N//(Glu)); 7.16-7.41 
(m, 20 H, Ar-H); 6.76 (br t, 1 H, N/7CH2); 6.70 (ddd, J  = 6.0, J = 9.1, J = 15.4, 1 H, 
CH2C7/=CH); 6.69 (d, J = 8.9, 1 H, N//(Leu)); 5.98 (d, J  = 15.4, 1 H, CH2CH=Ctf); 5.94 
(br, 1 H, Ntf(Arg)); 5.15-5.25 (m, 4 H, 2C 0 2CH2); 4.80 (m, 1 H, NHC//(Ser)); 4.72 (m,
1 H, OCH(CH2h); 4.47, 4.51 ( A B q , / =  1 1 .8 , 4 H, 20C/72Ph); 4.52 (dd, 7 = 2.1,7= 6.5,
1 H, NHCff(Thr)); 4.57 (dt, J  = 8.3, J = 5.4, 1 H, NHCWGlu)); 4.20-4.30 (m, 2 H, 
NHC//(Leu), NHCHC//(Thr) superimposed); 4.05 (app q, J  = 6.5, 1 H, NHCMArg)); 
3.84-3.90 (m, 1 H, CHaHbNCN2); 3.86 (dd, J  = 5.4, J = 9.5, 1 H, CHCHaHbO); 3.72-3.79 
(m, 1 H, CHaHbNCN2); 3.69 (s, 3 H, OMe); 3.63 (dd, J  = 5.2, J  = 9.5, 1 H, CHCHVO); 
3.45-3.52 (m, 1 H, CONHCHaHb); 2.97-3.07 (m, 1 H, CONHCHaHb); 2.40-2.50 (m, 1 H, 
CHzO^HhCO/Hex); 2.21-2.37 (m, 3 H, NHCH2C //2, CH2CHaHbC 02cHex
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superimposed); 2.09-2.20 (m, 1 H, Cf/aHbCH2C 0 2cHex); 1.80-1.91 (m, 1 H, 
C H ^C H zC O /H ex); 1.77-1.85 (br m, 2 H, OcHex); 1.68-1.72 (br m, 2 H, OcHex); 1.45- 
1.55 (br m, 6 H, CHCH2CH2CH2 (4 H), OcHex (1 H), NHCHCff(CH3)2 superimposed); 
1.42 (s, 9 H, C(CH3)3); 1.2-1.4 (br m, 5 H, OcHex); 1.22 (d. J = 6.4, 3 H, Cff3CHOCH2);
0.82 (d, J  = 6.2, 3 H, CHCa/73CbH3); 0.76 (d, J  = 6.2, 3 H, CHCaH3Cbtf3). 13C NMR 
(CDC13, 125 MHz); 172.7 (C=0); 172.3 (C=0); 171.84 (C=0); 171.77 (C=0); 170.3 
(C=0); 170.0 (C=0); 166.9 (C=0); 163.6 (C=0); 160.9 (C=0); 156.1 (C=0); 155.7 
(C=0); 140.6 (CH); 138.3 (C); 137.7 (C); 136.8 (C); 134.5 (C); 128.9 (CH); 128.8 (CH);
128.5 (CH); 128.4 (CH); 128.3 (CH); 128.2 (CH); 127.92 (CH); 127.87 (CH); 127.7 
(CH); 127.6 (CH); 127.5 (CH); 127.3 (CH); 126.4 (CH); 80.3 (C); 74.5 (CH); 73.0 (CH); 
72.8 (CH2); 71.7 (CH2); 69.2 (CH2); 69.0 (CH2); 67.0 (CH2); 58.4 (CH); 55.5 (CH); 52.8 
(CH); 52.3 (CH3); 51.7 (CH); 51.4 (CH); 44.3 (CH2); 40.3 (CH2); 37.9 (CH2); 31.5 (CH2); 
30.83 (CH2); 30.76 (CH2); 28.3 (CH3); 27.34 (CH2); 27.25 (CH2); 25.3 (CH2); 25.1 (CH2); 
24.6 (CH); 23.7 (CH2); 22.8 (CH3); 21.5 (CH3); 16.1 (CH3).
IR, solution cell, DCM (cm'1): 3387 (N-H stretch); 3055; 2936; 2862; 2307; 1719 (C=0 
stretch); 1670 (C=0 stretch); 1612; 1504.
HRMS calc, for C71H95N9O 17: 1346.6924 [M+H]+; found 1346.6952.
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4.2 -  Peptide Synthesis
4.2.1 -  Materials and Methods
All amino acids were Fmoc protected. The side-chain protection of Fmoc amino acids is 
shown in Table 1.
Amino Acid
Side-Chain
Protection
Serine rBu
Threonine rBu
Cysteine Trityl
Glutamic Acid rBu
Aspartic Acid fBu
Asparagine Trityl
Tyrosine rBu
Arginine Pbf
Table 1 -  Side-chain protective groups
(Pbf = 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)
Amino acids, HBTU and HOBt were purchased from CS Bio Co., ultra-pure DMF from 
AGTC Bioproducts Ltd., NMO from Rathbum Chemicals Ltd. and piperidine and DIPEA 
from Iris Biotech. All other reagents were obtained from Aldrich and were used as 
received.
Chlorotrityl resins were obtained from CS Bio Co. or GL Biochem Ltd., A-methyl amino 
polystyrene resins polystyrene resins from Novabiochem.
Peptide fragments were synthesized using a CEM Discover microwave peptide 
synthesizer and a CEM Liberty solvent-handling unit. Preparative HPLC and HPLC 
analyses and were carried out on a Varian ProStar system. Analytical HPLC was 
performed on Varian Microsorb MV 100-5 C l8 150x4.6 mm column, eluting with H2O
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(containing 0.1% TFA, ‘A ’) and acetonitrile (containing 0.1% TFA, ‘B’). The column 
was flushed with 95:5 A:B, isocratic flow continuing for 2 min. The percentage B was 
increased to 95% over 6 min, followed by 6 min isocratic flow. Preparative HPLC was 
performed on Phenomenex Jupiter 10pm C l8 250x10.0 mm column, eluting with A and
B. Two methods were used. The first was the same as for the analytical HPLC. In the 
second, the column was flushed with 75:25 A:B. The percentage B was increased to 95% 
over 12 min, followed by 2 min isocratic flow. Mass spectra were obtained using a 
Micromass Quattro.
4 .2 .2 - Typical resin handling procedures
Resins were always stored shrunk at RT. Shrinkage was achieved by addition of ether, 
shaking, draining and removal of solvent under vacuum for 3 h.
4.2.2.1 -  Resin Wash
A resin wash comprised (unless otherwise stated) three washes with DMF, followed by 
three with DCM. In each wash enough solvent was used to sufficiently submerge the 
resins, and the resins were shaken (ca. 10 s) prior to drainage and addition of the next 
round of washing solvent.
4.2.2.2 -  Fmoc Test
To check the loading of resins, a small portion of the loaded, shrunk resins (3-5 mg) were 
removed and piperidine in DMF (1 ml, 1:4 v:v) added. After 1 h, 0.5 ml of the solution 
was removed, made up to 5 ml with piperidine in DMF (1 ml, 1:4 v:v), and the solution 
analysed by UV to calculate the loading in mmol/g.
4.2.2.3 -  Kaiser Test
The Kaiser127 test for free, amines was carried out as follows. Solutions of ninhydrin in 
ethanol (5% w/v, 2 drops), phenol in ethanol (4:1 w/v, 2 drops) and KCN in pyridine (2% 
of lmmol/1 aqueous solution v:v, 2 drops) were added to the resins and the resultant 
mixture heated to 80 °C for 5 minutes. A blue colour is indicative of the free amine.
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4.2.2.4 -  Fmoc Deprotection
The resins were swollen in DMF for 1 h. Sufficient piperidine:DMF (1:5 v:v) to 
completely immerse the resins was added and the mixture left to stand for 2 mins. The 
deprotection solution was drained, and the resins washed with DMF (3x2 ml). 
Piperidine:DMF (1:5 v:v) was added to the resins and the mixture left to stand for 8 mins 
with occasional agitation. The solution was drained and the resins washed.
4.2.3 -  Preparation o f Resins
4.2.3.1 -  Typical loading o f chlorotrityl resins
Chlorotrityl resins (1 mmol/g, 0.5 g) were swollen in DMF (10 ml) for one hour, and then 
washed. DCM (10ml), acetic acid (0.25 mmol, 0.015 ml) and DIPEA (0.25 mmol, 0.043 
ml) were added, and the resins left to stand for 2 h, with occasional agitation. After a 
resin wash, Fmoc amino acid (1 mmol) and DIPEA (1 mmol, 0.17 ml) were added to 
DMF (10 ml) and the mixture stirred until complete dissolution of the amino acid had 
occurred. This solution was then added to the resins and the resultant mixture left to stand 
for 4 h, with occasional stirring. The resins were washed, shrunk and their loading 
determined by the Fmoc test. The resins were then swollen in DMF (10 ml) for one hour 
and washed with DCM:MeOH:DIPEA (17:2:1 v:v:v, 3x10 ml). Finally the resins were 
washed and shrunk for storage.
4.2.3.2 -  Preparation o f sulfonamide safety-catch linker resins
Aminomethyl polystyrene resins (1.13 mmol/g, 5.0 g) were swollen in DMF (15 ml) for 
one hour, and then washed with DIPEA in DMF (3 drops/5 ml, 3x15 ml) and DCM (3x15 
ml). Acetic anhydride (0.32 g, 3.15 mmol) in DCM (15 ml), DIPEA (1.1 ml, 6.0 mmol) 
and DMAP (38 mg, 0.25 mmol) were added to the resin, and the resultant mixture left to 
stand for 1 h with occasional stirring, after which time the resins were washed. 4- 
Sulfamylbutyric acid (1.25 g, 7.5 mmol) and HOBt (1.0 g, 7.5 mmol) were dissolved in 
DMF (15 ml), added to the resins and the resultant mixture shaken for 1 h. DIC (1.16 ml,
7.5 mmol) was then added and the resins shaken for 5 h and washed.
165
4.23.3 — Loading o f safety-catch linker resins
FmocLeu fluoride was prepared from FmocLeu (2.8 g, 8.0 mmol) as described in the 
literature.32 The resultant compound was dissolved in DCM (12 ml). The resultant 
solution (6 ml) and DIPEA (0.87 ml, 5.0 mmol) was added to the sulfonamide 
safety-catch linker resins and the mixture left to stand for 18 h with occasional agitation. 
The resins were washed, and checked for loading. Loading was 0.25 mmol/g, and so the 
loading procedure was repeated, increasing the loading to 0.40 mmol/g.
4.2.4 -  Microwave-enhanced SPPS
Peptide fragments were synthesized on a 0.1 mmol scale. 0.2 M amino acid solutions 
were used. Coupling solution consisted of 0.5 M HBTU/HOBt in DMF, activator base 
solution 2 M DIPEA in NMP and deprotection 20% piperidine in 0.1 M HOBt/DMF. 
Default cycles were used unless a double or triple coupling was required, in which case 
appropriate extra steps were added.
Prior to automated SPPS resins were swollen in DMF for 1 h. the loadings of resins were 
as follows -  FmocLeu-Chlorotrityl, 0.50 mmol/g; FmocGly-Chlorotrityl, 0.16 mmol/g; 
FmocAsn-Chlorotrityl, 0.16 mmol/g; FmocLeu-Safety-catch, 0.40 mmol/g.
4.2.5 -  Cleavage Protocols
4.2.5.1 -  TFA Cleavage
TFA cleavage was carried out on small samples of resins, typically 20 mg. The resins 
were swollen in DMF for 1 h, deprotected and washed. Sufficient cleavage solution 
(TFA:H20:EDT:TIS, 94:2.5:2.5:1 v:v:v:v) to immerse the resins was added and the 
resultant mixture was left for 4 h with occasional agitation. The crude cleavage mixture 
was drained, and the resins washed once with TFA and three times with DCM. All 
solutions were combined and concentrated to -0.5 ml under reduced pressure. In cases 
where a precipitate had formed, 2/3 drops of DCM were added and this gave a 
homogenous solution. The resultant solution was added to chilled ether (1 ml), and the 
mixture centrifuged. The supernatant was discarded and ether (1 ml) added to the pellet. 
Dispersion of the pellet was achieved by sonication (10 min), and the mixture centrifuged
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again. This process was repeated twice to remove unwanted deprotection byproducts. The 
product was then analysed using HPLC and mass spectrometry.
4.2.5.2 -  Cleavage from  Safety Catch Linkers
Cleavage from safety-catch linkers with homoallyl amine was achieved using the 
literature precedent,32 substituting homoallyl amine for the thiol. The solvent was 
removed in vacuo yielding the protected peptide. To prepare for HPLC analysis, 1.5 ml 
cleavage solution (TFA:H20:EDT:TIS, 94:2.5:2.5:1 v:v:v:v) added and the mixture left to 
stand for 4 h. The resultant solution was concentrated and treated in the same manner as 
the TFA-cleaved peptides.
4.2.5.2 -  Cleavage with Acetic Acid
Acetic acid cleavage was carried out on -100 mg of resins, typically. The resins were 
swollen in DMF for 1 h, deprotected and washed. To the deprotected resins was added 
Boc anhydride (10 equivalents in DCM). The resultant mixture was left to stand for 2 h 
with occasional agitation. The solution was the drained and the resins washed. The 
cleavage mixture (AcOH:TFE:DCM, 1:1:8 v:v:v) was added and the mixture left to stand 
for 2 h with occasional agitation. The resultant solution was separated and the resins 
washed with DCM. The combined solutions were washed twice with saturated NaHCC>3, 
dried with MgSC>4 and the solvent removed in vacuo yielding the cleaved, fully protected 
peptide.
4 .2 .6 - Manual SPPS
Where a manual coupling was required, a solution of amino acid (5.5 equiv.), HOBt (5 
equiv.), HBTU (5 equiv.) in a minimum volume of DMF was added to the swollen resins. 
If necessary, extra DMF was added to submerge the resins. DIPEA (5 equiv.) was then 
added and the mixture occasionally agitated. Every 2 h a few resin beads were removed, 
washed, and checked using the Kaiser test. When coupling was complete, the resins were 
washed.
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4 .2 .7 - On-Resin N-Acryloylation
The resins were swollen in DMF for 1 h, deprotected and washed. To the deprotected 
resins were added acryloyl chloride (2 equivalents in DCM at 0.67 M) and DIPEA (2 
equivalents). The resultant mixture was left to stand, with occasional agitation, and the 
Kaiser test was employed every 2 h. When acryloylation was complete the resins were 
washed.
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